{
    "questions": [
        {
            "id": "5a75eb6483b0d9ea66000004",
            "body": "What is Blount's disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19370370",
                "http://www.ncbi.nlm.nih.gov/pubmed/20609637",
                "http://www.ncbi.nlm.nih.gov/pubmed/25932193",
                "http://www.ncbi.nlm.nih.gov/pubmed/15481748",
                "http://www.ncbi.nlm.nih.gov/pubmed/27583129",
                "http://www.ncbi.nlm.nih.gov/pubmed/12077670",
                "http://www.ncbi.nlm.nih.gov/pubmed/8657465",
                "http://www.ncbi.nlm.nih.gov/pubmed/23610758",
                "http://www.ncbi.nlm.nih.gov/pubmed/7670990",
                "http://www.ncbi.nlm.nih.gov/pubmed/9702674"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370370",
                    "text": "BACKGROUND Blount's disease is a multi-planar deformity affecting the pediatric population which leads to varus alignment of the lower extremities.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20609637",
                    "text": "INTRODUCTION In stage\u00a01 of all currently accepted classifications for infantile tibia vara, the diagnosis is difficult between physiological bowing and true Blount's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25932193",
                    "text": "Blount's disease is an uncommon disorder of postero-medial proximal tibial physis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15481748",
                    "text": "Blount's disease or congenital tibia vara is a clinical entity characterized by tibia bowing, tibia torsion, and beaking of the medial tibia metaphysis on plain radiograph.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27583129",
                    "text": "Blount's disease is a progressive form of genu varum due to asymmetrical inhibition of the postero medial portion of the proximal tibial epiphysis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12077670",
                    "text": "This report is the first known case of SCFE associated with infantile Blount's disease.",
                    "offsetInBeginSection": 328,
                    "offsetInEndSection": 415,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8657465",
                    "text": "In view of the spontaneous recovery of all investigated patients, it must be doubted whether a diagnosis of infantile tibia vara can be made in early infancy, and whether infantile Blount's disease is a diagnosis in its own right.",
                    "offsetInBeginSection": 672,
                    "offsetInEndSection": 902,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23610758",
                    "text": "Infantile Blount's disease is a condition that causes genu varum and internal tibial torsion.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23610758",
                    "text": "Treatment options include observation, orthotics, corrective osteotomy, elevation of the medial tibial plateau, resection of a physeal bar, lateral hemi-epiphysiodesis, and guided growth of the proximal tibial physis.",
                    "offsetInBeginSection": 94,
                    "offsetInEndSection": 311,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7670990",
                    "text": "We postulate the hypothesis of the etiopathogenesis of the infantile type of Blount's disease as a disease related to a dysplastic linkage between epiphysis and metaphysis.",
                    "offsetInBeginSection": 95,
                    "offsetInEndSection": 267,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a2dcab750ff4455000023",
            "body": "Which are the constitutive parts of a Genomic Regulatory Block (GRB)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22666536",
                "http://www.ncbi.nlm.nih.gov/pubmed/17387144",
                "http://www.ncbi.nlm.nih.gov/pubmed/19374772",
                "http://www.ncbi.nlm.nih.gov/pubmed/22962458",
                "http://www.ncbi.nlm.nih.gov/pubmed/21619633",
                "http://www.ncbi.nlm.nih.gov/pubmed/22234889",
                "http://www.ncbi.nlm.nih.gov/pubmed/17989259"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666536",
                    "text": "The Sonic Hedgehog (Shh) genomic regulatory block (GRB) is one of the best functionally characterized examples, with several discrete enhancers reported within its introns, vast upstream gene-free region and neighboring genes (Lmbr1 and Rnf32).",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144",
                    "text": "We termed these chromosomal segments genomic regulatory blocks (GRBs).",
                    "offsetInBeginSection": 916,
                    "offsetInEndSection": 986,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144",
                    "text": "Reporter insertions distal to zebrafish developmental regulatory genes pax6.1/2, rx3, id1, and fgf8 and miRNA genes mirn9-1 and mirn9-5 recapitulate the expression patterns of these genes even if located inside or beyond bystander genes, suggesting that the regulatory domain of a developmental regulatory gene can extend into and beyond adjacent transcriptional units.",
                    "offsetInBeginSection": 546,
                    "offsetInEndSection": 915,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387144",
                    "text": "Bystander genes are not specifically under the control of the regulatory elements that drive the target genes and are expressed in patterns that are different from those of the target genes.",
                    "offsetInBeginSection": 355,
                    "offsetInEndSection": 545,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19374772",
                    "text": "BACKGROUND Genomic regulatory blocks (GRBs) are chromosomal regions spanned by highly conserved non-coding elements (HCNEs), most of which serve as regulatory inputs of one target gene in the region.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22962458",
                    "text": "These elements are organized as large clusters, so-called gene regulatory blocks (GRBs) around key developmental genes.",
                    "offsetInBeginSection": 315,
                    "offsetInEndSection": 434,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21619633",
                    "text": "They are therefore functionally related to a number of key protein coding developmental genes, that form genomic regulatory blocks (GRBs) with arrays of highly conserved non-coding elements (HCNEs) functioning as long-range enhancers that collaboratively regulate the expression of their target genes.",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 557,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21619633",
                    "text": "Furthermore these predictions include miRNAs of the miR-9 family, which are the only experimentally verified GRB target miRNAs.",
                    "offsetInBeginSection": 1937,
                    "offsetInEndSection": 2064,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22234889",
                    "text": "Developmental genes are regulated by complex, distantly located cis-regulatory modules (CRMs), often forming genomic regulatory blocks (GRBs) that are conserved among vertebrates and among insects.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17989259",
                    "text": "These arrays span key developmental regulatory genes, forming genomic regulatory blocks (GRBs).",
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 381,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a735cdc3b9d13c708000004",
            "body": "In November 2017,  in what phase  was  the clinical trial for the drug SYL040012?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24025752"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                    "text": "The objective of this study was to evaluate ocular tolerance, safety, and effect on intraocular pressure (IOP) of a topically administered small interfering RNA; SYL040012, on healthy volunteers.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                    "text": "SYL040012 was administered to one eye as a single dose to six subjects during interval 1.",
                    "offsetInBeginSection": 344,
                    "offsetInEndSection": 433,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                    "text": "During interval 2 two different doses of SYL040012 were administered to one eye on a daily basis to two separate groups of 12 subjects each, over a period of 7 days.",
                    "offsetInBeginSection": 434,
                    "offsetInEndSection": 599,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                    "text": "The study was an open-label, controlled, single-center study comprised of two intervals that enrolled 30 healthy subjects having IOP below 21 mmHg.",
                    "offsetInBeginSection": 196,
                    "offsetInEndSection": 343,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                    "text": "Administration of SYL040012 over a period of 7 days reduced IOP values in 15 out of 24 healthy subjects regardless of the dose used.",
                    "offsetInBeginSection": 908,
                    "offsetInEndSection": 1040,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                    "text": "SYL040012 was not detected in plasma at any time point.",
                    "offsetInBeginSection": 852,
                    "offsetInEndSection": 907,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                    "text": "SYL040012 was well tolerated locally.",
                    "offsetInBeginSection": 704,
                    "offsetInEndSection": 741,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                    "text": "IOP decrease was statistically significant in response to one of the doses tested and responsiveness to SYL040012 seemed to be greater in individuals with higher baseline IOP.",
                    "offsetInBeginSection": 1041,
                    "offsetInEndSection": 1216,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                    "text": "The contralateral eye was evaluated but not administered and served as control for the tolerance study.",
                    "offsetInBeginSection": 600,
                    "offsetInEndSection": 703,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025752",
                    "text": "No local or systemic adverse events related to the product developed in response to any of the doses studied.",
                    "offsetInBeginSection": 742,
                    "offsetInEndSection": 851,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a777ab9faa1ab7d2e00000a",
            "body": "What is the drug target(s) for Belsomra?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25336862"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25336862",
                    "text": "Idelalisib (Zydelig) for certain types of leukemia and lymphoma, peginterferon beta-1a (Plegridy) for relapsing forms of multiple sclerosis, and suvorexant (Belsomra) for insomnia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8861eb8cb19eca6b000001",
            "body": "List the two most important synaptic markers.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22206847",
                "http://www.ncbi.nlm.nih.gov/pubmed/24205365",
                "http://www.ncbi.nlm.nih.gov/pubmed/27906174",
                "http://www.ncbi.nlm.nih.gov/pubmed/25755633",
                "http://www.ncbi.nlm.nih.gov/pubmed/26017624",
                "http://www.ncbi.nlm.nih.gov/pubmed/26776762",
                "http://www.ncbi.nlm.nih.gov/pubmed/22609570",
                "http://www.ncbi.nlm.nih.gov/pubmed/7783952",
                "http://www.ncbi.nlm.nih.gov/pubmed/21074556",
                "http://www.ncbi.nlm.nih.gov/pubmed/20540992"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22206847",
                    "text": "The protein and messenger RNA (mRNA) levels of 7 synaptic markers (complexin-1, complexin-2, synaptophysin, synaptobrevin, syntaxin, synaptosomal-associated protein 25 (SNAP-25), and septin-5) were compared in the brains of nondemented and demented individuals ranging from 70 to 103 years of age.",
                    "offsetInBeginSection": 660,
                    "offsetInEndSection": 957,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24205365",
                    "text": "GluA2-containing AMPA receptors and their association with protein kinase M zeta (PKM\u03b6) and post-synaptic density-95 (PSD-95) are important for learning, memory and synaptic plasticity processes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906174",
                    "text": "Alzheimer's disease (AD) is characterized by synaptic and neuronal loss, which occurs at least partially through oxidative stress induced by oligomeric amyloid-\u03b2 (A\u03b2)-peptide.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25755633",
                    "text": "Synaptic failure and neurofibrillary degeneration are two major neuropathological substrates of cognitive dysfunction in Alzheimer's disease (AD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22609570",
                    "text": "Insulin-like growth factor-1 (IGF1) and its active peptide (1-3)IGF1 modulate brain growth and plasticity and are candidate molecules for treatment of brain disorders.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22609570",
                    "text": "IGF1 N-terminal portion is naturally cleaved to generate the tri-peptide (1-3)IGF1 (glycine-praline-glutamate).",
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7783952",
                    "text": "Of these latter proteins, one is integral (synaptophysin) the other peripheral (synapsin I) to the synaptic vesicle membranes.",
                    "offsetInBeginSection": 294,
                    "offsetInEndSection": 420,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20540992",
                    "text": "Orexin (Orx or hypocretin) is critically important for maintaining wakefulness, since in its absence, narcolepsy with cataplexy occurs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20540992",
                    "text": "None were immunostained for vesicular glutamate transporter 1 (VGluT1) or VGluT3 or for the vesicular transporter for GABA, vesicular GABA transporter (VGAT).",
                    "offsetInBeginSection": 861,
                    "offsetInEndSection": 1019,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20540992",
                    "text": "A similar proportion of the large Orx+ varicosities contained synaptophysin (Syp), a presynaptic marker for synaptic vesicles.",
                    "offsetInBeginSection": 1107,
                    "offsetInEndSection": 1233,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75ee7e83b0d9ea66000005",
            "body": "List symptoms of the Zieve's syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7110955",
                "http://www.ncbi.nlm.nih.gov/pubmed/2616809",
                "http://www.ncbi.nlm.nih.gov/pubmed/464793",
                "http://www.ncbi.nlm.nih.gov/pubmed/26203455",
                "http://www.ncbi.nlm.nih.gov/pubmed/548954",
                "http://www.ncbi.nlm.nih.gov/pubmed/11761804",
                "http://www.ncbi.nlm.nih.gov/pubmed/8819039",
                "http://www.ncbi.nlm.nih.gov/pubmed/966632"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955",
                    "text": "Zieve's syndrome therefore is not benign but precedes acute alcoholic hepatitis episodes on a normal, fibrotic or cirrhotic liver.",
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955",
                    "text": "Zieve's syndrome, characterized by jaundice, hyperlipaemia and haemolytic anaemia, usually develops in young, chronically alcoholic subjects with enlarged fatty liver.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110955",
                    "text": "However, the discovery of acute alcoholic hepatitis during repeat needle-biopsy of the liver confirms that in some cases steatosis may mask hyaline necrosis and neutrophil infiltration.",
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 507,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809",
                    "text": "The clinical manifestations of the syndrome contains no pathognomonic symptoms and suggests rather cholecystopathy.",
                    "offsetInBeginSection": 132,
                    "offsetInEndSection": 247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2616809",
                    "text": "This is possibly the cause of rare recognition of the syndrome.",
                    "offsetInBeginSection": 248,
                    "offsetInEndSection": 311,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/464793",
                    "text": "The Zieve's syndrome consists of the transient association of cholestatic jaundice, hemolytic anemia, hyperlipemia, in a chronic alcoholic.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/548954",
                    "text": "A patient with Zieve's syndrome is described.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 45,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11761804",
                    "text": "We report a case of recurrent Zieve's syndrome, consisting of jaundice, hemolytic anemia and hyperlipoproteinemia, initiated by alcohol abuse.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8819039",
                    "text": "Zieve's syndrome consists of transient haemolytic anaemic, jaundice, hyperlipidaemia and alcohol-induced liver disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/966632",
                    "text": "In 11 patients with alcohol-induced hyperlipemia, of whom 6 showed a Zieve Syndrome increased phospholipids, triglycerides and total cholesterol were found in the red cells stromal.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7636d39e632bc066000004",
            "body": "Which R packages have been developed for the discovery of mutational signatures in cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27091472",
                "http://www.ncbi.nlm.nih.gov/pubmed/29028923",
                "http://www.ncbi.nlm.nih.gov/pubmed/29145625",
                "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
                "http://www.ncbi.nlm.nih.gov/pubmed/26163694"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27091472",
                    "text": "RESULTS MutSpec includes a set of tools that perform variant annotation and use advanced statistics for the identification of mutation signatures present in cancer genomes and for comparing the obtained signatures with those published in the COSMIC database and other sources.",
                    "offsetInBeginSection": 699,
                    "offsetInEndSection": 975,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923",
                    "text": "Results We proposed two complementary ways of measuring confidence and stability of decomposition results and applied them to analyze mutational signatures in breast cancer genomes.",
                    "offsetInBeginSection": 882,
                    "offsetInEndSection": 1063,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923",
                    "text": "We identified both very stable and highly unstable signatures, as well as signatures that previously have not been associated with breast cancer.",
                    "offsetInBeginSection": 1064,
                    "offsetInEndSection": 1209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028923",
                    "text": "The decomposition of a cancer genome's mutation catalog into mutations consistent with such signatures can provide valuable information about cancer etiology.",
                    "offsetInBeginSection": 484,
                    "offsetInEndSection": 642,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145625",
                    "text": "Deciphering mutational signatures in cancer is a new topic in cancer research.",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 334,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145625",
                    "text": "mSignatureDB (http://tardis.cgu.edu.tw/msignaturedb) integrates R packages and in-house scripts to determine the contributions of the published signatures in 15 780 individual tumors from 73 TCGA/ICGC cancer projects, making comparison of signature patterns within and between projects become possible.",
                    "offsetInBeginSection": 875,
                    "offsetInEndSection": 1177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145625",
                    "text": "A cancer genome bears the cumulative effects of mutational processes during tumor development.",
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
                    "text": "RESULTS Here we present a new method for the statistical estimation of mutational signatures based on an empirical Bayesian treatment of the NMF model.",
                    "offsetInBeginSection": 749,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591080",
                    "text": "These signatures have been identified from high throughput sequencing data generated from cancer genomes by using non-negative matrix factorisation (NMF) techniques.",
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 356,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26163694",
                    "text": "UNLABELLED Mutational signatures are patterns in the occurrence of somatic single-nucleotide variants that can reflect underlying mutational processes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8dc57ffcd1d6a10c000025",
            "body": "Are the human bombesin receptors, GRPR and NMBR, frequently overexpressed G-protein-coupled-receptors by lung-cancers?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10828496",
                "http://www.ncbi.nlm.nih.gov/pubmed/23096238",
                "http://www.ncbi.nlm.nih.gov/pubmed/12959933",
                "http://www.ncbi.nlm.nih.gov/pubmed/8018339",
                "http://www.ncbi.nlm.nih.gov/pubmed/19628633",
                "http://www.ncbi.nlm.nih.gov/pubmed/11463790",
                "http://www.ncbi.nlm.nih.gov/pubmed/10679759",
                "http://www.ncbi.nlm.nih.gov/pubmed/23826298",
                "http://www.ncbi.nlm.nih.gov/pubmed/25209280",
                "http://www.ncbi.nlm.nih.gov/pubmed/26030739"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10828496",
                    "text": "In this study, we used the reverse transcription-polymerase chain reaction (RT-PCR) method to evaluate the mRNA expression of three bombesin receptor subtypes: gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), in 22 specimens of human epithelial ovarian cancer and in two human ovarian cancer lines.",
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 668,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23096238",
                    "text": "Mammalian bombesin-like peptides neuromedin B (NMB) and gastrin-releasing peptide (GRP) act by activating NMB receptors (NMBR, BBl) and GRP receptors (GRPR,BB2), respectively.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23096238",
                    "text": "These two bombesin receptors are members of the G-protein-coupled receptor (GPCR) superfamily.In the brain, NMBR and GRPR are highly expressed in the brain areas involved in memory processing and emotional responses, such as the hippocampus and the amygdaloid nuclei.",
                    "offsetInBeginSection": 176,
                    "offsetInEndSection": 443,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12959933",
                    "text": "Dexamethasone and bombesin increased GRPR mRNA, bombesin downregulated NMBR, and neither agent affected BRS-3.",
                    "offsetInBeginSection": 1077,
                    "offsetInEndSection": 1187,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12959933",
                    "text": "To test the hypothesis that such effects are mediated by known mammalian bombesin receptors [gastrin-releasing peptide (GRP)/bombesin-preferring receptor (GRPR), neuromedin B (NMB) receptor (NMBR), and the orphan bombesin receptor subtype-3 (BRS-3)], we analyzed the ontogeny of GRPR, NMBR, and BRS-3 gene expression in mouse lung.",
                    "offsetInBeginSection": 148,
                    "offsetInEndSection": 479,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8018339",
                    "text": "Three receptors have been identified for bombesin and its analogs, namely gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3).",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 448,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19628633",
                    "text": "The mammalian bombesin (Bn) peptides, neuromedin B (NMB) and gastrin-releasing peptide (GRP), have widespread actions in many tissues, and their effects are mediated by two closely related G-protein-coupled receptors, the NMBR and GRPR.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10679759",
                    "text": "Three bombesin receptor subtypes, termed gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin receptor subtype 3 (BRS-3), have been identified in rodents and humans.",
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 366,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23826298",
                    "text": "receptors for gastrin-releasing peptide (GRPr) and neuromedin B (NMBr) differentially regulate itch scratching.",
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 305,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26030739",
                    "text": "We purified peptide E as a low-affinity ligand for hBRS3, which was also found to be an agonist for the other two mammalian bombesin receptors such as gastrin-releasing peptide receptor (GRPR) and neuromedin B receptor (NMBR).",
                    "offsetInBeginSection": 1361,
                    "offsetInEndSection": 1587,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7602be83b0d9ea6600000f",
            "body": "Describe King\u2013Kopetzky syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16760737",
                "http://www.ncbi.nlm.nih.gov/pubmed/20512338",
                "http://www.ncbi.nlm.nih.gov/pubmed/25709171",
                "http://www.ncbi.nlm.nih.gov/pubmed/835533",
                "http://www.ncbi.nlm.nih.gov/pubmed/4017281",
                "http://www.ncbi.nlm.nih.gov/pubmed/9777339",
                "http://www.ncbi.nlm.nih.gov/pubmed/6703533",
                "http://www.ncbi.nlm.nih.gov/pubmed/17326116",
                "http://www.ncbi.nlm.nih.gov/pubmed/23565480",
                "http://www.ncbi.nlm.nih.gov/pubmed/3144988"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16760737",
                    "text": "Goldberg-Shprintzen syndrome is a rare autosomal recessive condition that describes the association of Hirschsprung disease with microcephaly, developmental delay and characteristic facies.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16760737",
                    "text": "We describe two brothers from a non-consanguineous family who have classical features of Goldberg-Shprintzen syndrome.",
                    "offsetInBeginSection": 190,
                    "offsetInEndSection": 308,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/835533",
                    "text": "It is suggested that this syndrome is inherited as an autosomal-recessive condition.",
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 349,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281",
                    "text": "Syndrome) the Aase Syndrome and Diamond-Blackfan Anemia.",
                    "offsetInBeginSection": 211,
                    "offsetInEndSection": 267,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281",
                    "text": "), Thrombocytopenia Absent Radii Syndrome (T.A.R.",
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 210,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6703533",
                    "text": "Authors describe the phenotype and review the literature on this syndrome.",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 233,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6703533",
                    "text": "A new case of Robinow dwarfism syndrome, in a 26 month old child is described.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116",
                    "text": "Although there is considerable variability, most individuals with Down syndrome have mental retardation and speech and language deficits, particularly in language production and syntax and poor speech intelligibility.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 217,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565480",
                    "text": "BACKGROUND Wolfram syndrome is a rare hereditary or sporadic neurodegenerative disorder also known as DIDMOAD.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3144988",
                    "text": "This report surveys literature on four syndromes with major manifestations in the craniofacial region, i.e., Laband syndrome, de Barsy syndrome, Wiedemann-Rautenstrauch syndrome, and LADD syndrome.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67c284b750ff4455000011",
            "body": "What is GenomeVIP?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28522612"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "GenomeVIP orchestrates the analysis of whole-genome and exome sequence data using a set of robust and popular task-specific tools, including VarScan, GATK, Pindel, BreakDancer, Strelka, and Genome STRiP, through a web interface.",
                    "offsetInBeginSection": 790,
                    "offsetInEndSection": 1018,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "GenomeVIP has been used for genomic analysis in large-data projects such as the TCGA PanCanAtlas and in other projects, such as the ICGC Pilots, CPTAC, ICGC-TCGA DREAM Challenges, and the 1000 Genomes SV Project.",
                    "offsetInBeginSection": 1019,
                    "offsetInEndSection": 1231,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "Here, we introduce the Genome Variant Investigation Platform (GenomeVIP), an open-source framework for performing genomics variant discovery and annotation using cloud- or local high-performance computing infrastructure.",
                    "offsetInBeginSection": 569,
                    "offsetInEndSection": 789,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "Identifying genomic variants is a fundamental first step toward the understanding of the role of inherited and acquired variation in disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "The accelerating growth in the corpus of sequencing data that underpins such analysis is making the data-download bottleneck more evident, placing substantial burdens on the research community to keep pace.",
                    "offsetInBeginSection": 142,
                    "offsetInEndSection": 348,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "Here, we demonstrate GenomeVIP's ability to provide high-confidence annotated somatic, germline, and de novo variants of potential biological significance using publicly available data sets.",
                    "offsetInBeginSection": 1232,
                    "offsetInEndSection": 1422,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28522612",
                    "text": "As a result, the search for alternative approaches to the traditional \"download and analyze\" paradigm on local computing resources has led to a rapidly growing demand for cloud-computing solutions for genomics analysis.",
                    "offsetInBeginSection": 349,
                    "offsetInEndSection": 568,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a981e66fcd1d6a10c00002f",
            "body": "According to guidelines, insulin resistance is one risk factor in the diagnosis of metabolic syndrome, name 3 more risk factors.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16762931",
                "http://www.ncbi.nlm.nih.gov/pubmed/15547646",
                "http://www.ncbi.nlm.nih.gov/pubmed/16505579",
                "http://www.ncbi.nlm.nih.gov/pubmed/12643148",
                "http://www.ncbi.nlm.nih.gov/pubmed/15940204",
                "http://www.ncbi.nlm.nih.gov/pubmed/21068471",
                "http://www.ncbi.nlm.nih.gov/pubmed/17125447",
                "http://www.ncbi.nlm.nih.gov/pubmed/17456293",
                "http://www.ncbi.nlm.nih.gov/pubmed/19108808",
                "http://www.ncbi.nlm.nih.gov/pubmed/15529616"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15547646",
                    "text": "Insulin resistance is the key factor for the clustering of risk factors characterizing the metabolic syndrome.",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 382,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16505579",
                    "text": "Soon, metabolic syndrome will overtake cigarette smoking as the number one risk factor for heart disease among the US population.",
                    "offsetInBeginSection": 1182,
                    "offsetInEndSection": 1311,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16505579",
                    "text": "The syndrome has been given several names, including- the metabolic syndrome, the insulin resistance syndrome, the plurimetabolic syndrome, and the deadly quartet.",
                    "offsetInBeginSection": 75,
                    "offsetInEndSection": 238,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12643148",
                    "text": "Also, there is new and better understanding of the complex dyslipidemias and other risk factors strongly associated with the metabolic syndrome, which greatly increase the risk of clinical atherosclerotic events.",
                    "offsetInBeginSection": 394,
                    "offsetInEndSection": 606,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17125447",
                    "text": "Abdominal adiposity is considered high-risk fat, and it is associated with insulin resistance, hyperglycemia, dyslipidemia, hypertension, and prothrombotic and/or proinflammatory states.",
                    "offsetInBeginSection": 905,
                    "offsetInEndSection": 1091,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17125447",
                    "text": "First-line therapy for individuals with metabolic syndrome should be directed to the major CVD risk factors, namely, elevated low-density lipoprotein cholesterol levels, hypertension, and diabetes, and it should emphasize lifestyle modification.",
                    "offsetInBeginSection": 1226,
                    "offsetInEndSection": 1471,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17125447",
                    "text": "Until additional research better defines the most appropriate therapies, conventional cardiovascular risk factors, such as lipid levels, blood pressure, and diabetes, should be managed in individuals with metabolic syndrome according to nationally accepted clinical guidelines.",
                    "offsetInBeginSection": 1472,
                    "offsetInEndSection": 1749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19108808",
                    "text": "The metabolic syndrome has 5 criteria: central obesity, hypertriglyceridemia, low high-density lipoprotein (HDL) levels, fasting hyperglycemia, and hypertension.",
                    "offsetInBeginSection": 1021,
                    "offsetInEndSection": 1182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15529616",
                    "text": "Pathogenesis of metabolic syndrome implies 3 potential etiological mechanisms: obesity and adipose tissue disorders, insulin resistance, and a constellation of independent factors.",
                    "offsetInBeginSection": 64,
                    "offsetInEndSection": 244,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15529616",
                    "text": "In addition, other components commonly aggregate with the major components: elevated apolipoprotein B, small LDL particles, insulin resistance and hyperinsulinemia, impaired glucose tolerance (IGT), elevated C-reactive protein (CRP), and variation in coagulation factors (plasminogen activator inhibitor [PAI]-I and fibrinogen).",
                    "offsetInBeginSection": 484,
                    "offsetInEndSection": 812,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76080683b0d9ea66000015",
            "body": "Is cilengitide effective for treatment of glioblastoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21739168",
                "http://www.ncbi.nlm.nih.gov/pubmed/25163906",
                "http://www.ncbi.nlm.nih.gov/pubmed/24014381",
                "http://www.ncbi.nlm.nih.gov/pubmed/24442484",
                "http://www.ncbi.nlm.nih.gov/pubmed/23354807",
                "http://www.ncbi.nlm.nih.gov/pubmed/22866207",
                "http://www.ncbi.nlm.nih.gov/pubmed/22976135",
                "http://www.ncbi.nlm.nih.gov/pubmed/21417900",
                "http://www.ncbi.nlm.nih.gov/pubmed/17277694",
                "http://www.ncbi.nlm.nih.gov/pubmed/18616418"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21739168",
                    "text": "Cilengitide is a cyclic pentapeptide that is a specific inhibitor of the \u03b1v\u03b23 and \u03b1v\u03b25 integrins.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014381",
                    "text": "BACKGROUND Cilengitide, an \u03b1v integrin antagonist, has demonstrated activity in recurrent adult glioblastoma (GBM).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014381",
                    "text": "CONCLUSIONS We conclude that cilengitide is not effective as a single agent for refractory pediatric HGG.",
                    "offsetInBeginSection": 1417,
                    "offsetInEndSection": 1522,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24442484",
                    "text": "The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT \u2192 TMZ) in newly diagnosed glioblastoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22866207",
                    "text": "A foundation of encouraging preclinical studies led to a well-designed clinical development plan that culminated in a pivotal phase III study of cilengitide in combination with radiation therapy and temozolomide chemotherapy for newly diagnosed glioblastoma patients.",
                    "offsetInBeginSection": 545,
                    "offsetInEndSection": 812,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22866207",
                    "text": "Although several integrin inhibitors are under clinical evaluation, cilengitide is the most clinically advanced and is emerging as a prototype for this class of anticancer therapy.",
                    "offsetInBeginSection": 364,
                    "offsetInEndSection": 544,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22976135",
                    "text": "Among them, cilengitide is a novel integrin antagonist for the treatment of glioblastoma.",
                    "offsetInBeginSection": 648,
                    "offsetInEndSection": 737,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22976135",
                    "text": "Cilengitide is currently being assessed in phase III trials for patients with glioblastoma multiforme and in phase II trials for other types of cancers, demonstrating promising therapeutic outcomes to date.",
                    "offsetInBeginSection": 1016,
                    "offsetInEndSection": 1222,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21417900",
                    "text": "Cilengitide is currently under evaluation in a pivotal, randomized Phase III study (Cilengitide in Combination With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Phase III Randomized Clinical Trial [CENTRIC]) for newly diagnosed GBM.",
                    "offsetInBeginSection": 734,
                    "offsetInEndSection": 983,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21417900",
                    "text": "Cilengitide and other integrin-targeting therapeutics have preclinical activity against many cancer subtypes including glioblastoma (GBM), the most common and deadliest CNS tumor.",
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 422,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a3464b750ff4455000026",
            "body": "Which algorithm has been developed in order to improve multiple circular sequence alignment using refined sequences?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                "http://www.ncbi.nlm.nih.gov/pubmed/19627599"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                    "text": "RESULTS We present MARS, a new heuristic method for improving Multiple circular sequence Alignment using Refined Sequences.",
                    "offsetInBeginSection": 917,
                    "offsetInEndSection": 1040,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                    "text": "A solution for these inconsistencies would be to identify a suitable rotation (cyclic shift) for each sequence; these refined sequences may in turn lead to improved multiple sequence alignments using the preferred multiple sequence alignment program.",
                    "offsetInBeginSection": 664,
                    "offsetInEndSection": 914,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                    "text": "CONCLUSIONS Analysing multiple sequences simultaneously is fundamental in biological research and multiple sequence alignment has been found to be a popular method for this task.",
                    "offsetInBeginSection": 1729,
                    "offsetInEndSection": 1907,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                    "text": "Our results show, among others, that the average pairwise distance in the multiple sequence alignment of a dataset of widely-studied mitochondrial DNA sequences is reduced by around 5% when MARS is applied before a multiple sequence alignment is performed.",
                    "offsetInBeginSection": 1470,
                    "offsetInEndSection": 1726,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28088189",
                    "text": "We present here a method, which can be used in conjunction with any multiple sequence alignment program, to address this problem effectively and efficiently.",
                    "offsetInBeginSection": 2023,
                    "offsetInEndSection": 2180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                    "text": "RESULTS In this paper we propose an efficient algorithm that identifies the most interesting region to cut circular genomes in order to improve phylogenetic analysis when using standard multiple sequence alignment algorithms.",
                    "offsetInBeginSection": 876,
                    "offsetInEndSection": 1101,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                    "text": "Researchers interested in aligning circular DNA sequences must first rotate them to the \"right\" place using an essentially manual process, before they can use multiple sequence alignment tools.",
                    "offsetInBeginSection": 680,
                    "offsetInEndSection": 873,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                    "text": "CONCLUSION The results show that a circularization and rotation pre-processing step significantly improves the efficiency of public available multiple sequence alignment algorithms when used in the alignment of circular DNA sequences.",
                    "offsetInBeginSection": 1796,
                    "offsetInEndSection": 2030,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                    "text": "Although a large number of multiple sequence alignment algorithms have been proposed to date, they all deal with linear DNA and cannot handle directly circular DNA.",
                    "offsetInBeginSection": 515,
                    "offsetInEndSection": 679,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19627599",
                    "text": "The software package Arlequin was used to evaluate the standard genetic measures of the alignments obtained with and without the use of the CSA algorithm with two well known multiple alignment algorithms, the CLUSTALW and the MAVID tools, and also the visualization tool SinicView.",
                    "offsetInBeginSection": 1512,
                    "offsetInEndSection": 1793,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a74e9ad0384be955100000a",
            "body": "What is a SERM?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11795362",
                "http://www.ncbi.nlm.nih.gov/pubmed/24667357",
                "http://www.ncbi.nlm.nih.gov/pubmed/26343247",
                "http://www.ncbi.nlm.nih.gov/pubmed/12036407",
                "http://www.ncbi.nlm.nih.gov/pubmed/24930824",
                "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
                "http://www.ncbi.nlm.nih.gov/pubmed/23925896",
                "http://www.ncbi.nlm.nih.gov/pubmed/18279543",
                "http://www.ncbi.nlm.nih.gov/pubmed/28978566",
                "http://www.ncbi.nlm.nih.gov/pubmed/15500393"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667357",
                    "text": "One such example is the tissue selective estrogen complex, which partners a SERM with 1 or more estrogens, with the aim of blending the desired estrogen-receptor agonist activities of estrogens on vasomotor symptoms, vulvar-vaginal atrophy, and loss of bone mass with the tissue selectivity of a SERM.",
                    "offsetInBeginSection": 1065,
                    "offsetInEndSection": 1366,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12036407",
                    "text": "Tamoxifen is a SERM that acts as an oestrogen antagonist in breast tissue and is currently being used for the treatment and prevention of breast cancer.",
                    "offsetInBeginSection": 486,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12036407",
                    "text": "Oestrogen and another SERM, raloxifene, have been shown to prevent osteoporosis.",
                    "offsetInBeginSection": 759,
                    "offsetInEndSection": 839,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24930824",
                    "text": "Tamoxifen, a pioneering selective estrogen receptor modulator (SERM), has long been a therapeutic choice for all stages of estrogen receptor (ER)-positive breast cancer.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
                    "text": "A new target in treating postmenopausal osteoporosis is the tissue estrogen complex or the pairing of a SERM with a conjugated estrogen known as a tissue selective estrogen complex (TSEC).",
                    "offsetInBeginSection": 1528,
                    "offsetInEndSection": 1716,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446043",
                    "text": "Several agents are available in the U.S., including bisphosphonates, hormone therapy, calcitonin, parathyroid hormone and the selective estrogen receptor modulator (SERM) raloxifene.",
                    "offsetInBeginSection": 675,
                    "offsetInEndSection": 857,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23925896",
                    "text": "Estrogen and selective estrogen receptor modulator (SERM) treatments for acromegaly have received limited attention since the development of newer pharmacologic therapies.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18279543",
                    "text": "Other SERMs have entered clinical development more recently, including benzothiophenes (raloxifene and arzoxifene), benzopyrans (ormeloxifene, levormeloxifene, and EM-800), lasofoxifene, pipendoxifene, bazedoxifene, HMR-3339, and fulvestrant, an anti-estrogen which is approved for breast cancer treatment.",
                    "offsetInBeginSection": 1049,
                    "offsetInEndSection": 1355,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15500393",
                    "text": "An ideal SERM is a compound with an oestrogen antagonist effect on the breast and uterus but oestrogen agonist effect on bone.",
                    "offsetInBeginSection": 127,
                    "offsetInEndSection": 253,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15500393",
                    "text": "Recently, raloxifene, a second-generation SERM, has been used in the treatment of familial adenomatous polyposis patients affected by desmoid tumour.",
                    "offsetInBeginSection": 469,
                    "offsetInEndSection": 618,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7610ca83b0d9ea6600001b",
            "body": "What is the role of nimotuzumab in treatment of pontine glioma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24696052",
                "http://www.ncbi.nlm.nih.gov/pubmed/25926743",
                "http://www.ncbi.nlm.nih.gov/pubmed/24847085",
                "http://www.ncbi.nlm.nih.gov/pubmed/23754473",
                "http://www.ncbi.nlm.nih.gov/pubmed/21171927",
                "http://www.ncbi.nlm.nih.gov/pubmed/23926436",
                "http://www.ncbi.nlm.nih.gov/pubmed/23043252"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052",
                    "text": "Findings on the role of EGFR signaling in the onset of childhood DIPG prompted the use of nimotuzumab, an anti-EGFR monoclonal antibody.",
                    "offsetInBeginSection": 92,
                    "offsetInEndSection": 228,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052",
                    "text": "Radiotherapy is the only treatment definitely indicated for diffuse pontine gliomas (DIPG).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696052",
                    "text": "Assuming a potential synergy with both radiotherapy and vinorelbine, a pilot phase 2 protocol was launched that combined nimotuzumab with concomitant radiation and vinorelbine.",
                    "offsetInBeginSection": 229,
                    "offsetInEndSection": 405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743",
                    "text": "We found that nimotuzumab with or without radiotherapy, chemotherapy in newly diagnosed or recurrent HGG, such as glioblastoma multiforme (GBM), anaplastic astrocytomas (AA), and diffuse intrinsic pontine glioma (DIPG), might improve the response rate or the survival time.",
                    "offsetInBeginSection": 499,
                    "offsetInEndSection": 772,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743",
                    "text": "We review the humanized epidermal growth factor receptor (EGFR) and the major EGFR target drugs in HGG treatments, focusing on the EGFR antibody nimotuzumab as a new therapeutic strategy in HGG.",
                    "offsetInBeginSection": 304,
                    "offsetInEndSection": 498,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25926743",
                    "text": "In conclusion, nimotuzumab is a very well-tolerated drug with acceptable toxicity, and it may have promising value in the combination treatment.",
                    "offsetInBeginSection": 773,
                    "offsetInEndSection": 917,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24847085",
                    "text": "CONCLUSIONS Modest activity of nimotuzumab in DIPG, which has been shown previously, was confirmed: A small subset of DIPG patients appeared to benefit from anti-EGFR antibody treatment.",
                    "offsetInBeginSection": 1499,
                    "offsetInEndSection": 1685,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754473",
                    "text": "Primary metastatic diffuse intrinsic pontine glioma (DIPG) is relatively rare and associated with a dismal prognosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754473",
                    "text": "Combining craniospinal irradiation (CSI) with concurrent temozolomide and nimotuzumab therapy may slightly improve tumor control and overall survival.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 268,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21171927",
                    "text": "The activity of nimotuzumab, a humanized anti-EGFR monoclonal antibody, was therefore studied within a Phase II trial in 47 relapsing pediatric patients with DIPG and high-grade gliomas, showing an interesting, persistent response, especially in the first group treated.",
                    "offsetInBeginSection": 571,
                    "offsetInEndSection": 841,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a35b7b750ff4455000027",
            "body": "What is libgapmis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24564250"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "libgapmis is based on an algorithm computing a modified version of the traditional dynamic-programming matrix for sequence alignment.",
                    "offsetInBeginSection": 1240,
                    "offsetInEndSection": 1373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "The open-source code of libgapmis is available at http://www.exelixis-lab.org/gapmis.",
                    "offsetInBeginSection": 2289,
                    "offsetInEndSection": 2374,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "CONCLUSIONS We present libgapmis, a library for extending pairwise short-read alignments.",
                    "offsetInBeginSection": 1942,
                    "offsetInEndSection": 2031,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "RESULTS In this article, we present libgapmis, a library for extending pairwise short-read alignments.",
                    "offsetInBeginSection": 1042,
                    "offsetInEndSection": 1144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "We show that libgapmis is better-suited and more efficient than existing algorithms for this task.",
                    "offsetInBeginSection": 2032,
                    "offsetInEndSection": 2130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "The fact that the reads are rather short and that the gap occurrence frequency observed in various studies is rather low suggest that aligning (parts of) those reads with a single gap is in fact desirable.",
                    "offsetInBeginSection": 834,
                    "offsetInEndSection": 1039,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "After aligning a substring of the reference sequence against the high-quality prefix of a short read--the seed--an important problem is to find the best possible alignment between a substring of the reference sequence succeeding and the remaining suffix of low quality of the read--extend.",
                    "offsetInBeginSection": 544,
                    "offsetInEndSection": 833,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "BACKGROUND A wide variety of short-read alignment programmes have been published recently to tackle the problem of mapping millions of short reads to a reference genome, focusing on different aspects of the procedure such as time and memory efficiency, sensitivity, and accuracy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "The seed-and-extend strategy is applied in most short-read alignment programmes.",
                    "offsetInBeginSection": 463,
                    "offsetInEndSection": 543,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24564250",
                    "text": "The library also provides the user the flexibility to split the read into fragments, based on the observed gap occurrence frequency and the length of the read, thereby allowing for a variable, but bounded, number of gaps in the alignment.",
                    "offsetInBeginSection": 1701,
                    "offsetInEndSection": 1939,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76016683b0d9ea6600000d",
            "body": "Down's syndrome occurs when an individual has an extra copy or part of a copy of chromosome 21, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19458618",
                "http://www.ncbi.nlm.nih.gov/pubmed/25738006",
                "http://www.ncbi.nlm.nih.gov/pubmed/1838097",
                "http://www.ncbi.nlm.nih.gov/pubmed/19212162",
                "http://www.ncbi.nlm.nih.gov/pubmed/11399108",
                "http://www.ncbi.nlm.nih.gov/pubmed/28959732",
                "http://www.ncbi.nlm.nih.gov/pubmed/26243569",
                "http://www.ncbi.nlm.nih.gov/pubmed/2880544"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458618",
                    "text": "Furthermore, we show that the modest increase in expression afforded by a single extra transgenic copy of Dscr1 is sufficient to confer significant suppression of tumour growth in mice, and that such resistance is a consequence of a deficit in tumour angiogenesis arising from suppression of the calcineurin pathway.",
                    "offsetInBeginSection": 600,
                    "offsetInEndSection": 916,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25738006",
                    "text": "Downs syndrome (DS) occurs due to an extra copy of chromosome 21.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 65,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1838097",
                    "text": "Analysis of individual distribution of satellite between homologues of chromosome 21 provides new possibilities for determination of the origin of extra chromosome in the patients with trisomy 21.",
                    "offsetInBeginSection": 802,
                    "offsetInEndSection": 998,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1838097",
                    "text": "The difference in the copy number between two homologues chromosomes, 13 and 21 reaches up to 5 times.",
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 704,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19212162",
                    "text": "Down syndrome is a genetic disorder, occurring when an individual has all or part of an extra copy of chromosome 21.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11399108",
                    "text": "The augmented antioxidant protection resulting from an extra copy of chromosome 21 may, with time, selectively protect human oocytes from apoptosis, increasing their proportion with age, explaining the higher incidence of this disease.",
                    "offsetInBeginSection": 872,
                    "offsetInEndSection": 1107,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26243569",
                    "text": "Down syndrome, which arises in individuals carrying an extra copy of chromosome 21, is associated with a greatly increased risk of early-onset Alzheimer disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2880544",
                    "text": "An extra copy of human chromosome 21 has been known for over twenty years to be the chromosomal abnormality in Down's syndrome; however, the biochemical and molecular basis governing expression of the phenotype is still poorly understood.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 238,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2880544",
                    "text": "Results presented here showed that a 0.58-kb repetitive sequence probe can be used to identify deletions, translocations, and other more complicated rearrangements of chromosome 21 seen in patients with abnormalities of this chromosome.",
                    "offsetInBeginSection": 1268,
                    "offsetInEndSection": 1504,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2880544",
                    "text": "For the detection of deletions and other rearrangements, especially in small chromosomes such as 21, it is the former property that makes it very efficient in the initial assignment of a chromosome location.",
                    "offsetInBeginSection": 1803,
                    "offsetInEndSection": 2010,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7615af83b0d9ea6600001f",
            "body": "Is vorinostat effective for glioblastoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20135194",
                "http://www.ncbi.nlm.nih.gov/pubmed/24576944",
                "http://www.ncbi.nlm.nih.gov/pubmed/29016887",
                "http://www.ncbi.nlm.nih.gov/pubmed/19307505",
                "http://www.ncbi.nlm.nih.gov/pubmed/23996800",
                "http://www.ncbi.nlm.nih.gov/pubmed/22028388",
                "http://www.ncbi.nlm.nih.gov/pubmed/22086447",
                "http://www.ncbi.nlm.nih.gov/pubmed/24838514",
                "http://www.ncbi.nlm.nih.gov/pubmed/22090453",
                "http://www.ncbi.nlm.nih.gov/pubmed/22923449"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194",
                    "text": "Histone deacetylase (HDAC) inhibitors represent a promising class of anti-cancer agents that are actively being evaluated in the context of clinical trials in solid tumors, including glioblastoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20135194",
                    "text": "The effects of the HDAC inhibitor vorinostat and SN38, which is the active metabolite of the topoisomerase I inhibitor CPT-11, was evaluated using the clonogenic assay.",
                    "offsetInBeginSection": 694,
                    "offsetInEndSection": 862,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944",
                    "text": "We present two patients with glioblastoma multiforme who developed severe hemolytic anemia shortly after initiating therapy with vorinostat, a pan-active histone deacetylase inhibitor, while on prophylactic dapsone.",
                    "offsetInBeginSection": 827,
                    "offsetInEndSection": 1042,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944",
                    "text": "Patients undergoing treatment for glioblastoma multiforme are routinely placed on prophylactic treatment for Pneumocystis jirovecii pneumonia because of significant therapy-induced lymphopenia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19307505",
                    "text": "PURPOSE Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086447",
                    "text": "Histone deacetylase inhibitors (HDACIs) represent a class of agents that can modulate gene expression to reduce tumor growth, and we and others have noted some antiglioma activity from HDACIs, such as vorinostat, although insufficient to warrant use as monotherapy.",
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 346,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24838514",
                    "text": "Multiple phase II trials with vorinostat in combination with targeted agents, temozolomide and radiotherapy are currently recruiting.",
                    "offsetInBeginSection": 1155,
                    "offsetInEndSection": 1288,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24838514",
                    "text": "Vorinostat is the most advanced HDAC inhibitor that entered clinical trials in glioblastoma, showing activity in recurrent disease.",
                    "offsetInBeginSection": 1023,
                    "offsetInEndSection": 1154,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22090453",
                    "text": "Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown evidence of single-agent activity in glioblastoma (GBM), and in preclinical studies, we have demonstrated significant synergistic cytotoxicity between HDAC inhibitors and proteasome inhibitors in GBM cell lines.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 273,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22923449",
                    "text": "A phase I/II trial of vorinostat with radiotherapy and concomitant TMZ in newly diagnosed glioblastoma is underway.",
                    "offsetInBeginSection": 1527,
                    "offsetInEndSection": 1642,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a7869b750ff4455000028",
            "body": "Describe SNP2TFBS",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27899579"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
                    "text": "SNP2TFBS is also accessible over a web interface, enabling users to view the information provided for an individual SNP, to extract SNPs based on various search criteria, to annotate uploaded sets of SNPs or to display statistics about the frequencies of binding sites affected by selected SNPs.",
                    "offsetInBeginSection": 762,
                    "offsetInEndSection": 1057,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
                    "text": "SNP2TFBS is a computational resource intended to support researchers investigating the molecular mechanisms underlying regulatory variation in the human genome.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
                    "text": "The database essentially consists of a collection of text files providing specific annotations for human single nucleotide polymorphisms (SNPs), namely whether they are predicted to abolish, create or change the affinity of one or several transcription factor (TF) binding sites.",
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 440,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
                    "text": "These data files are regenerated at regular intervals by an automatic procedure that takes as input a reference genome, a comprehensive SNP catalogue and a collection of PWMs.",
                    "offsetInBeginSection": 586,
                    "offsetInEndSection": 761,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
                    "text": "A SNP's effect on TF binding is estimated based on a position weight matrix (PWM) model for the binding specificity of the corresponding factor.",
                    "offsetInBeginSection": 441,
                    "offsetInEndSection": 585,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899579",
                    "text": "Homepage: http://ccg.vital-it.ch/snp2tfbs/.",
                    "offsetInBeginSection": 1058,
                    "offsetInEndSection": 1101,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7706b79e632bc066000009",
            "body": "What is trismus?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26098612",
                "http://www.ncbi.nlm.nih.gov/pubmed/26058916",
                "http://www.ncbi.nlm.nih.gov/pubmed/23193958",
                "http://www.ncbi.nlm.nih.gov/pubmed/20236743",
                "http://www.ncbi.nlm.nih.gov/pubmed/24985733",
                "http://www.ncbi.nlm.nih.gov/pubmed/24669774",
                "http://www.ncbi.nlm.nih.gov/pubmed/22632890",
                "http://www.ncbi.nlm.nih.gov/pubmed/28122104",
                "http://www.ncbi.nlm.nih.gov/pubmed/27461633",
                "http://www.ncbi.nlm.nih.gov/pubmed/27627138"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26058916",
                    "text": "Trismus is characterized by a reduced ability to open the mouth, directly affecting many aspects of daily life, such as chewing, swallowing, speaking and maintaining oral hygiene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26058916",
                    "text": "Radiotherapy in the head and neck area is identified as one of the most frequent causes of trismus in head and neck cancer (HNC) patients.",
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 398,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23193958",
                    "text": "Trismus severely impairs HRQL and negatively affects daily life activities in patients with H&N cancer.",
                    "offsetInBeginSection": 1632,
                    "offsetInEndSection": 1735,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236743",
                    "text": "Trismus is a serious problem for some patients after oral and oropharyngeal cancer, and it has a detrimental impact on quality of life and function.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669774",
                    "text": "UNLABELLED Trismus, a well-known sequelae after treatment of head and neck cancer, decreases a patient's oral function and quality of life.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22632890",
                    "text": "Trismus is frequently a sequel of temporomandibular joint (TMJ) involvement in a zygomaticomaxillary complex (ZMC) fracture.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28122104",
                    "text": "In conclusion, exercise with TheraBite improved MIO and trismus-related symptoms in patients with trismus secondary to head and neck cancer.",
                    "offsetInBeginSection": 1050,
                    "offsetInEndSection": 1190,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28122104",
                    "text": "Trismus is a common symptom in patients with head and neck cancer that affects many aspects of daily life negatively.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27461633",
                    "text": "Early rehabilitative measures are useful in preventing progression of trismus.",
                    "offsetInBeginSection": 1981,
                    "offsetInEndSection": 2059,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27627138",
                    "text": "BACKGROUND Trismus, a restricted mouth opening in head and neck cancer patients may be caused by tumor infiltration in masticatory muscles, radiation-induced fibrosis or scarring after surgery.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67ab79b750ff445500000b",
            "body": "CURB65 score is used for stratification of which disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28168816",
                "http://www.ncbi.nlm.nih.gov/pubmed/20529344",
                "http://www.ncbi.nlm.nih.gov/pubmed/20920140",
                "http://www.ncbi.nlm.nih.gov/pubmed/18304365",
                "http://www.ncbi.nlm.nih.gov/pubmed/16928720",
                "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                "http://www.ncbi.nlm.nih.gov/pubmed/24931899"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529344",
                    "text": "METHODS We assessed clinical parameters and five biomarkers, the precursor levels of adrenomedullin (ADM), endothelin-1 (ET1), atrial-natriuretic peptide (ANP), anti-diuretic hormone (copeptin), and procalcitonin in patients with LRTI and CAP enrolled in the multicenter ProHOSP study.",
                    "offsetInBeginSection": 232,
                    "offsetInEndSection": 517,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20920140",
                    "text": "The CURB65 score was as effective in predicting early mortality in our cohort of acute COPD exacerbations as it was in previous cohorts with community acquired pneumonia.",
                    "offsetInBeginSection": 1509,
                    "offsetInEndSection": 1679,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20920140",
                    "text": "The CURB65 score was developed to predict mortality risk in community acquired pneumonia.",
                    "offsetInBeginSection": 228,
                    "offsetInEndSection": 317,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "CONCLUSIONS The new CURB65-A risk score combining CURB65 risk classes with ProADM cut-off values accurately predicts adverse events and mortality in patients with CAP and non-CAP-LRTI.",
                    "offsetInBeginSection": 1744,
                    "offsetInEndSection": 1928,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "We aimed to derive a practical algorithm combining the CURB65 score with ProADM-levels in patients with community-acquired pneumonia (CAP) and non-CAP-LRTI.",
                    "offsetInBeginSection": 162,
                    "offsetInEndSection": 318,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "RESULTS CURB65 and ProADM predicted both adverse events and mortality similarly well in CAP and non-CAP-LRTI.",
                    "offsetInBeginSection": 658,
                    "offsetInEndSection": 767,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "The combined CURB65-A risk score provided better prediction of death and adverse events than the CURB65 score in the entire cohort and in CAP and non-CAP-LRTI patients.",
                    "offsetInBeginSection": 768,
                    "offsetInEndSection": 936,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "A composite score (CURB65-A) was created combining CURB65 classes with ProADM cut-offs to further risk-stratify patients.",
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 655,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539743",
                    "text": "If outpatient treatment was recommended for CURB65-A risk class I and short hospitalization for CURB65-A risk class II, 17.9% and 40.8% of 1217 hospitalized patients could have received ambulatory treatment or a short hospitalization, respectively.",
                    "offsetInBeginSection": 1493,
                    "offsetInEndSection": 1741,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24931899",
                    "text": "CONCLUSION Presepsin is a valuable biomarker in predicting severity and outcome in CAP patients in the ED and Presepsin in combination with CURB65 score significantly enhanced the predictive accuracy.",
                    "offsetInBeginSection": 1704,
                    "offsetInEndSection": 1904,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6cfe27b750ff4455000029",
            "body": "What is SMiLE-seq?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28092692"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                    "text": "Here, we present a novel, semiautomated protein-DNA interaction characterization technology, selective microfluidics-based ligand enrichment followed by sequencing (SMiLE-seq).",
                    "offsetInBeginSection": 127,
                    "offsetInEndSection": 303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                    "text": "SMiLE-seq is neither limited by DNA bait length nor biased toward strong affinity binders; it probes the DNA-binding properties of TFs over a wide affinity range in a fast and cost-effective fashion.",
                    "offsetInBeginSection": 304,
                    "offsetInEndSection": 503,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                    "text": "We validated SMiLE-seq by analyzing 58 full-length human, mouse, and Drosophila TFs from distinct structural classes.",
                    "offsetInBeginSection": 504,
                    "offsetInEndSection": 621,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                    "text": "De novo motif discovery on all JUN-FOS heterodimers and several nuclear receptor-TF complexes provided novel insights into partner-specific heterodimer DNA-binding preferences.",
                    "offsetInBeginSection": 747,
                    "offsetInEndSection": 923,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                    "text": "We also successfully analyzed the DNA-binding properties of uncharacterized human C2H2 zinc-finger proteins and validated several using ChIP-exo.",
                    "offsetInBeginSection": 924,
                    "offsetInEndSection": 1069,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                    "text": "Resolving the DNA-binding specificities of transcription factors (TFs) is of critical value for understanding gene regulation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28092692",
                    "text": "All tested TFs yielded DNA-binding models with predictive power comparable to or greater than that of other in vitro assays.",
                    "offsetInBeginSection": 622,
                    "offsetInEndSection": 746,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a77072c9e632bc06600000a",
            "body": "What is craniosynostosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29093661",
                "http://www.ncbi.nlm.nih.gov/pubmed/17980312",
                "http://www.ncbi.nlm.nih.gov/pubmed/27622416",
                "http://www.ncbi.nlm.nih.gov/pubmed/27226847",
                "http://www.ncbi.nlm.nih.gov/pubmed/26910679",
                "http://www.ncbi.nlm.nih.gov/pubmed/24071792",
                "http://www.ncbi.nlm.nih.gov/pubmed/20108486",
                "http://www.ncbi.nlm.nih.gov/pubmed/28623672",
                "http://www.ncbi.nlm.nih.gov/pubmed/28654618",
                "http://www.ncbi.nlm.nih.gov/pubmed/18344207"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29093661",
                    "text": "Syndromic forms of craniosynostosis arise from mutations in genes belonging to the Fibroblast Growth Factor Receptor (FGFR) family and the interconnected molecular pathways in most cases.",
                    "offsetInBeginSection": 361,
                    "offsetInEndSection": 548,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27622416",
                    "text": "Prenatal ultrasound`s detection rate of craniosynostosis is low.",
                    "offsetInBeginSection": 735,
                    "offsetInEndSection": 799,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27226847",
                    "text": "FGFR2, FGFR3, FGFR1, TWIST1 and EFNB1 genes are major causative genes of genetic syndromes associated with craniosynostosis.",
                    "offsetInBeginSection": 632,
                    "offsetInEndSection": 756,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26910679",
                    "text": "Among various craniosynostosis forms, sagittal nonsyndromic craniosynostosis is the most prevalent.",
                    "offsetInBeginSection": 114,
                    "offsetInEndSection": 213,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26910679",
                    "text": "FGFR1-3 mutational hotspots and the entire TWIST1, RAB23, and BMP2 coding regions were screened because of their known roles in human nonsyndromic or syndromic sagittal craniosynostosis, expression patterns, and/or animal model studies.",
                    "offsetInBeginSection": 615,
                    "offsetInEndSection": 851,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24071792",
                    "text": "RESULTS The incidence rate of craniosynostosis was highest for first-degree relatives of probands with metopic craniosynostosis (6.4%), followed by those with complex craniosynostosis (4.9%), sagittal craniosynostosis (3.8%), lambdoid craniosynostosis (3.9%), and coronal craniosynostosis (0.7%).",
                    "offsetInBeginSection": 457,
                    "offsetInEndSection": 753,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20108486",
                    "text": "Mutations in the genes encoding fibroblast growth factor receptors 1, 2 and 3 (FGFR-1, FGFR-2, FGFR-3), TWIST and MSX2 (muscle segment homebox 2) have been identified in certain syndromic craniosynostosis.",
                    "offsetInBeginSection": 814,
                    "offsetInEndSection": 1019,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28623672",
                    "text": "Craniosynostosis is a developmental craniofacial anomaly, resulting in impairment of brain development and abnormally shaped skull.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28654618",
                    "text": "When anomalies outside the skull are present, craniosynostosis is often part of a syndrome and usually involves multiple sutures (syndromic craniosynostosis).",
                    "offsetInBeginSection": 1017,
                    "offsetInEndSection": 1175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28654618",
                    "text": "Understand the craniofacial dysmorphology associated with nonsyndromic craniosynostosis.",
                    "offsetInBeginSection": 86,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67b152b750ff445500000e",
            "body": "Describe nursemaid's elbow injury.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19657259",
                "http://www.ncbi.nlm.nih.gov/pubmed/27294496",
                "http://www.ncbi.nlm.nih.gov/pubmed/21317693",
                "http://www.ncbi.nlm.nih.gov/pubmed/11153321",
                "http://www.ncbi.nlm.nih.gov/pubmed/7773660",
                "http://www.ncbi.nlm.nih.gov/pubmed/7560033"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259",
                    "text": "Activities such as swinging a child by the hands or pulling on the pronated upper extremity can cause nursemaid's elbow.",
                    "offsetInBeginSection": 324,
                    "offsetInEndSection": 444,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259",
                    "text": "Nursemaid's elbow is a common injury in young children that can often be prevented.",
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 227,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259",
                    "text": "Prevention of nursemaid's elbow in children may be accomplished with education of parents, daycare workers, and teachers on the mechanism of this common injury.",
                    "offsetInBeginSection": 445,
                    "offsetInEndSection": 605,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19657259",
                    "text": "This injury occurs when the radial head subluxates from its normal position at the elbow joint.",
                    "offsetInBeginSection": 228,
                    "offsetInEndSection": 323,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496",
                    "text": "This article also reviews successful reduction maneuvers for nursemaid's elbow.",
                    "offsetInBeginSection": 803,
                    "offsetInEndSection": 882,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294496",
                    "text": "Nursemaid's elbow and elbow fractures are both common causes of acute elbow pain, but the mechanism of injury is quite different.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317693",
                    "text": "Nursemaid's elbow (subluxation of the radial head) is a common pediatric upper extremity injury encountered in the emergency and urgent care settings.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11153321",
                    "text": "Nursemaid's elbow, also known as a pulled elbow or a subluxated radial head, may result from the specific activities described above and is the most common dislocation injury handled by pediatricians.",
                    "offsetInBeginSection": 520,
                    "offsetInEndSection": 720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7773660",
                    "text": "Subluxation of the radial head, or \"nursemaid's elbow,\" is a common injury among children aged 1 to 4 years.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7560033",
                    "text": "Acute annular ligament interposition into the radiocapitellar joint (\"nursemaid's elbow\") is a common injury in children younger than 5 years.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d08d5b750ff445500002c",
            "body": "Which stapled peptide has been designed to target Ctf4?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28815832"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "Herein, we report the design, optimization, and validation of double-click stapled peptides encoding the Ctf4-interacting peptide (CIP) of the replicative helicase subunit Sld5.",
                    "offsetInBeginSection": 313,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "By screening stapling positions in the Sld5 CIP, we identified an unorthodox i,i+6 stapled peptide with improved, submicromolar binding to Ctf4.",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 635,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "The mode of interaction with Ctf4 was confirmed by a crystal structure of the stapled Sld5 peptide bound to Ctf4.",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "The stapled Sld5 peptide was able to displace the Ctf4 partner DNA polymerase\u2005\u03b1 from the replisome in yeast extracts.",
                    "offsetInBeginSection": 750,
                    "offsetInEndSection": 870,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "The Ctf4/AND-1 protein hub, which links DNA replication, repair, and chromosome segregation, represents a novel target for the synthetic lethality approach.",
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 312,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "Our study provides proof-of-principle evidence for the development of small-molecule inhibitors of the human CTF4 orthologue AND-1.",
                    "offsetInBeginSection": 871,
                    "offsetInEndSection": 1002,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28815832",
                    "text": "The exploitation of synthetic lethality by small-molecule targeting of pathways that maintain genomic stability is an attractive chemotherapeutic approach.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a773c50faa1ab7d2e000002",
            "body": "Has ATF4 transcription factor been linked to cancer and neoplastic transformation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                "http://www.ncbi.nlm.nih.gov/pubmed/21338441"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "text": "Here, we report that ATF4 promotes oncogene-induced neoplastic transformation by suppressing the expression of cellular senescence-associated genes.",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 409,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "text": "Many cancers overexpress ATF4, a stress-induced transcription factor that promotes cell survival under hypoxic conditions and other stresses of the tumor microenvironment, but the potential contributions of ATF4 to oncogenesis itself have been little explored.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 260,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "text": "In wild-type cells these oncogenes induced expression of the murine Atf4 gene along with the cyclin-dependent kinase inhibitor Cdkn2a, which encodes the cell senescence-associated proteins p16INK4 and p19ARF.",
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 771,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "text": "Conversely, genetic ablation of ATF4 led to constitutive expression of p16INK4a and p19ARF, triggering cellular senescence.",
                    "offsetInBeginSection": 889,
                    "offsetInEndSection": 1012,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "text": "Our findings define a central function for ATF4 in promoting oncogenic transformation by suppressing a central pathway of cellular senescence.",
                    "offsetInBeginSection": 1013,
                    "offsetInEndSection": 1155,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "text": "Elevated levels of ATF4 were sufficient to suppress expression of these proteins and drive oncogenic transformation.",
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "text": "Strikingly, primary embryo fibroblasts from ATF4-deficient mice were resistant to transformation by coexpression of H-ras(V12) and SV40 large T antigen.",
                    "offsetInBeginSection": 410,
                    "offsetInEndSection": 562,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441",
                    "text": "These include mitogen-activated protein kinase kinase (MAPKK), CCAAT/enhancer-binding protein (C/EBP), activating transcription factor 4 (ATF4) and C/EBP-homologous protein (CHOP).",
                    "offsetInBeginSection": 234,
                    "offsetInEndSection": 414,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441",
                    "text": "The RAS/mitogen-activated protein kinase (MAPK) pathway molecules (in particular MAPK/ERK kinase 1 (MEK1) and C/EBP transcription factors) include tribbles-binding proteins that are involved in leukemogenesis, and the role of Trib1 as a linker between MAPK signaling and C/EBP degradation is proposed.",
                    "offsetInBeginSection": 641,
                    "offsetInEndSection": 942,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21338441",
                    "text": "Tribbles proteins are also involved in a series of non-neoplastic disorders including metabolic and neurological diseases.",
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 640,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68eabab750ff4455000015",
            "body": "Is there an association between Klinefelter syndrome and breast cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22274665",
                "http://www.ncbi.nlm.nih.gov/pubmed/16106025",
                "http://www.ncbi.nlm.nih.gov/pubmed/1690312",
                "http://www.ncbi.nlm.nih.gov/pubmed/7841064",
                "http://www.ncbi.nlm.nih.gov/pubmed/9283592",
                "http://www.ncbi.nlm.nih.gov/pubmed/21246928",
                "http://www.ncbi.nlm.nih.gov/pubmed/3111653",
                "http://www.ncbi.nlm.nih.gov/pubmed/11976824",
                "http://www.ncbi.nlm.nih.gov/pubmed/23464700",
                "http://www.ncbi.nlm.nih.gov/pubmed/20698148"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16106025",
                    "text": "CONCLUSIONS These results support a hormonal etiology for breast cancer in men and for prostate cancer and suggest that men with Klinefelter syndrome may be at substantially elevated risks for non-Hodgkin lymphoma, breast cancer, and, perhaps, lung cancer.",
                    "offsetInBeginSection": 1368,
                    "offsetInEndSection": 1624,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16106025",
                    "text": "Compared with the general population, men with Klinefelter syndrome had higher mortality from lung cancer (SMR = 1.5, 95% CI = 1.0 to 2.0), breast cancer (SMR = 57.8, 95% CI = 18.8 to 135.0), and non-Hodgkin lymphoma (SMR = 3.5, 95% CI = 1.6 to 6.6) and lower mortality from prostate cancer (SMR = 0, 95% CI = 0 to 0.7).",
                    "offsetInBeginSection": 737,
                    "offsetInEndSection": 1057,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7841064",
                    "text": "Many case reports have suggested an association between Klinefelter syndrome (KS) and cancer, but studies of the cancer incidence in larger groups of men with KS are lacking.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9283592",
                    "text": "Patients with a 47,XXY karyotype (Klinefelter syndrome) appear to have an increased risk of developing cancer, especially male breast cancer and germ cell tumors, but rarely malignant hematologic disorders.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21246928",
                    "text": "Klinefelter syndrome has been consistently associated with breast cancer in men (MBC).",
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21246928",
                    "text": "Klinefelter syndrome, in which patients carry XXY chromosome, may be present in men with breast cancer for this reason they often develop gynecomastia.",
                    "offsetInBeginSection": 1285,
                    "offsetInEndSection": 1436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3111653",
                    "text": "There is evidence, however, to suggest that Klinefelter's males have an increased risk of breast cancer that approaches three percent.",
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 457,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11976824",
                    "text": "Since the early 1960s, numerous reports have appeared of an increased risk of malignant neoplasms among patients with Klinefelter syndrome.",
                    "offsetInBeginSection": 439,
                    "offsetInEndSection": 578,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23464700",
                    "text": "Male breast cancer risk factors show strong association with BRCA2 mutations, as well as Klinefelter syndrome.",
                    "offsetInBeginSection": 418,
                    "offsetInEndSection": 528,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20698148",
                    "text": "Patients with 47, XXY karyotype (Klinefelter syndrome) appear to have increased risk of developing cancer, especially male breast cancer, germ cell tumours and non Hodgkin lymphomas, but rarely acute myeloid leukaemia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d1733b750ff4455000030",
            "body": "Which resource contains accurate enhancer predictions in the developing limb?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28827824"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "Here we present the Limb-Enhancer Genie (LEG), a collection of highly accurate, genome-wide predictions of enhancers in the developing limb, available through a user-friendly online interface.",
                    "offsetInBeginSection": 415,
                    "offsetInEndSection": 607,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "We predict limb enhancers using a combination of >50 published limb-specific datasets and clusters of evolutionarily conserved transcription factor binding sites, taking advantage of the patterns observed at previously in vivo validated elements.",
                    "offsetInBeginSection": 608,
                    "offsetInEndSection": 854,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "Moreover, we describe general features that can guide the type of datasets to include when predicting tissue-specific enhancers genome-wide, while providing an accessible resource to the general biological community and facilitating the functional interpretation of genetic studies of limb malformations.",
                    "offsetInBeginSection": 1285,
                    "offsetInEndSection": 1589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "Epigenomic mapping of enhancer-associated chromatin modifications facilitates the genome-wide discovery of tissue-specific enhancers in vivo.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "More sophisticated, integrative methods have been described, but commonly suffer from limited accessibility to the resulting predictions and reduced biological interpretability.",
                    "offsetInBeginSection": 237,
                    "offsetInEndSection": 414,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "However, reliance on single chromatin marks leads to high rates of false-positive predictions.",
                    "offsetInBeginSection": 142,
                    "offsetInEndSection": 236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "Our results indicate that including a previously unappreciated score that quantifies tissue-specific nuclease accessibility significantly improves prediction performance.",
                    "offsetInBeginSection": 1015,
                    "offsetInEndSection": 1185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "By combining different statistical models, our approach outperforms current state-of-the-art methods and provides interpretable measures of feature importance.",
                    "offsetInBeginSection": 855,
                    "offsetInEndSection": 1014,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28827824",
                    "text": "We demonstrate the utility of our approach through in vivo validation of newly predicted elements.",
                    "offsetInBeginSection": 1186,
                    "offsetInEndSection": 1284,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7877c0faa1ab7d2e00000c",
            "body": "What is the first line treatment for sarcoidosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26357609",
                "http://www.ncbi.nlm.nih.gov/pubmed/28696638",
                "http://www.ncbi.nlm.nih.gov/pubmed/26478443",
                "http://www.ncbi.nlm.nih.gov/pubmed/26419478",
                "http://www.ncbi.nlm.nih.gov/pubmed/26120005",
                "http://www.ncbi.nlm.nih.gov/pubmed/26330764",
                "http://www.ncbi.nlm.nih.gov/pubmed/23196575",
                "http://www.ncbi.nlm.nih.gov/pubmed/27598883",
                "http://www.ncbi.nlm.nih.gov/pubmed/27846819",
                "http://www.ncbi.nlm.nih.gov/pubmed/10719453"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357609",
                    "text": "For symptomatic patients, the first line treatment includes corticosteroids or ursodeoxycholic acid.",
                    "offsetInBeginSection": 892,
                    "offsetInEndSection": 992,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28696638",
                    "text": "Systemic corticosteroids are the first line treatment in sarcoidosis.",
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 392,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26419478",
                    "text": "While corticosteroids remain the first line of treatment, tumour necrosis factor alpha (TNF-\u03b1) inhibitors have been investigated as one potential steroid sparing treatment for sarcoidosis.",
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 311,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26419478",
                    "text": "Paradoxically, in some patients treated with biologic TNF-\u03b1 inhibitors for other diseases, treatment can induce the development of sarcoidosis.",
                    "offsetInBeginSection": 541,
                    "offsetInEndSection": 685,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26120005",
                    "text": "This case reports a rare presentation of preschool sarcoidosis as well as the novel and successful use of pulse methylprednisolone in paediatric pulmonary sarcoidosis.",
                    "offsetInBeginSection": 505,
                    "offsetInEndSection": 672,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26330764",
                    "text": "Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases.",
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 474,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26330764",
                    "text": "Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 272,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196575",
                    "text": "For patients who are refractory to or intolerant of corticosteroid therapy, second-line agents include azathioprine, methotrexate, cyclosporine, cyclophosphamide, and mycophenolate mofetil (MMF).",
                    "offsetInBeginSection": 1008,
                    "offsetInEndSection": 1203,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27598883",
                    "text": "Oral corticosteroids are the first line of treatment.",
                    "offsetInBeginSection": 1211,
                    "offsetInEndSection": 1264,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10719453",
                    "text": "TREATMENT Corticosteroid therapy is given as first line treatment with a satisfactory effect in most cases.",
                    "offsetInBeginSection": 817,
                    "offsetInEndSection": 924,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68f005b750ff4455000016",
            "body": "Which personality disorder is treated using dialectical behavior therapy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16173357",
                "http://www.ncbi.nlm.nih.gov/pubmed/17496179",
                "http://www.ncbi.nlm.nih.gov/pubmed/9603574",
                "http://www.ncbi.nlm.nih.gov/pubmed/7977884",
                "http://www.ncbi.nlm.nih.gov/pubmed/15930077",
                "http://www.ncbi.nlm.nih.gov/pubmed/19755574",
                "http://www.ncbi.nlm.nih.gov/pubmed/20579633",
                "http://www.ncbi.nlm.nih.gov/pubmed/27642799",
                "http://www.ncbi.nlm.nih.gov/pubmed/18186120",
                "http://www.ncbi.nlm.nih.gov/pubmed/25373068"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173357",
                    "text": "Treatment outcome data for Dialectical Behavior Therapy of borderline personality disorder and Trauma Model Therapy of dissociative identity disorder are reviewed.",
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 340,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17496179",
                    "text": "OBJECTIVE The authors describe the use of dialectical behavior therapy (DBT) in treating borderline personality disorder during psychiatry residency, and assess the status of DBT education within psychiatry residencies in the United States.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 240,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9603574",
                    "text": "Dialectical behavior therapy, an outpatient psychosocial treatment for chronically suicidal women with borderline personality disorder, has been adapted for use in a partial hospital program for women.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7977884",
                    "text": "CONCLUSIONS These results suggest that dialectical behavior therapy is a promising psychosocial intervention for improving interpersonal functioning among severely dysfunctional patients with borderline personality disorder.",
                    "offsetInBeginSection": 882,
                    "offsetInEndSection": 1106,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15930077",
                    "text": "OBJECTIVE The aim of this study was to determine the efficacy and safety of dialectical behavior therapy plus olanzapine compared with dialectical behavior therapy plus placebo in patients with borderline personality disorder.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19755574",
                    "text": "CONCLUSIONS These results suggest that individuals with borderline personality disorder benefited equally from dialectical behavior therapy and a well-specified treatment delivered by psychiatrists with expertise in the treatment of borderline personality disorder.",
                    "offsetInBeginSection": 1458,
                    "offsetInEndSection": 1723,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20579633",
                    "text": "A central component of Dialectical Behavior Therapy (DBT) is the teaching of specific behavioral skills with the aim of helping individuals with Borderline Personality Disorder (BPD) replace maladaptive behaviors with skillful behavior.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27642799",
                    "text": "Dialectical behavior therapy (DBT) was originally developed by Marsha Linehan (1991) for the treatment of borderline personality disorder, but because of the core deficits in emotion regulation in disruptive behavior disorders, DBT is also increasingly being recommended for the treatment of CD and APD.",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 646,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18186120",
                    "text": "Dialectical behavior therapy (DBT) was originally designed as a treatment of emotionally dysregulated, impulsive, and dramatic disorders (e.g., borderline personality disorder) and populations (e.g., parasuicidal women).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 220,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25373068",
                    "text": "CONTEXT Dialectical Behavior Therapy (DBT) is an evidence-based therapy developed for the treatment of suicidal behaviors and disorders characterized by emotional and behavioral dyscontrol that is effective in veteran populations.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d186db750ff4455000031",
            "body": "Is there any role of Dlx1 and Dlx2 transcription factors in cortical interneurons?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29028947",
                "http://www.ncbi.nlm.nih.gov/pubmed/17259176",
                "http://www.ncbi.nlm.nih.gov/pubmed/17582322",
                "http://www.ncbi.nlm.nih.gov/pubmed/28821666",
                "http://www.ncbi.nlm.nih.gov/pubmed/16766712",
                "http://www.ncbi.nlm.nih.gov/pubmed/19026749"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028947",
                    "text": "The postnatal functions of the Dlx1&2 transcription factors in cortical interneurons (CINs) are unknown.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176",
                    "text": "Dlx1/Dlx2 null mice die at birth with an abnormal cortical phenotype, including impaired differentiation and migration of GABAergic interneurons to the neocortex.",
                    "offsetInBeginSection": 79,
                    "offsetInEndSection": 241,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176",
                    "text": "This is the first report that DLX1 or DLX2 can function as transcriptional repressors.",
                    "offsetInBeginSection": 967,
                    "offsetInEndSection": 1053,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259176",
                    "text": "Of importance, there is up-regulated and aberrant expression of NRP-2 in the forebrains of Dlx1/Dlx2 null mice.",
                    "offsetInBeginSection": 855,
                    "offsetInEndSection": 966,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17582322",
                    "text": "In this issue of Neuron, Rubenstein and colleagues demonstrate that the homeobox proteins Dlx1 and Dlx2 promote interneuron migration in part by preventing the premature expression of PAK3, a serine/threonine kinase that is later involved in neurite outgrowth and other aspects of interneuron maturation.",
                    "offsetInBeginSection": 172,
                    "offsetInEndSection": 476,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28821666",
                    "text": "DLX1 and/or DLX2 activated the transcription of both Gad genes, and defects in Dlx function disrupted the differentiation of GABAergic interneurons with global reduction in GABA levels in the forebrains of the Dlx1/Dlx2 double knock-out mouse in vivo Identification of Gad genes as direct Dlx transcriptional targets is significant; it extends our understanding of Dlx gene function in the developing forebrain beyond the regulation of tangential interneuron migration to the differentiation of GABAergic interneurons arising from the basal telencephalon, and may help to unravel the pathogenesis of several developmental brain disorders.SIGNIFICANCE STATEMENT GABA is the major inhibitory neurotransmitter in the brain.",
                    "offsetInBeginSection": 1014,
                    "offsetInEndSection": 1734,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28821666",
                    "text": "We have discovered that specific promoter regulatory elements of glutamic acid decarboxylase isoforms (Gad1 and Gad2), which regulate GABA synthesis from the excitatory neurotransmitter glutamate, are direct transcriptional targets of both DLX1 and DLX2 homeoproteins in vivo Further gain- and loss-of-function studies in vitro and in vivo demonstrated that both DLX1 and DLX2 are necessary and sufficient for Gad gene expression.",
                    "offsetInBeginSection": 583,
                    "offsetInEndSection": 1013,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28821666",
                    "text": "We show that Dlx1/Dlx2 homeobox genes regulate GABA synthesis during forebrain development through direct activation of glutamic acid decarboxylase enzyme isoforms that convert glutamate to GABA.",
                    "offsetInBeginSection": 1735,
                    "offsetInEndSection": 1930,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16766712",
                    "text": "Toward elucidating the mechanisms underlying the generation of interneuron diversity, we have studied in mice the expression patterns in differentiating and mature neocortical interneurons of 8 transcription factors, including 6 homeobox (Dlx1, Dlx2, Dlx5, Arx, Lhx6, Cux2), 1 basic helix-loop-helix, (NPAS1), and 1 bZIP (MafB).",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026749",
                    "text": "DLX1 and DLX2 transcription factors are necessary for forebrain GABAergic neuron differentiation, migration, and survival.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a79d0b8faa1ab7d2e00000d",
            "body": "What cellular process are okazaki fragments associated with?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21278448",
                "http://www.ncbi.nlm.nih.gov/pubmed/14693726",
                "http://www.ncbi.nlm.nih.gov/pubmed/28159842",
                "http://www.ncbi.nlm.nih.gov/pubmed/23451868",
                "http://www.ncbi.nlm.nih.gov/pubmed/25814667",
                "http://www.ncbi.nlm.nih.gov/pubmed/19779567",
                "http://www.ncbi.nlm.nih.gov/pubmed/24035200",
                "http://www.ncbi.nlm.nih.gov/pubmed/227871",
                "http://www.ncbi.nlm.nih.gov/pubmed/16427006",
                "http://www.ncbi.nlm.nih.gov/pubmed/21441898"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448",
                    "text": "Therefore, efficient processing of Okazaki fragments is vital for DNA replication and cell proliferation.",
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 368,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278448",
                    "text": "During this process, primase-synthesized RNA/DNA primers are removed, and Okazaki fragments are joined into an intact lagging strand DNA.",
                    "offsetInBeginSection": 369,
                    "offsetInEndSection": 506,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28159842",
                    "text": "During DNA replication in eukaryotic cells, short single-stranded DNA segments known as Okazaki fragments are first synthesized on the lagging strand.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28159842",
                    "text": "The Okazaki fragments originate from \u223c35-nucleotide-long RNA-DNA primers.",
                    "offsetInBeginSection": 151,
                    "offsetInEndSection": 226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23451868",
                    "text": "Substrate specificity allows FEN1 to process intermediates of Okazaki fragment maturation, long-patch base excision repair, telomere maintenance, and stalled replication fork rescue.",
                    "offsetInBeginSection": 206,
                    "offsetInEndSection": 388,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25814667",
                    "text": "During replication, Okazaki fragment maturation is a fundamental process that joins discontinuously synthesized DNA fragments into a contiguous lagging strand.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19779567",
                    "text": "We propose that TbPIF5 unwinds RNA primers after lagging strand synthesis, thus facilitating processing of Okazaki fragments.",
                    "offsetInBeginSection": 1315,
                    "offsetInEndSection": 1440,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24035200",
                    "text": "Lagging strand DNA replication requires the concerted actions of DNA polymerase \u03b4, Fen1 and DNA ligase I for the removal of the RNA/DNA primers before ligation of Okazaki fragments.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/227871",
                    "text": "These intermediates accumulated during excision of RNA primers in the presence of adenine 9-beta-D-arabinoside 5'-triphosphate, and those Okazaki fragments blocked by RNA primers (class III) were found to have originated the farthest from the 5' ends of long nascent DNA strands.",
                    "offsetInBeginSection": 2359,
                    "offsetInEndSection": 2638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/227871",
                    "text": "However, when washed nuclei were incubated in the abscence of cytosol, both class I and class II Okazaki fragments accumulated despite the excision of RNA primers: class III Okazaki fragments and RNA-DNA covalent linkages both disappeared at similar rates.",
                    "offsetInBeginSection": 1172,
                    "offsetInEndSection": 1428,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68f633b750ff4455000019",
            "body": "Is creatinine assessment included in the MELD score?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27480755",
                "http://www.ncbi.nlm.nih.gov/pubmed/15482344",
                "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                "http://www.ncbi.nlm.nih.gov/pubmed/24601755",
                "http://www.ncbi.nlm.nih.gov/pubmed/22380485",
                "http://www.ncbi.nlm.nih.gov/pubmed/20827408",
                "http://www.ncbi.nlm.nih.gov/pubmed/17370333",
                "http://www.ncbi.nlm.nih.gov/pubmed/22178107",
                "http://www.ncbi.nlm.nih.gov/pubmed/27779785",
                "http://www.ncbi.nlm.nih.gov/pubmed/18482269"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344",
                    "text": "The MELD score has a short-term prognostic yield that is better than what is provided by both the CTP and CTP creatinine-modified scores, even in cirrhotic patients who are not critically ill.",
                    "offsetInBeginSection": 1912,
                    "offsetInEndSection": 2104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15482344",
                    "text": "However, the MELD score proved to be better at defining patients' prognosis in the short-term as compared with both the traditional CTP score (P=0.012) and the creatinine-modified CTP (P=0.047).",
                    "offsetInBeginSection": 1404,
                    "offsetInEndSection": 1598,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                    "text": "CONCLUSION Incorporating eGFR obtained by the 6-variable MDRD equation into the MELD score showed an equal predictive performance in in-hospital mortality compared to a creatinine-based MELD score.",
                    "offsetInBeginSection": 3159,
                    "offsetInEndSection": 3356,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                    "text": "MELD-MDRD-6 included 6-variable MDRD eGFR as one of the variables and showed an improvement over MELD score, as suggested by an increase in chi-square (2293.82 vs 2198.32) and a decrease in -2 log (likelihood) (2810.77 vs 2664.79).",
                    "offsetInBeginSection": 2353,
                    "offsetInEndSection": 2584,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                    "text": "Finally, when serum creatinine was replaced by CKD-EPI eGFR, it showed a slight improvement compared to the original MELD score (chi-square: 2199.16, -2 log (likelihood): 2773.07).",
                    "offsetInBeginSection": 2585,
                    "offsetInEndSection": 2765,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293714",
                    "text": "MELD-MDRD-4 excluded serum creatinine, with the coefficients refit among the remaining 3 variables, i.e., total bilirubin, INR and 4-variable MDRD eGFR.",
                    "offsetInBeginSection": 2014,
                    "offsetInEndSection": 2166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24601755",
                    "text": "The MELD-Bicarbonate equation, which included three variables (international normalized ratio, creatinine level, and HCO3 level), showed better prognostic value than the original MELD score in critically ill patients with cirrhosis.",
                    "offsetInBeginSection": 1362,
                    "offsetInEndSection": 1594,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20827408",
                    "text": "Changes in MELD score simple during the admission, which were calculated by CRE and TBI [3.8 \u00d7 log (bilirubin (mg/dl)] + 9.6 \u00d7 log [Creatinine (mg/dl) + 6.43], were significant predictor for patients with type 1 HRS.",
                    "offsetInBeginSection": 1423,
                    "offsetInEndSection": 1641,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17370333",
                    "text": "Univariate analysis showed that age, duration of jaundice, jaundice-encephalopathy interval (JEI), grade of encephalopathy, presence of cerebral edema, bilirubin, prothrombin time, creatinine, and MELD score were significantly different between survivors and nonsurvivors.",
                    "offsetInBeginSection": 787,
                    "offsetInEndSection": 1059,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22178107",
                    "text": "MELD score, CKD-EPI formula creatinine-based eGFR and cystatin C-based eGFR were evaluated in 100 cirrhotic patients.",
                    "offsetInBeginSection": 466,
                    "offsetInEndSection": 583,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d196db750ff4455000032",
            "body": "Which resource has been developed in order to study the transcriptional regulation of GABAergic cell fate?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27710791"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27710791",
                    "text": "Thus, these subpallial enhancer transgenic lines are data and tool\u00a0resources to study transcriptional regulation of GABAergic cell fate.",
                    "offsetInBeginSection": 896,
                    "offsetInEndSection": 1033,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27710791",
                    "text": "Elucidating the transcriptional circuitry controlling forebrain development requires an understanding of\u00a0enhancer activity and regulation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27710791",
                    "text": "We used these unique tools to generate a comprehensive regional fate map of the mouse subpallium, including sources for specific subtypes of amygdala neurons.",
                    "offsetInBeginSection": 319,
                    "offsetInEndSection": 477,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27710791",
                    "text": "We then focused on deciphering transcriptional mechanisms that control enhancer activity.",
                    "offsetInBeginSection": 478,
                    "offsetInEndSection": 567,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27710791",
                    "text": "Using machine-learning computations, in\u00a0vivo chromosomal occupancy of 13 transcription factors that regulate subpallial patterning and differentiation and analysis of enhancer activity in Dlx1/2 and Lhx6 mutants, we elucidated novel molecular mechanisms that regulate region-specific enhancer activity in the developing brain.",
                    "offsetInBeginSection": 568,
                    "offsetInEndSection": 895,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27710791",
                    "text": "We generated stable transgenic mouse lines that express CreERT2 and GFP from ten different enhancer elements with activity in distinct domains within the embryonic basal ganglia.",
                    "offsetInBeginSection": 140,
                    "offsetInEndSection": 318,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a79d195faa1ab7d2e00000e",
            "body": "Is celiac disease caused by gliadin-induced transglutaminase-2 (TG2)-dependent events ?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24240659"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                    "text": "The present study examined the capability of different oat cultivars of activating the gliadin-induced transglutaminase-2 (TG2)-dependent events in some in vitro models of CD.",
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 450,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                    "text": "PURPOSE Celiac disease (CD) is an autoimmune enteropathy, triggered by dietary gluten.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                    "text": "CONCLUSION We found significant differences among oat cultivars in eliciting the TG2-mediated events of CD inflammation.",
                    "offsetInBeginSection": 1125,
                    "offsetInEndSection": 1245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                    "text": "METHODS K562(S) cells agglutination, transepithelial electrical resistance of T84-cell monolayers, intracellular levels of TG2 and phosphorylated form of protein 42-44 in T84 cells were the early gliadin-dependent events studied.",
                    "offsetInBeginSection": 591,
                    "offsetInEndSection": 820,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                    "text": "The ability of a cultivar to activate the above-described events was associated with the electrophoretic pattern of oat proteins and their reactivity to anti-gliadin antibodies.",
                    "offsetInBeginSection": 945,
                    "offsetInEndSection": 1122,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                    "text": "Oats are included in the list of gluten-free ingredients by European Regulation, but the safety of oats in CD is still a matter of debate.",
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 274,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                    "text": "The only treatment is a strict gluten-free diet.",
                    "offsetInBeginSection": 87,
                    "offsetInEndSection": 135,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                    "text": "RESULTS The results showed that the Nave oat cultivar elicited these events, whereas Irina and Potenza varieties did not.",
                    "offsetInBeginSection": 823,
                    "offsetInEndSection": 944,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                    "text": "In addition, we compared this capability with the electrophoresis pattern of peptic-tryptic digests of the proteins of the oat cultivars.",
                    "offsetInBeginSection": 451,
                    "offsetInEndSection": 588,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240659",
                    "text": "Therefore, the safety of an oat cultivar in CD might be screened in vitro by means of biochemical and biological assays, before starting a clinical trial to definitely assess its safety.",
                    "offsetInBeginSection": 1246,
                    "offsetInEndSection": 1432,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68f965b750ff445500001a",
            "body": "Clue cells are characteristics to which causative bacteria of vaginitis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                "http://www.ncbi.nlm.nih.gov/pubmed/6610607",
                "http://www.ncbi.nlm.nih.gov/pubmed/12838684",
                "http://www.ncbi.nlm.nih.gov/pubmed/10932748"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                    "text": "The specific aetiologies of vaginitis are many.",
                    "offsetInBeginSection": 111,
                    "offsetInEndSection": 158,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                    "text": "Vaginitis of undetermined aetiology is more complex and is characterized by a purulent vaginal discharge, a pH of 4.0-4.6, numerous WBC's, and a high concentration of bacteria.",
                    "offsetInBeginSection": 823,
                    "offsetInEndSection": 999,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                    "text": "One of the most common entities, however, is \"non-specific vaginitis\" which can be subdivided into: Gardnerella vaginitis, anaerobic vaginosis, and vaginitis of undetermined aetiology.",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 343,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                    "text": "The role of Gardnerella as a causative agent for vaginitis has been studied in depth but its specific role remains controversial.",
                    "offsetInBeginSection": 344,
                    "offsetInEndSection": 473,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                    "text": "The microbiology of this vaginitis includes many facultative Gram-negative rods and Gram-positive cocci.",
                    "offsetInBeginSection": 1000,
                    "offsetInEndSection": 1104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                    "text": "Anaerobic vaginosis can be diagnosed by noting on microscopic examination the presence of clue cells, free-floating bacteria and numerous white blood cells (WBC's).",
                    "offsetInBeginSection": 474,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3497132",
                    "text": "Vaginitis is a complex syndrome that is probably the most common outpatient disease seen by the gynaecologist.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12838684",
                    "text": "Gardnerella vaginalis is found in vaginal flora of women with bacterial vaginitis as well as in healthy women, while anaerobic bacteria such as Mobiluncus and Prevotella are the causative agents for bacterial vaginosis.",
                    "offsetInBeginSection": 257,
                    "offsetInEndSection": 476,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10932748",
                    "text": "Lactobacillus populations, which are usually dominant in healthy women, are replaced by a polymicrobial group of organisms that includes G. vaginalis, anaerobic Gram-negative rods such as Prevotella species, Peptostreptococcus species, Mycoplasma hominis, Ureaplasma urealyticum, and often Mobiluncus species.",
                    "offsetInBeginSection": 479,
                    "offsetInEndSection": 788,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10932748",
                    "text": "They also described a \"new\" causative organism, which they named \"Haemophilus vaginalis\", subsequently renamed Gardnerella vaginalis.",
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 332,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d1db1b750ff4455000033",
            "body": "What is the purpose of the FaceBase consortium?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21458441",
                "http://www.ncbi.nlm.nih.gov/pubmed/27287806",
                "http://www.ncbi.nlm.nih.gov/pubmed/26168040"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458441",
                    "text": "The FaceBase Consortium consists of ten interlinked research and technology projects whose goal is to generate craniofacial research data and technology for use by the research community through a central data management and integrated bioinformatics hub.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458441",
                    "text": "Funded by the National Institute of Dental and Craniofacial Research (NIDCR) and currently focused on studying the development of the middle region of the face, the Consortium will produce comprehensive datasets of global gene expression patterns, regulatory elements and sequencing; will generate anatomical and molecular atlases; will provide human normative facial data and other phenotypes; conduct follow up studies of a completed genome-wide association study; generate independent data on the genetics of craniofacial development, build repositories of animal models and of human samples and data for community access and analysis; and will develop software tools and animal models for analyzing and functionally testing and integrating these data.",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 1011,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21458441",
                    "text": "The FaceBase website (http://www.facebase.org) will serve as a web home for these efforts, providing interactive tools for exploring these datasets, together with discussion forums and other services to support and foster collaboration within the craniofacial research community.",
                    "offsetInBeginSection": 1012,
                    "offsetInEndSection": 1291,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806",
                    "text": "The FaceBase Consortium, funded by the National Institute of Dental and Craniofacial Research, National Institutes of Health, is designed to accelerate understanding of craniofacial developmental biology by generating comprehensive data resources to empower the research community, exploring high-throughput technology, fostering new scientific collaborations among researchers and human/computer interactions, facilitating hypothesis-driven research and translating science into improved health care to benefit patients.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 521,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806",
                    "text": "The resources generated by the FaceBase projects include a number of dynamic imaging modalities, genome-wide association studies, software tools for analyzing human facial abnormalities, detailed phenotyping, anatomical and molecular atlases, global and specific gene expression patterns, and transcriptional profiling over the course of embryonic and postnatal development in animal models and humans.",
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 924,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27287806",
                    "text": "The integrated data visualization tools, faceted search infrastructure, and curation provided by the FaceBase Hub offer flexible and intuitive ways to interact with these multidisciplinary data.",
                    "offsetInBeginSection": 925,
                    "offsetInEndSection": 1119,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040",
                    "text": "The NIH FACEBASE consortium was established in part to create a central resource for craniofacial researchers.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040",
                    "text": "This FACEBASE resource is designed to promote discovery by the craniofacial research community.",
                    "offsetInBeginSection": 1241,
                    "offsetInEndSection": 1336,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040",
                    "text": "One purpose is to provide a molecular anatomy of craniofacial development.",
                    "offsetInBeginSection": 111,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26168040",
                    "text": "To this end we have used a combination of laser capture microdissection and RNA-Seq to define the gene expression programs driving development of the murine palate.",
                    "offsetInBeginSection": 186,
                    "offsetInEndSection": 350,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a79d25dfaa1ab7d2e00000f",
            "body": "Does wheat belongs to the genus Avena, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24226111",
                "http://www.ncbi.nlm.nih.gov/pubmed/8984007",
                "http://www.ncbi.nlm.nih.gov/pubmed/12669804",
                "http://www.ncbi.nlm.nih.gov/pubmed/25120168",
                "http://www.ncbi.nlm.nih.gov/pubmed/10464792",
                "http://www.ncbi.nlm.nih.gov/pubmed/29083384"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984007",
                    "text": "A cloned repetitive sequence, pAvKB30, obtained from an Avena vaviloviana (AB genome) genomic library, along with two polymerase chain reaction products derived from the conserved region of the reverse transcriptase (RT) gene of retrotransposons, were characterized molecularly and cytologically.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 296,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984007",
                    "text": "The cloned DNA fragment was a dispersed repeat present in all Avena species used in this study (A. strigosa, A. clauda, A. vaviloviana, A. magna, and A. sativa).",
                    "offsetInBeginSection": 297,
                    "offsetInEndSection": 458,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12669804",
                    "text": "The DNA sequence of an extracellular (EXC) domain of an oat (Avena sativa L.) receptor-like kinase (ALrk10) gene was amplified from 23 accessions of 15 Avena species (6 diploid, 6 tetraploid, and 3 hexaploid).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25120168",
                    "text": "The present results identify a novel protein family affecting cereal kernel texture and would further elucidate the phylogenetic evolution of Avena genus.",
                    "offsetInBeginSection": 1334,
                    "offsetInEndSection": 1488,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25120168",
                    "text": "Among cereals, Avena sativa is characterized by an extremely soft endosperm texture, which leads to some negative agronomic and technological traits.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25120168",
                    "text": "Each VIN protein in diploid oat species was found to be synthesized by a single Vin gene whereas, in hexaploid A. sativa, three Vin-1, three Vin-2 and two Vin-3 genes coding for VIN-1, VIN-2 and VIN-3, respectively, were described and assigned to the A, C or D genomes based on similarity to their counterparts in diploid species.",
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 841,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10464792",
                    "text": "Further, the chromosomes involved in three C-A and three C-D intergenomic translocations in Avena murphyi (AC genomes) and Avena sativa cv.",
                    "offsetInBeginSection": 1101,
                    "offsetInEndSection": 1240,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10464792",
                    "text": "A repetitive sequence, pAs17, was isolated from Avena strigosa (As genome) and characterized.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29083384",
                    "text": "The water-insoluble storage proteins of cereals (prolamins) are called \"gluten\" in wheat, barley, and rye, and \"avenins\" in oat.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29083384",
                    "text": "The avenins in the genus Avena (cultivated oat as well as various wild species of which gene bank accessions were analyzed) are free of the known CD immunogenic epitopes from wheat, barley, and rye.",
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 603,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68fd01b750ff445500001b",
            "body": "What is included in the fourth generation HIV test?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23984592",
                "http://www.ncbi.nlm.nih.gov/pubmed/29062724",
                "http://www.ncbi.nlm.nih.gov/pubmed/28846743",
                "http://www.ncbi.nlm.nih.gov/pubmed/24342480",
                "http://www.ncbi.nlm.nih.gov/pubmed/24342477",
                "http://www.ncbi.nlm.nih.gov/pubmed/16908076",
                "http://www.ncbi.nlm.nih.gov/pubmed/19320855",
                "http://www.ncbi.nlm.nih.gov/pubmed/28710996",
                "http://www.ncbi.nlm.nih.gov/pubmed/25464967",
                "http://www.ncbi.nlm.nih.gov/pubmed/11595590"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592",
                    "text": "To evaluate its performance to diagnose acute HIV infection (AHI), E4G was compared with fourth generation Ag/Ab ELISA test kits, a third generation PA test kit, WB and real-time PCR for the testing of 25 AHI clinical specimens.",
                    "offsetInBeginSection": 721,
                    "offsetInEndSection": 949,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984592",
                    "text": "In 2008, the Espline HIV Ag/Ab test kit (E4G, Fujirebio Inc. Japan) was marketed in Japan belonging to the fourth generation of HIV test kits characterized by its ability to detect both viral antigens (Ag) and anti-HIV-1/2 antibodies (Ab).",
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 611,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29062724",
                    "text": "CONCLUSION The fourth generation DC offered no advantage over current third generation RT in the diagnosis of HIV infection.",
                    "offsetInBeginSection": 1654,
                    "offsetInEndSection": 1778,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29062724",
                    "text": "Determine Combo (DC) is the first fourth generation RT that detects both p24 antigen (p24Ag) and HIV antibodies (Ab), theoretically reducing the window period and increasing detection rates.",
                    "offsetInBeginSection": 215,
                    "offsetInEndSection": 405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16908076",
                    "text": "The LG HIV Ag-Ab Plus, a new fourth generation diagnostic assay for HIV infection, was evaluated in comparison to the Enzygnost HIV Integral, an established fourth generation HIV assay.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19320855",
                    "text": "All HIV-1-positive samples were reactive by the three fourth-generation systems.",
                    "offsetInBeginSection": 1098,
                    "offsetInEndSection": 1178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28710996",
                    "text": "STUDY DESIGN 5029 VOICE participants were evaluated with third-generation Alere Determine\u2122 HIV-1/2, OraQuick ADVANCE\u00ae Rapid HIV-1/2, Uni-Gold\u2122 Recombigen\u00ae HIV-1/2 and Bio-Rad GS HIV-1/2+O EIA; and fourth-generation Alere Determine\u2122 HIV-1/2 Ag/Ab Combo, Conformit\u00e9 Europ\u00e9ene (CE)-Marked Alere\u2122 HIV Combo and Bio-Rad HIV Combo Ag/Ab EIA.",
                    "offsetInBeginSection": 464,
                    "offsetInEndSection": 811,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25464967",
                    "text": "RESULTS Fourth generation immunoassays identified 34 out of 39 HIV early infections using dried serum spot, whereas the Determine\u2122 HIV-1/2 rapid test detected 24 out of 39 HIV positive serum (87.2% vs 61.5% respectively, p = 0.009).",
                    "offsetInBeginSection": 686,
                    "offsetInEndSection": 920,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25464967",
                    "text": "CONCLUSION Fourth generation Ag/Ab immunoassays performed on dried serum spot had good performance for HIV testing during the early phases of HIV infection.",
                    "offsetInBeginSection": 1304,
                    "offsetInEndSection": 1460,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11595590",
                    "text": "This second diagnostic window was caused by the absence of HIV specific antibodies and the decline of HIV p24 antigen concentrations below the detection limits of the fourth generation assays.",
                    "offsetInBeginSection": 1068,
                    "offsetInEndSection": 1260,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d2558b750ff4455000036",
            "body": "Does Uc.160 promote cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28382457"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "CONCLUSIONS These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC.",
                    "offsetInBeginSection": 1498,
                    "offsetInEndSection": 1597,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.",
                    "offsetInBeginSection": 399,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "Cancer-specific DNA methylation in the promoter region of Uc.160 was observed by bisulfite genomic DNA sequencing analysis.",
                    "offsetInBeginSection": 1143,
                    "offsetInEndSection": 1266,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "We also revealed that Uc.160+ inhibited the phosphorylation of Akt by regulating phosphatase and tensin homolog (PTEN) expression.",
                    "offsetInBeginSection": 1365,
                    "offsetInEndSection": 1495,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "RESULTS On the basis of the qRT-PCR and ISH results, Uc.160+ expression in adenoma and GC tissues was clearly downregulated compared with that in nonneoplastic mucosa tissues of the stomach.",
                    "offsetInBeginSection": 952,
                    "offsetInEndSection": 1142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "It has been reported that T-UCRs have distinct signatures in human cancers.",
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 243,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "BACKGROUND Transcribed ultraconserved regions (T-UCRs) are a novel class of noncoding RNAs that are highly conserved among the orthologous regions in most vertebrates.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "We previously discovered the downregulation of T-UCR expression in gastric cancer (GC), indicating that T-UCRs could play an important role in GC biology.",
                    "offsetInBeginSection": 244,
                    "offsetInEndSection": 398,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "METHODS We analyzed the expression pattern of Uc.160+ in nonneoplastic and tumor tissues of the stomach by using uantitative reverse transcription polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH), specifically focusing on the mechanism of transcriptional regulation and target genes that are regulated by T-UCRs.",
                    "offsetInBeginSection": 493,
                    "offsetInEndSection": 824,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "The effect of DNA methylation on Uc.160+ expression was further confirmed by reporter gene assay.",
                    "offsetInBeginSection": 1267,
                    "offsetInEndSection": 1364,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8712af61bb38fb24000002",
            "body": "What is the link between psoriatic arthritis and depression",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21794775",
                "http://www.ncbi.nlm.nih.gov/pubmed/27258525",
                "http://www.ncbi.nlm.nih.gov/pubmed/27221798",
                "http://www.ncbi.nlm.nih.gov/pubmed/28507445",
                "http://www.ncbi.nlm.nih.gov/pubmed/19151962",
                "http://www.ncbi.nlm.nih.gov/pubmed/24407907",
                "http://www.ncbi.nlm.nih.gov/pubmed/23908539",
                "http://www.ncbi.nlm.nih.gov/pubmed/22015150",
                "http://www.ncbi.nlm.nih.gov/pubmed/28733473",
                "http://www.ncbi.nlm.nih.gov/pubmed/28320454"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794775",
                    "text": "CONCLUSION The prevalence of anxiety symptoms and the prevalence of depression symptoms are high among patients suffering psoriatic arthritis in the studied population.",
                    "offsetInBeginSection": 1439,
                    "offsetInEndSection": 1607,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27258525",
                    "text": "Further stratified analyses revealed a more rapid and significant reduction in depression/insomnia in those undergoing continuous biologics therapy, younger than 45 years, without psoriatic arthritis and not taking concomitant methotrexate, when compared with their counterparts.The results suggest that biologics therapy may be associated with reduced rates of depression and insomnia, and a reduced rate of regular antidepressants use in psoriasis patients.",
                    "offsetInBeginSection": 1174,
                    "offsetInEndSection": 1633,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27221798",
                    "text": "Many epidemiological studies have shown that psoriasis is associated with psoriatic arthritis as well as cardiovascular and metabolic diseases.",
                    "offsetInBeginSection": 83,
                    "offsetInEndSection": 226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28507445",
                    "text": "CONCLUSION Prevalence of fatigue was moderate to intense in <25% of patients with psoriatic arthritis.",
                    "offsetInBeginSection": 1722,
                    "offsetInEndSection": 1824,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24407907",
                    "text": "The use of pressure algometry in the evaluation of chronic pain in patients affected by rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis that display comorbid depression could represent an additional and integrative method to improve pain/depression overlap management or research.",
                    "offsetInBeginSection": 1367,
                    "offsetInEndSection": 1669,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23908539",
                    "text": "However, the other manifestations of psoriatic disease including metabolic syndrome, atherosclerotic cardiovascular disease, depression, poor self-esteem, and self-destructive habits including obesity, smoking and excess alcohol consumption are underappreciated.",
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 390,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28733473",
                    "text": "OBJECTIVE To investigate the predictive value of baseline depression/anxiety on the likelihood of achieving joint remission in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) as well as the associations between baseline depression/anxiety and the components of the remission criteria at follow-up.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 305,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28320454",
                    "text": "Peripheral arthritis is the most common symptom of psoriatic arthritis and patients also frequently experience involvement of the entheses, spine, skin, and nails.",
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 365,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28320454",
                    "text": "Risks also arise from comorbidities that are associated with psoriatic arthritis such as cardiovascular disease, obesity, diabetes mellitus, and gastrointestinal inflammation.",
                    "offsetInBeginSection": 876,
                    "offsetInEndSection": 1051,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28320454",
                    "text": "Psoriatic arthritis is a part of the family of diseases referred to as spondyloarthropathies, a diverse group of chronic inflammatory disorders with common clinical, radiographic, and genetic features.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6900ebb750ff445500001d",
            "body": "Which disease is diagnosed using the Finkelstein's test?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15680568",
                "http://www.ncbi.nlm.nih.gov/pubmed/23340762",
                "http://www.ncbi.nlm.nih.gov/pubmed/12723309",
                "http://www.ncbi.nlm.nih.gov/pubmed/26538761",
                "http://www.ncbi.nlm.nih.gov/pubmed/15792200",
                "http://www.ncbi.nlm.nih.gov/pubmed/1402284",
                "http://www.ncbi.nlm.nih.gov/pubmed/10070674"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568",
                    "text": "PURPOSE Finkelstein's test is the classic diagnostic test for de Quervain's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15680568",
                    "text": "Finkelstein hypothesized that the entry of the muscle bellies of the extensor pollicis brevis (EPB) and abductor pollicis longus (APL) tendons into the first extensor compartment was responsible for the findings observed in his now eponymous test.",
                    "offsetInBeginSection": 85,
                    "offsetInEndSection": 332,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762",
                    "text": "The purpose of the study was to compare the accuracy of the Eichhoff's test and wrist hyperflexion and abduction of the thumb test to diagnose correctly de Quervain's disease by comparing clinical findings using those tests with the results on ultrasound.",
                    "offsetInBeginSection": 633,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762",
                    "text": "To compare the Eichhoff's test with a new test, the wrist hyperflexion and abduction of the thumb test, we set up a prospective study over a period of three years for a cohort of 100 patients (88 women, 12 men) presenting spontaneous pain over the radial side of the styloid of the radius (de Quervain tendinopathy).",
                    "offsetInBeginSection": 316,
                    "offsetInEndSection": 632,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340762",
                    "text": "Our results support that the wrist hyperflexion and abduction of the thumb test is a more precise tool for the diagnosis of de Quervain's disease than the Eichhoff's test and thus could be adopted to guide clinical diagnosis in the early stages of de Quervain's tendinopathy.",
                    "offsetInBeginSection": 1337,
                    "offsetInEndSection": 1612,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26538761",
                    "text": "The clinical criteria used were Finkelstein's test, tenderness over radial styloid (Ritchie's tenderness scale), grip strength, pain (visual analog scale [VAS]) and radiological criteria was ultrasonographic assessment of change in thickness of APL and EPB tendon sheath.",
                    "offsetInBeginSection": 828,
                    "offsetInEndSection": 1099,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26538761",
                    "text": "MATERIALS AND METHODS Thirty patients clinically diagnosed de Quervains tenosynovitis were included in the study and randomly assigned to two groups.",
                    "offsetInBeginSection": 535,
                    "offsetInEndSection": 684,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15792200",
                    "text": "Three different descriptions of Finkelstein's test were used as described in current literature.",
                    "offsetInBeginSection": 726,
                    "offsetInEndSection": 822,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15792200",
                    "text": "We also found that Finkelstein's test was inaccurately described in literature since Leao's incorrect description in 1958 (quoting Eichhoff's manoeuvre) and the mistake persisted for over 50 years before it could be accredited.",
                    "offsetInBeginSection": 1099,
                    "offsetInEndSection": 1326,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10070674",
                    "text": "Although Sun's was derived as a test for discrete data and Finkelstein's and Fay's tests were derived under a grouped continuous model, by writing all tests under one general model we see that as long as the regularity conditions hold, any of these three classes of tests may be applied to either grouped continuous or discrete data.",
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 485,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e1280b750ff4455000037",
            "body": "For which type of cancer can uc.189 be used as a potential prognostic biomarker?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28941722"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                    "text": "Uc.189 might be considered as a novel molecule involved in ESCC progression, which provides a potential prognostic biomarker and therapeutic target.",
                    "offsetInBeginSection": 1124,
                    "offsetInEndSection": 1272,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                    "text": "High expression of uc.189 might reflect poor prognosis of ESCC and indicate a potential diagnostic target in ESCC patients.",
                    "offsetInBeginSection": 1000,
                    "offsetInEndSection": 1123,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                    "text": "This study was to identify the prognostic value of uc.189 expression in esophageal squamous cell carcinomas (ESCC).",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 371,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                    "text": "Ultraconserved elements (UCEs) encoding noncoding RNAs serve as important regulators in cancer biology.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                    "text": "Until now, the role of the UCE uc.189 in human cancers remains undefined and the clinical significance of uc.189 in esophageal cancers remains unknown.",
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                    "text": "The expression of uc.189 was significantly higher in human ESCC compared with the adjacent noncancerous tissues (122/152, 80.3%, p<0.01), and the high level of uc.189 expression was significantly correlated with invasion of the tumor (p=0.009), advanced clinical stage (p=0.000), lymph node metastasis (p=0.000), and poor prognosis.",
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 999,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                    "text": "Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression level of uc.189 in matched cancerous tissues and adjacent noncancerous tissues from 152 patients with ESCC.",
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 572,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28941722",
                    "text": "The correlation of uc.189 with clinicopathological features and prognosis were also analyzed.",
                    "offsetInBeginSection": 573,
                    "offsetInEndSection": 666,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a87140a61bb38fb24000003",
            "body": "What is Chronic Wasting Disease (CWD) in deer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27575545",
                "http://www.ncbi.nlm.nih.gov/pubmed/17553219",
                "http://www.ncbi.nlm.nih.gov/pubmed/12680636",
                "http://www.ncbi.nlm.nih.gov/pubmed/16439622",
                "http://www.ncbi.nlm.nih.gov/pubmed/27711208",
                "http://www.ncbi.nlm.nih.gov/pubmed/17020952",
                "http://www.ncbi.nlm.nih.gov/pubmed/18387626",
                "http://www.ncbi.nlm.nih.gov/pubmed/28193766",
                "http://www.ncbi.nlm.nih.gov/pubmed/17092889",
                "http://www.ncbi.nlm.nih.gov/pubmed/15542685"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575545",
                    "text": "Chronic wasting disease (CWD) is an invariably fatal transmissible spongiform encephalopathy of white-tailed deer, mule deer, elk, and moose.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17553219",
                    "text": "Chronic wasting disease (CWD) of deer and elk is a widespread health concern because its potential for crossspecies transmission is undetermined.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16439622",
                    "text": "The emergence of chronic wasting disease (CWD) in deer and elk in an increasingly wide geographic area, as well as the interspecies transmission of bovine spongiform encephalopathy to humans in the form of variant Creutzfeldt Jakob disease, have raised concerns about the zoonotic potential of CWD.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 298,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27711208",
                    "text": "The recent discovery of chronic wasting disease (CWD) in captive deer facilities in Texas has increased concern about the potential emergence of CWD in free-ranging deer.",
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 290,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17020952",
                    "text": "Chronic wasting disease (CWD), a prion disease of deer and elk, is highly prevalent in some regions of North America.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18387626",
                    "text": "Chronic wasting disease (CWD), a prion disease of North American deer, elk and moose, affects both free-ranging and captive cervids.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18387626",
                    "text": "In western blots, the PrP(CWD) glycoform profile resembled that of CWD in deer, typified by a dominant diglycosylated glycoform.",
                    "offsetInBeginSection": 924,
                    "offsetInEndSection": 1052,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28193766",
                    "text": "The etiology of chronic wasting disease (CWD), a relatively new and burgeoning prion epidemic in deer, elk, and moose (members of the cervid family), is more enigmatic.",
                    "offsetInBeginSection": 497,
                    "offsetInEndSection": 665,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17092889",
                    "text": "Chronic wasting disease (CWD) is a fatal, emerging disease of cervids associated with transmissible protease-resistant prion proteins.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15542685",
                    "text": "We generated mice expressing cervid prion protein to produce a transgenic system simulating chronic wasting disease (CWD) in deer and elk.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a69031bb750ff445500001e",
            "body": "Can doxycycline cause photosensitivity?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9214073",
                "http://www.ncbi.nlm.nih.gov/pubmed/17160610",
                "http://www.ncbi.nlm.nih.gov/pubmed/26299894",
                "http://www.ncbi.nlm.nih.gov/pubmed/10233667",
                "http://www.ncbi.nlm.nih.gov/pubmed/21879777",
                "http://www.ncbi.nlm.nih.gov/pubmed/23182067",
                "http://www.ncbi.nlm.nih.gov/pubmed/17315050",
                "http://www.ncbi.nlm.nih.gov/pubmed/3684731",
                "http://www.ncbi.nlm.nih.gov/pubmed/15262663",
                "http://www.ncbi.nlm.nih.gov/pubmed/26189561"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17160610",
                    "text": "Treatment with doxycycline is cheap and relatively safe, but gastrointestinal symptoms and photosensitivity reactions can be expected more often than with ceftriaxone.",
                    "offsetInBeginSection": 1913,
                    "offsetInEndSection": 2080,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10233667",
                    "text": "Chronic actinic dermatitis (CAD) is an uncommon, eczematous photosensitive eruption affecting predominantly elderly men and to which drug-induced photosensitivity may sometimes appear clinically identical.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21879777",
                    "text": "Tetracycline, doxycycline, nalidixic acid, voriconazole, amiodarone, hydrochlorothiazide, naproxen, piroxicam, chlorpromazine and thioridazine are among the most commonly implicated medications.",
                    "offsetInBeginSection": 1107,
                    "offsetInEndSection": 1301,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182067",
                    "text": "CONCLUSION Topical or oral corticosteroids followed by prophylactic doxycycline can be effective in rapidly resolving acute flareups and preventing recurrences of NSAGU.",
                    "offsetInBeginSection": 1580,
                    "offsetInEndSection": 1749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182067",
                    "text": "Eight (47%) commenced doxycycline prophylaxis.",
                    "offsetInBeginSection": 966,
                    "offsetInEndSection": 1012,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17315050",
                    "text": "Anti-inflammatory-dose doxycycline should not be used by individuals with known hypersensitivity to tetracyclines or increased photosensitivity, or by pregnant or nursing women (anti-inflammatory-dose doxycycline is a pregnancy category-D medication).",
                    "offsetInBeginSection": 1381,
                    "offsetInEndSection": 1632,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3684731",
                    "text": "Doxycycline is considered by authoritative sources to be generally comparable in side effects to other tetracyclines and penicillins, with the exception that it increases photosensitivity.",
                    "offsetInBeginSection": 433,
                    "offsetInEndSection": 621,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3684731",
                    "text": "As part of a study investigating new methods of detecting adverse drug reactions, adult outpatients receiving new prescriptions for 1 of 4 antibiotics (doxycycline, penicillin VK, ampicillin, or tetracycline) were assigned to 1 of 2 methods of monitoring adverse drug reactions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 278,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15262663",
                    "text": "BACKGROUND It has been hypothesized that certain Mycoplasma species may cause Gulf War veterans' illnesses (GWVIs), chronic diseases characterized by pain, fatigue, and cognitive symptoms, and that affected patients may benefit from doxycycline treatment.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26189561",
                    "text": "Doxycycline is a commonly used tetracycline antibiotic showing the broad spectrum of antibacterial action.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e21b4b750ff445500003a",
            "body": "Are paralog genes co-regulated?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18493055",
                "http://www.ncbi.nlm.nih.gov/pubmed/27634932",
                "http://www.ncbi.nlm.nih.gov/pubmed/20621981",
                "http://www.ncbi.nlm.nih.gov/pubmed/20660482"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055",
                    "text": "By analyzing paralogs of testis-biased genes, we identified \"co-regulated\" paralogous pairs in which both genes are testis biased, \"anti-regulated\" pairs in which one paralog is testis biased and the other downregulated in testes, and \"neutral\" pairs in which one paralog is testis biased and the other constitutively expressed.",
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 839,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18493055",
                    "text": "Gene duplications have been broadly implicated in the generation of testis-specific genes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932",
                    "text": "In eukaryotes, genes are regulated in part by distal enhancer elements through looping interactions with gene promoters.",
                    "offsetInBeginSection": 279,
                    "offsetInEndSection": 399,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932",
                    "text": "Paralog genes arise from gene duplication events during evolution, which often lead to similar proteins that cooperate in common pathways and in protein complexes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634932",
                    "text": "We show that paralog gene pairs are enriched for co-localization in the same TAD, share more often common enhancer elements than expected and have increased contact frequencies over large genomic distances.",
                    "offsetInBeginSection": 923,
                    "offsetInEndSection": 1129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621981",
                    "text": "Some RIDGEs (28%) consist of paralog genes while another subset (30%) are specifically dysregulated in tumors but not in normal tissues.",
                    "offsetInBeginSection": 733,
                    "offsetInEndSection": 869,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20660482",
                    "text": "CPEB2, CPEB3 and CPEB4 are paralog proteins very similar among themselves referred as the CPEB2 subfamily.",
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 239,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20660482",
                    "text": "We also showed that the endogenous miRNAs co-regulate CPEB2, CPEB3 and CPEB4 transcripts, supporting our hypothesis that these genes have a common regulatory mechanism mediated by miRNAs.",
                    "offsetInBeginSection": 995,
                    "offsetInEndSection": 1182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20660482",
                    "text": "The cytoplasmic polyadenylation element binding-protein (CPEB) is an RNA-binding protein that participates in translational control.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20660482",
                    "text": "Most predicted target sites for these families are located in paralog positions suggesting that these putative regulatory motifs were already present in the ancestral gene.",
                    "offsetInBeginSection": 499,
                    "offsetInEndSection": 671,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a87145861bb38fb24000004",
            "body": "What causes Black Lung?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2933965",
                "http://www.ncbi.nlm.nih.gov/pubmed/17300721",
                "http://www.ncbi.nlm.nih.gov/pubmed/16304297",
                "http://www.ncbi.nlm.nih.gov/pubmed/28450031",
                "http://www.ncbi.nlm.nih.gov/pubmed/2806196",
                "http://www.ncbi.nlm.nih.gov/pubmed/17516558",
                "http://www.ncbi.nlm.nih.gov/pubmed/16497850",
                "http://www.ncbi.nlm.nih.gov/pubmed/26437452",
                "http://www.ncbi.nlm.nih.gov/pubmed/7810543",
                "http://www.ncbi.nlm.nih.gov/pubmed/11170158"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721",
                    "text": "CONCLUSION Cigarette smoke exposure to a guinea pig model causes oxidative damage, inflammation, apoptosis and lung injury that are prevented by supplementation of black tea.",
                    "offsetInBeginSection": 1426,
                    "offsetInEndSection": 1600,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17300721",
                    "text": "Since black tea has antioxidant property, we examined the preventive effect of black tea on cigarette smoke-induced oxidative damage, apoptosis and lung injury in a guinea pig model.",
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16304297",
                    "text": "CONCLUSIONS Our analysis suggests that the lower surgical rate among black patients with early stage lung cancer is mainly due to low rates of acceptance of surgical treatment.",
                    "offsetInBeginSection": 1448,
                    "offsetInEndSection": 1624,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28450031",
                    "text": "METHODS We collected survival time data for 105,121 Hispanic, non-Hispanic Asian, non-Hispanic black, and non-Hispanic white patients with early-stage (IA, IB, IIA, and IIB) lung cancer diagnosed between 2004 and 2013 from the Surveillance, Epidemiology, and End-Results registries.",
                    "offsetInBeginSection": 411,
                    "offsetInEndSection": 693,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28450031",
                    "text": "BACKGROUND Black patients with lung cancer diagnosed at early stages-for which surgical resection offers a potential cure-experience worse overall survival than do their white counterparts.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2806196",
                    "text": "The results of these studies support a preeminent role for elastase in neutrophil-induced lung lesions.",
                    "offsetInBeginSection": 1483,
                    "offsetInEndSection": 1586,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17516558",
                    "text": "CONCLUSIONS The findings suggest that carbon black, or chemicals associated with the production of carbon black, had an effect on later stages of lung cancer carcinogenesis at two of the plants but that no such effect was found at the other plants.",
                    "offsetInBeginSection": 1330,
                    "offsetInEndSection": 1578,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26437452",
                    "text": "In this study, we show that insoluble nanoparticulate carbon black (nCB) accumulates in human myeloid dendritic cells (mDCs) from emphysematous lung and in CD11c(+) lung antigen presenting cells (APC) of mice exposed to smoke.",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 500,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26437452",
                    "text": "Delivered by smoking or intranasally, nCB persisted indefinitely in mouse lung, activated lung APCs, and promoted T helper 17 cell differentiation through double-stranded DNA break (DSB) and ASC-mediated inflammasome assembly in phagocytes.",
                    "offsetInBeginSection": 575,
                    "offsetInEndSection": 815,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7810543",
                    "text": "The case-control analysis found employment in preparation and carding operations (where most of the black males worked) to be associated with a slightly reduced lung cancer risk, although not statistically significant, whereas spinning and twisting employment was associated with a statistically significant increased lung cancer risk compared to other plant operations.",
                    "offsetInBeginSection": 2305,
                    "offsetInEndSection": 2675,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f7e6ab750ff4455000052",
            "body": "List four principles of medical ethics.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11794075",
                "http://www.ncbi.nlm.nih.gov/pubmed/14519842",
                "http://www.ncbi.nlm.nih.gov/pubmed/7463428",
                "http://www.ncbi.nlm.nih.gov/pubmed/26793677",
                "http://www.ncbi.nlm.nih.gov/pubmed/23975951",
                "http://www.ncbi.nlm.nih.gov/pubmed/15183570",
                "http://www.ncbi.nlm.nih.gov/pubmed/21625670",
                "http://www.ncbi.nlm.nih.gov/pubmed/25516952",
                "http://www.ncbi.nlm.nih.gov/pubmed/16731739"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11794075",
                    "text": "Only 6% of both graduates and students were able to list the four principles of medical ethics as described by Raanan.",
                    "offsetInBeginSection": 810,
                    "offsetInEndSection": 928,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14519842",
                    "text": "It is hypothesised and argued that \"the four principles of medical ethics\" can explain and justify, alone or in combination, all the substantive and universalisable claims of medical ethics and probably of ethics more generally.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428",
                    "text": "Through a critique of six positions regarding the aims of medical ethics, four principles are established which are the basis of a philosophy of education for medical ethics.",
                    "offsetInBeginSection": 264,
                    "offsetInEndSection": 438,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7463428",
                    "text": "The paper concludes with practical examples of a clinically-based medical ethics programme following from the four principles.",
                    "offsetInBeginSection": 594,
                    "offsetInEndSection": 720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26793677",
                    "text": "There are four principles of medical ethics; Beneficence, Respect for autonomy, Non-maleficence, and Justice.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26793677",
                    "text": "It is not easy to apply to principles of medical ethics in the special circumstances of obstetrics and gynecology.",
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 224,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15183570",
                    "text": "The unique role of the chief ethics officer in a sports medicine office is described and guided by the four principles of ethics, as well as the principles and codes of ethics of the American Medical Association, the International Sports Medicine Federation, and the American Academy of Orthopaedic Surgeons.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 308,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15183570",
                    "text": "The chief ethics officer should understand and be conversant with these principles and these codes of medical ethics, and transmit this information in order to further patient goals, physician goals, and employee goals.",
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 528,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516952",
                    "text": "With the development of medical technology and health services, it became necessary to expand the four basic principles of medical ethics and link them to human rights.",
                    "offsetInBeginSection": 114,
                    "offsetInEndSection": 282,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516952",
                    "text": "This paper highlights the methodology and principles employed by Muslim jurists in deriving rulings in the field of medical ethics, and it explains how ethical principles are interpreted through the lens of Islamic theory.",
                    "offsetInBeginSection": 515,
                    "offsetInEndSection": 737,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e22b9b750ff445500003b",
            "body": "What is CellMaps?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27296979"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979",
                    "text": "AVAILABILITY AND IMPLEMENTATION The application is available at: http://cellmaps.babelomics.org/ and the code can be found in: https://github.com/opencb/cell-maps The client is implemented in JavaScript and the server in C and Java.",
                    "offsetInBeginSection": 406,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979",
                    "text": "UNLABELLED : CellMaps is an HTML5 open-source web tool that allows displaying, editing, exploring and analyzing biological networks as well as integrating metadata into them.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979",
                    "text": "CellMaps can easily be integrated in any web page by using an available JavaScript API.",
                    "offsetInBeginSection": 316,
                    "offsetInEndSection": 403,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979",
                    "text": "CONTACT jdopazo@cipf.es   SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.",
                    "offsetInBeginSection": 641,
                    "offsetInEndSection": 751,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296979",
                    "text": "Computations and analyses are remotely executed in high-end servers, and all the functionalities are available through RESTful web services.",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 315,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8714e261bb38fb24000005",
            "body": "Is polyadenylation a process that stabilizes a protein by adding a string of Adenosine residues to the end of the molecule?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2408761",
                "http://www.ncbi.nlm.nih.gov/pubmed/9933592",
                "http://www.ncbi.nlm.nih.gov/pubmed/3037325",
                "http://www.ncbi.nlm.nih.gov/pubmed/16467265",
                "http://www.ncbi.nlm.nih.gov/pubmed/3019671",
                "http://www.ncbi.nlm.nih.gov/pubmed/2160581",
                "http://www.ncbi.nlm.nih.gov/pubmed/9242905",
                "http://www.ncbi.nlm.nih.gov/pubmed/11557765",
                "http://www.ncbi.nlm.nih.gov/pubmed/12270133",
                "http://www.ncbi.nlm.nih.gov/pubmed/9223284"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9933592",
                    "text": "The data show that the degradosome requires a single-stranded \"toehold\" 3' to a secondary structure to recognize and degrade the RNA molecule efficiently; polyadenylation can provide this single-stranded 3'-end.",
                    "offsetInBeginSection": 940,
                    "offsetInEndSection": 1151,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467265",
                    "text": "Polyadenylation is a process of endonucleolytic cleavage of the mRNA, followed by addition of up to 250 adenosine residues to the 3' end of the mRNA.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467265",
                    "text": "Polyadenylation is essential for eukaryotic mRNA expression, and CstF-64 is a subunit of the CstF polyadenylation factor that is required for accurate polyadenylation.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 317,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3019671",
                    "text": "Processing at the L3 polyadenylation site of human adenovirus-2 involves endonucleolytic cleavage generating the 3' terminal sequence -UAOH to which adenosine residues are added.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2160581",
                    "text": "These included CYC1 (iso-1-cytochrome c), HIS4 (histidine biosynthesis), GAL7 (galactose-1-phosphate uridyltransferase), H2B2 (histone H2B2), PRT2 (a protein of unknown function), and CBP1 (cytochrome b mRNA processing).",
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 485,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2160581",
                    "text": "Ammonium sulfate fractionation of a Saccharomyces cerevisiae whole-cell extract yielded a preparation which carried out correct and efficient endonucleolytic cleavage and polyadenylation of yeast precursor mRNA substrates corresponding to a variety of yeast genes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 264,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9242905",
                    "text": "The diversity of polyadenylation sites suggests that mRNA polyadenylation in prokaryotes is a relatively indiscriminate process that can occur at all mRNA's 3'-ends and does not require specific consensus sequences as in eukaryotes.",
                    "offsetInBeginSection": 516,
                    "offsetInEndSection": 748,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11557765",
                    "text": "We show that a 3'- to 5'-exoribonuclease activity is responsible for the preferential degradation of polyadenylated mRNAs as compared with non-polyadenylated mRNAs, and that 20-30 adenosine residues constitute the optimal poly(A) tail size for inducing degradation of RNA substrates in vitro.",
                    "offsetInBeginSection": 478,
                    "offsetInEndSection": 770,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12270133",
                    "text": "It is demonstrated that XCCA adds cytosine and adenosine residues to the ends of prepared tRNA and is therefore a functional CCA-adding enzyme.",
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 418,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9223284",
                    "text": "Polyadenylation of premessenger RNAs occurs posttranscriptionally in the nucleus of eukaryotic cells by cleavage of the precursor and polymerization of adenosine residues.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f829eb750ff4455000054",
            "body": "Can multiple myeloma patients develop hyperviscosity syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7699907",
                "http://www.ncbi.nlm.nih.gov/pubmed/2385441",
                "http://www.ncbi.nlm.nih.gov/pubmed/22827791",
                "http://www.ncbi.nlm.nih.gov/pubmed/9046114",
                "http://www.ncbi.nlm.nih.gov/pubmed/26623375",
                "http://www.ncbi.nlm.nih.gov/pubmed/694674",
                "http://www.ncbi.nlm.nih.gov/pubmed/14631546",
                "http://www.ncbi.nlm.nih.gov/pubmed/5415687",
                "http://www.ncbi.nlm.nih.gov/pubmed/1201229",
                "http://www.ncbi.nlm.nih.gov/pubmed/17315105"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907",
                    "text": "Plasmapheresis is known as an efficient method for rapid improvement of the hyperviscosity syndrome, and double filtration plasmapheresis is most commonly used for plasma exchange of multiple myeloma patients in our country.",
                    "offsetInBeginSection": 520,
                    "offsetInEndSection": 744,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7699907",
                    "text": "Five to 10 percent of patients with multiple myeloma are suffered from the hyperviscosity syndrome because of increased serum viscosity due to the presence of myeloma protein.",
                    "offsetInBeginSection": 246,
                    "offsetInEndSection": 421,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441",
                    "text": "The present report describes a patient with IgA myeloma complicated by hyperviscosity syndrome and multiple bone fractures.",
                    "offsetInBeginSection": 1290,
                    "offsetInEndSection": 1413,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2385441",
                    "text": "And this syndrome has been associated frequently with macroglobulinemia of Waldenstr\u00f6m, occasionally with immunoglobulin (Ig) G myeloma, rarely with IgA myeloma, and with other dysproteinemia.",
                    "offsetInBeginSection": 864,
                    "offsetInEndSection": 1057,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22827791",
                    "text": "Hyperglobulinemia of multiple myeloma (MM) plays a role in hyperviscosity syndrome (HVS).",
                    "offsetInBeginSection": 205,
                    "offsetInEndSection": 294,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9046114",
                    "text": "PE is the most effective method in the treatment of hyperviscosity syndrome often seen with multiple myeloma and Waldenstr\u00f6m's macroglobulinemia, and it is therapy of choice for this complication.",
                    "offsetInBeginSection": 961,
                    "offsetInEndSection": 1158,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26623375",
                    "text": "The present study reported for the first time the use of double filtration plasmapheresis to reduce clinical signs of hyperviscosity syndrome in a dog with multiple myeloma.",
                    "offsetInBeginSection": 527,
                    "offsetInEndSection": 700,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14631546",
                    "text": "Monoclonal hypergammaglobulinemia resulting in hyperviscosity syndrome is seen in multiple myeloma and Waldenstr\u00f6m's macroglobulinemia.",
                    "offsetInBeginSection": 106,
                    "offsetInEndSection": 242,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1201229",
                    "text": "Two cases of multiple myeloma with IgA gammopathy and the syndrome of serum hyperviscosity are reported.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1201229",
                    "text": "The hyperviscosity syndrome is being diagnosed with increasing frequency in association with IgA multiple myeloma, and should be investigated in all cases with monoclonal proteins exceeding a concentration of 3-0 g/dl.",
                    "offsetInBeginSection": 754,
                    "offsetInEndSection": 972,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e2578b750ff445500003d",
            "body": "Which package in Bioconductor has been developed with the aim to analyze differential DNA loops from sequencing data?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22847932",
                "http://www.ncbi.nlm.nih.gov/pubmed/29028898",
                "http://www.ncbi.nlm.nih.gov/pubmed/27008016",
                "http://www.ncbi.nlm.nih.gov/pubmed/24227674",
                "http://www.ncbi.nlm.nih.gov/pubmed/24979058",
                "http://www.ncbi.nlm.nih.gov/pubmed/27347386",
                "http://www.ncbi.nlm.nih.gov/pubmed/26834993",
                "http://www.ncbi.nlm.nih.gov/pubmed/26578583",
                "http://www.ncbi.nlm.nih.gov/pubmed/29052185",
                "http://www.ncbi.nlm.nih.gov/pubmed/26819470"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932",
                    "text": "MOTIVATION RNA sequencing is becoming a standard for expression profiling experiments and many tools have been developed in the past few years to analyze RNA-Seq data.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22847932",
                    "text": "RESULTS We developed 'easyRNASeq', an R package that simplifies the processing of RNA sequencing data, hiding the complex interplay of the required packages behind a single functionality.",
                    "offsetInBeginSection": 558,
                    "offsetInEndSection": 745,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028898",
                    "text": "To systematically assess changes in DNA looping architecture between samples, we introduce diffloop, an R/Bioconductor package that provides a suite of functions for the quality control, statistical testing, annotation, and visualization of DNA loops.",
                    "offsetInBeginSection": 288,
                    "offsetInEndSection": 539,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27008016",
                    "text": "The protocol provides a detailed description for the comparative analysis of DNA-IP sequencing data including basic data processing, quality controls, and identification of differential enrichment using the Bioconductor package \"MEDIPS\".",
                    "offsetInBeginSection": 638,
                    "offsetInEndSection": 875,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27008016",
                    "text": "We present a protocol for genome-wide comparative analysis of DNA-IP sequencing data to identify statistically significant differential sequencing coverage between two conditions by considering variation across replicates.",
                    "offsetInBeginSection": 415,
                    "offsetInEndSection": 637,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24227674",
                    "text": "RESULTS Here, we present a major update of the R/Bioconductor package MEDIPS, which allows for an arbitrary number of replicates per group and integrates sophisticated statistical methods for the detection of differential coverage between experimental conditions.",
                    "offsetInBeginSection": 625,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058",
                    "text": "We have previously developed an R/Bioconductor package 'exomePeak' for detecting RNA methylation sites under a specific experimental condition or the identifying the differential RNA methylation sites in a case control study from MeRIP-Seq data.",
                    "offsetInBeginSection": 488,
                    "offsetInEndSection": 733,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24979058",
                    "text": "We therein provide here a detailed and easy-to-use protocol of using exomePeak R/Bioconductor package along with other software programs for analysis of MeRIP-Seq data, which covers raw reads alignment, RNA methylation site detection, motif discovery, differential RNA methylation analysis, and functional analysis.",
                    "offsetInBeginSection": 983,
                    "offsetInEndSection": 1298,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27347386",
                    "text": "In the context of the ever-growing need for tools analyzing\u00a0Ribo-seq reads, we have developed 'RiboProfiling', a new Bioconductor open-source\u00a0package.",
                    "offsetInBeginSection": 403,
                    "offsetInEndSection": 555,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29052185",
                    "text": "The methylPipe Bioconductor package is adopted for the identification of the differentially methylated regions, and all the steps from the raw data to the required input are described in detail.",
                    "offsetInBeginSection": 642,
                    "offsetInEndSection": 836,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8715a961bb38fb24000006",
            "body": "Silent Allosteric Modulation of mGluR5 is a form of treatment for what disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28683325"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325",
                    "text": "Our data show that mGluR5's role in A\u03b2o-dependent AD phenotypes is separate from its role in glutamate signaling and silent allosteric modulation of mGluR5 has promise as a disease-modifying AD intervention with a broad therapeutic window.",
                    "offsetInBeginSection": 821,
                    "offsetInEndSection": 1061,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325",
                    "text": "We used a potent mGluR5 silent allosteric modulator (SAM, BMS-984923) to separate its well-known physiological role in glutamate signaling from a pathological role in mediating amyloid-\u03b2 oligomer (A\u03b2o) action.",
                    "offsetInBeginSection": 184,
                    "offsetInEndSection": 395,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325",
                    "text": "Metabotropic glutamate receptor 5 (mGluR5) has been implicated in Alzheimer's disease (AD) pathology.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325",
                    "text": "Binding of the SAM to mGluR5 does not change glutamate signaling but strongly reduces mGluR5 interaction with cellular prion protein (PrPC) bound to A\u03b2o.",
                    "offsetInBeginSection": 396,
                    "offsetInEndSection": 550,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325",
                    "text": "Critically, 4\u00a0weeks of SAM treatment rescues memory deficits and synaptic depletion in the APPswe/PS1\u0394E9 transgenic mouse brain.",
                    "offsetInBeginSection": 690,
                    "offsetInEndSection": 820,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325",
                    "text": "The SAM compound prevents A\u03b2o-induced signal transduction in brain slices and in an AD transgenic mouse model, the APPswe/PS1\u0394E9 strain.",
                    "offsetInBeginSection": 551,
                    "offsetInEndSection": 689,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683325",
                    "text": "We sought to understand whether mGluR5's role in AD requires glutamate signaling.",
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 183,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f853ab750ff4455000055",
            "body": "Which disease can be diagnosed with the \"probe to bone\" test?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7853630",
                "http://www.ncbi.nlm.nih.gov/pubmed/27369321",
                "http://www.ncbi.nlm.nih.gov/pubmed/21219428",
                "http://www.ncbi.nlm.nih.gov/pubmed/17259493",
                "http://www.ncbi.nlm.nih.gov/pubmed/7770390",
                "http://www.ncbi.nlm.nih.gov/pubmed/24356116",
                "http://www.ncbi.nlm.nih.gov/pubmed/18601422",
                "http://www.ncbi.nlm.nih.gov/pubmed/19141236",
                "http://www.ncbi.nlm.nih.gov/pubmed/1922909",
                "http://www.ncbi.nlm.nih.gov/pubmed/19485522"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27369321",
                    "text": "The probe-to-bone (PTB) test is a commonly used clinical test for osteomyelitis (OM), but its utility has been questioned in clinical settings where the prevalence of OM is low.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21219428",
                    "text": "CONCLUSIONS Clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain X-ray, or especially both, are positive.",
                    "offsetInBeginSection": 1470,
                    "offsetInEndSection": 1750,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21219428",
                    "text": "AIMS To investigate the accuracy of the sequential combination of the probe-to-bone test and plain X-rays for diagnosing osteomyelitis in the foot of patients with diabetes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 173,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21219428",
                    "text": "All patients with positive results on either the probe-to-bone test or plain X-ray underwent an appropriate surgical procedure, which included obtaining a bone specimen that was processed for histology and culture.",
                    "offsetInBeginSection": 537,
                    "offsetInEndSection": 751,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17259493",
                    "text": "OBJECTIVE We sought to assess the accuracy of the probe-to-bone (PTB) test in diagnosing foot osteomyelitis in a cohort of diabetic patients with bone culture proven disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7770390",
                    "text": "CONCLUSIONS The minisatellite probes MS31 and MS43 were found to be sensitive, effective tests for bone marrow transplants which can be used in routine follow-up.",
                    "offsetInBeginSection": 835,
                    "offsetInEndSection": 997,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24356116",
                    "text": "However, scintigraphy is a nuclear scanning test to trace bone healing during stress fracture and osteomyelitis and thus can be used to probe the osseointegration process in vivo in the context of the dental implant.",
                    "offsetInBeginSection": 82,
                    "offsetInEndSection": 298,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18601422",
                    "text": "In the Osteoprobe IItrade mark, the probe assembly, which is designed to penetrate soft tissue, consists of a reference probe (a 22 gauge hypodermic needle) and a test probe (a small diameter, sharpened rod) which slides through the inside of the reference probe.",
                    "offsetInBeginSection": 347,
                    "offsetInEndSection": 610,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18601422",
                    "text": "The distance that the test probe is indented into the bone can be measured relative to the position of the reference probe.",
                    "offsetInBeginSection": 680,
                    "offsetInEndSection": 803,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1922909",
                    "text": "Bone biopsy in an invasive method of diagnosing aluminium related bone disease (ABD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e33e4b750ff4455000041",
            "body": "Describe annotatr",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28369316"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316",
                    "text": "Results We developed the annotatr Bioconductor package to flexibly and quickly summarize and plot annotations of genomic regions.",
                    "offsetInBeginSection": 646,
                    "offsetInEndSection": 775,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316",
                    "text": "Availability and Implementation http://bioconductor.org/packages/annotatr/ and https://github.com/rcavalcante/annotatr.",
                    "offsetInBeginSection": 1348,
                    "offsetInEndSection": 1467,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316",
                    "text": "Existing tools are limited by a lack of annotation sources and flexible options, the time it takes to annotate regions, an artificial one-to-one region-to-annotation mapping, a lack of visualization options to easily summarize data, or some combination thereof.",
                    "offsetInBeginSection": 382,
                    "offsetInEndSection": 643,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316",
                    "text": "A common analysis step is to annotate such genomic regions to genomic annotations (promoters, exons, enhancers, etc.).",
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 381,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316",
                    "text": "Overall, annotatr enables a richer biological interpretation of experiments.",
                    "offsetInBeginSection": 1269,
                    "offsetInEndSection": 1345,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316",
                    "text": "These may include differentially methylated CpGs/regions, transcription factor binding sites, interacting chromatin regions, or GWAS-associated SNPs, among others.",
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 262,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316",
                    "text": "The annotatr package reports all intersections of regions and annotations, giving a better understanding of the genomic context of the regions.",
                    "offsetInBeginSection": 776,
                    "offsetInEndSection": 919,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316",
                    "text": "A variety of graphics functions are implemented to easily plot numerical or categorical data associated with the regions across the annotations, and across annotation intersections, providing insight into how characteristics of the regions differ across the annotations.",
                    "offsetInBeginSection": 920,
                    "offsetInEndSection": 1190,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316",
                    "text": "We demonstrate that annotatr is up to 27\u00d7 faster than comparable R packages.",
                    "offsetInBeginSection": 1191,
                    "offsetInEndSection": 1268,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369316",
                    "text": "Motivation Analysis of next-generation sequencing data often results in a list of genomic regions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8718c861bb38fb24000008",
            "body": "What are check point inhibitors?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27528363",
                "http://www.ncbi.nlm.nih.gov/pubmed/26775673",
                "http://www.ncbi.nlm.nih.gov/pubmed/28878676",
                "http://www.ncbi.nlm.nih.gov/pubmed/28865357",
                "http://www.ncbi.nlm.nih.gov/pubmed/27403706"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363",
                    "text": "OBJECTIVE To clarify the role of immune check point inhibitors in GBM management.",
                    "offsetInBeginSection": 490,
                    "offsetInEndSection": 571,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363",
                    "text": "CONCLUSION Immune check-point inhibitors should be considered a promising treatment option in GBM.",
                    "offsetInBeginSection": 980,
                    "offsetInEndSection": 1078,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363",
                    "text": "METHODS Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials.",
                    "offsetInBeginSection": 574,
                    "offsetInEndSection": 772,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528363",
                    "text": "RESULTS Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management.",
                    "offsetInBeginSection": 841,
                    "offsetInEndSection": 977,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775673",
                    "text": "CONCLUSION Our meta-analysis has demonstrated that the use of immune check point inhibitors is associated with an increased risk of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency compared with control.",
                    "offsetInBeginSection": 685,
                    "offsetInEndSection": 911,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676",
                    "text": "Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a novel class of inhibitors that function as a tumor suppressing factor via modulation of immune cell-tumor cell interaction.",
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 423,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28878676",
                    "text": "In recent times, more than four check point antibody inhibitors have been commercialized for targeting PD-1, PDL-1, and CTLA-4.",
                    "offsetInBeginSection": 588,
                    "offsetInEndSection": 715,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27403706",
                    "text": "check point inhibitors.",
                    "offsetInBeginSection": 296,
                    "offsetInEndSection": 319,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27403706",
                    "text": "Patients with BRAFv600 mutations can be treated with a combination of a BRAF-inhibitor and an MEK-inhibitor.",
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 192,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27403706",
                    "text": "AREAS COVERED We conducted a comprehensive review of the literature on the efficacy and predictive markers, safety, and pharmacoeconomics of ipilimumab in melanoma Expert commentary: Ipilimumab was the first check point inhibitor reaching the clinic, gaining FDA and EMA approval for metastatic melanoma in 2011.",
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 634,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f87c5b750ff4455000056",
            "body": "Are patients with Sjogren syndrome at increased risk for lymphoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27336863",
                "http://www.ncbi.nlm.nih.gov/pubmed/17562045",
                "http://www.ncbi.nlm.nih.gov/pubmed/16462517",
                "http://www.ncbi.nlm.nih.gov/pubmed/25368273",
                "http://www.ncbi.nlm.nih.gov/pubmed/2110929",
                "http://www.ncbi.nlm.nih.gov/pubmed/24159176",
                "http://www.ncbi.nlm.nih.gov/pubmed/20084442",
                "http://www.ncbi.nlm.nih.gov/pubmed/12064854",
                "http://www.ncbi.nlm.nih.gov/pubmed/24153350",
                "http://www.ncbi.nlm.nih.gov/pubmed/1608349"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336863",
                    "text": "The heightened risk of non-Hodgkin lymphoma (NHL) development in primary Sjogren syndrome (SS) is well established.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462517",
                    "text": "RECENT FINDINGS Despite a lack of a strong association between rheumatoid arthritis and cancer overall, studies show an increased risk for the development of lymphoma in rheumatoid arthritis.",
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462517",
                    "text": "Data substantiate an increased risk of certain cancers in systemic lupus erythematosus; the risk appears to be most heightened for lymphoma.",
                    "offsetInBeginSection": 911,
                    "offsetInEndSection": 1051,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25368273",
                    "text": "The average risk of lymphoma in RA may be composed of a markedly increased risk in patients with most severe disease.",
                    "offsetInBeginSection": 937,
                    "offsetInEndSection": 1054,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2110929",
                    "text": "Clinical features such as age, duration of disease, extent of lymphadenopathy, splenomegaly, or parotid swelling failed to identify those subsets of patients with lymphadenopathy at increased risk for lymphoma.",
                    "offsetInBeginSection": 1026,
                    "offsetInEndSection": 1236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24159176",
                    "text": "Several autoimmune diseases, including primary Sj\u00f6gren's syndrome (pSS), are associated with an increased risk for lymphoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24159176",
                    "text": "The rs2230926 exonic variant was associated with an increased risk for pSS complicated by lymphoma (odds ratio, 3.36 [95% confidence interval, 1.34-8.42], and odds ratio, 3.26 [95% confidence interval, 1.31-8.12], vs controls and pSS patients without lymphoma, respectively; P = .011).",
                    "offsetInBeginSection": 720,
                    "offsetInEndSection": 1005,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20084442",
                    "text": "These findings suggest that patients with pSS who have ACA may be a subgroup of patients at increased risk of extraglandular systemic manifestations and lymphoma.",
                    "offsetInBeginSection": 668,
                    "offsetInEndSection": 830,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12064854",
                    "text": "In contrast to secondary SS, the risk for developing non-Hodgkin's lymphoma is highly increased in patients with primary SS.",
                    "offsetInBeginSection": 293,
                    "offsetInEndSection": 417,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24153350",
                    "text": "Sjogren's syndrome (SS) is a chronic autoimmune disorder with the highest risk for lymphoma development among all autoimmune diseases.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e3d21b750ff4455000043",
            "body": "What is BBCAnalyzer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28241736"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "RESULTS BBCAnalyzer (Bases By CIGAR Analyzer) provides a novel visual approach to facilitate this step of time-consuming, manual inspection of common mutation sites.",
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 666,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "CONCLUSIONS BBCAnalyzer provides a unique, novel approach to facilitate variant calling where classical tools frequently fail to call.",
                    "offsetInBeginSection": 1412,
                    "offsetInEndSection": 1546,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "BBCAnalyzer is able to visualize base counts at predefined positions or regions in any sequence alignment data that are available as BAM files.",
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 810,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "Any expected mutations (e.g.",
                    "offsetInBeginSection": 373,
                    "offsetInEndSection": 401,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "Video demonstrating the exemplary usage of the web application \"BBCAnalyzer\".",
                    "offsetInBeginSection": 2026,
                    "offsetInEndSection": 2103,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "Thereby, the tool provides a straightforward solution for evaluating any list of expected mutations like hotspot mutations, or even whole regions of interest.",
                    "offsetInBeginSection": 811,
                    "offsetInEndSection": 969,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "Information on the counted number of bases, the reference bases, known mutations or polymorphisms, called mutations and base qualities is summarized in a single plot.",
                    "offsetInBeginSection": 1060,
                    "offsetInEndSection": 1226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "hotspot mutations), that have not been called by the software, need to be investigated manually.",
                    "offsetInBeginSection": 402,
                    "offsetInEndSection": 498,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "BACKGROUND Deriving valid variant calling results from raw next-generation sequencing data is a particularly challenging task, especially with respect to clinical diagnostics and personalized medicine.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241736",
                    "text": "A documentation of the R package (Additional file 1) as well as the web application (Additional file 2) with detailed descriptions, examples of all input- and output elements, exemplary code as well as exemplary data are included.",
                    "offsetInBeginSection": 1671,
                    "offsetInEndSection": 1901,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a871a6861bb38fb24000009",
            "body": "What disease is the ALK tyrosine kinase associated with?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27573755",
                "http://www.ncbi.nlm.nih.gov/pubmed/20223922",
                "http://www.ncbi.nlm.nih.gov/pubmed/25407901",
                "http://www.ncbi.nlm.nih.gov/pubmed/25351247",
                "http://www.ncbi.nlm.nih.gov/pubmed/18923525",
                "http://www.ncbi.nlm.nih.gov/pubmed/21829174",
                "http://www.ncbi.nlm.nih.gov/pubmed/27217763",
                "http://www.ncbi.nlm.nih.gov/pubmed/23714228",
                "http://www.ncbi.nlm.nih.gov/pubmed/23154552",
                "http://www.ncbi.nlm.nih.gov/pubmed/26811689"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755",
                    "text": "Two ALK tyrosine kinase inhibitors (TKIs), crizotinib and ceritinib, are currently approved in Europe for use in ALK-positive NSCLC and several others are in development.",
                    "offsetInBeginSection": 1103,
                    "offsetInEndSection": 1273,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20223922",
                    "text": "NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) and TPM3-ALK (nonmuscular tropomyosin 3-anaplastic lymphoma kinase) are oncogenic tyrosine kinases implicated in the pathogenesis of human ALK-positive lymphoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 212,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25407901",
                    "text": "In contrast, ALK tyrosine kinase inhibitor (ALK TKI) crizotinib has shown superior effects in combating NSCLCs with EML4-ALK.",
                    "offsetInBeginSection": 450,
                    "offsetInEndSection": 575,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25407901",
                    "text": "It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib.",
                    "offsetInBeginSection": 254,
                    "offsetInEndSection": 449,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25407901",
                    "text": "BACKGROUND The translocations of the anaplastic lymphoma kinase (ALK) gene with the echinoderm microtubule-associated protein-like 4 (EML4) gene on chromosome 2p have been identified in non-small-cell lung cancers (NSCLCs) as oncogenic driver mutations.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 253,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25351247",
                    "text": "Although tyrosine kinase inhibitors abrogating ALK activity are currently in clinical use for the treatment of ALK-positive (ALK(+)) disease, monotherapy with ALK tyrosine kinase inhibitors may not be an adequate solution for ALK(+) neuroblastoma patients.",
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 340,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27217763",
                    "text": "Crizotinib was the first ALK tyrosine kinase inhibitor licensed for the treatment of metastatic ALK-positive NSCLC based on a randomized Phase III trial.",
                    "offsetInBeginSection": 167,
                    "offsetInEndSection": 320,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23714228",
                    "text": "CASE PRESENTATION We report that a case of EML4-ALK-positive NSCLC with EGFR mutation had a response of stable disease to both an EGFR tyrosine kinase inhibitor (EGFR-TKI) and ALK inhibitor.",
                    "offsetInBeginSection": 355,
                    "offsetInEndSection": 545,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23714228",
                    "text": "BACKGROUND The EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) fusion oncogene represents a novel molecular target in a small subset of non-small-cell lung cancers (NSCLCs).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26811689",
                    "text": "Anaplastic lymphoma kinase (ALK) rearrangement lung cancer responds to ALK tyrosine kinase inhibitors.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f8dc6b750ff4455000058",
            "body": "Is trastuzumab associated cardiotoxicity reversible?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26836985",
                "http://www.ncbi.nlm.nih.gov/pubmed/19669637",
                "http://www.ncbi.nlm.nih.gov/pubmed/24905295",
                "http://www.ncbi.nlm.nih.gov/pubmed/18514938",
                "http://www.ncbi.nlm.nih.gov/pubmed/21310845",
                "http://www.ncbi.nlm.nih.gov/pubmed/15177418",
                "http://www.ncbi.nlm.nih.gov/pubmed/18484781",
                "http://www.ncbi.nlm.nih.gov/pubmed/23282614",
                "http://www.ncbi.nlm.nih.gov/pubmed/14613026",
                "http://www.ncbi.nlm.nih.gov/pubmed/19147689"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985",
                    "text": "The cardiotoxicity of antibodies has been associated to trastuzumab, a humanized anti-ErbB2 monoclonal antibody currently in clinical use for the therapy of breast carcinomas, which induces cardiac dysfunction when used in monotherapy, or in combination with anthracyclines.",
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 837,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836985",
                    "text": "Two categories of cardiotoxic side effects of antineoplastic drugs have been previously proposed: Type I cardiotoxicity, defined as permanent cardiotoxicity, is usually caused by anthracyclines; Type II cardiotoxicity, considered as reversible cardiotoxicity, has been mainly related to monoclonal antibodies.",
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 562,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637",
                    "text": "INTRODUCTION Although having high clinical efficacy in the treatment of human epidermal growth factor receptor-2 (HER2+) metastatic breast cancer, trastuzumab has been associated with cardiotoxicity, and the etiology and pathogenesis of this condition is currently under investigation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 285,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19669637",
                    "text": "RESULTS The increased risk of cardiotoxicity is lower when trastuzumab is given as monotherapy (3%-7%) compared with anthracyclines + trastuzumab therapy (27%).",
                    "offsetInBeginSection": 442,
                    "offsetInEndSection": 602,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18514938",
                    "text": "Although reversible in most cases, cardiotoxicity frequently results in the discontinuation of trastuzumab.",
                    "offsetInBeginSection": 356,
                    "offsetInEndSection": 463,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21310845",
                    "text": "The long-term significance of these events, isolating known cardiotoxic effects of anthracyclines from those of trastuzumab, and the appropriateness of referring to trastuzumab-related cardiotoxicity as reversible rather than responsive to trastuzumab withdrawal and heart failure medical therapy, are issues that continue to be debated.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 487,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21310845",
                    "text": "The use of trastuzumab in the adjuvant and metastatic treatment of breast cancer is associated with both symptomatic and asymptomatic cardiotoxicity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18484781",
                    "text": "Cardiotoxicity has been shown to be potentiated when the agent is used concurrently or sequentially with an anthracycline, and this has limited the use of trastuzumab in some patients.",
                    "offsetInBeginSection": 533,
                    "offsetInEndSection": 717,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18484781",
                    "text": "Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor tyrosine kinase HER2/ErbB2.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19147689",
                    "text": "Concomitant anthracycline therapy significantly increases the risk for cardiotoxicity during trastuzumab treatment, and such regimens are therefore not recommended.",
                    "offsetInBeginSection": 415,
                    "offsetInEndSection": 579,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e3fe3b750ff4455000044",
            "body": "Does the human lncRNA LINC-PINT promote tumorigenesis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29078818"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "RESULTS Here we characterize the function of the p53-regulated human lncRNA LINC-PINT in cancer.",
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 501,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "We find that LINC-PINT is downregulated in multiple types of cancer and acts as a tumor suppressor lncRNA by reducing the invasive phenotype of cancer cells.",
                    "offsetInBeginSection": 502,
                    "offsetInEndSection": 659,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "CONCLUSIONS Our findings support a conserved functional co-dependence between LINC-PINT and PRC2 and lead us to propose a new mechanism where the lncRNA regulates the availability of free PRC2 at the proximity of co-regulated genomic loci.",
                    "offsetInBeginSection": 970,
                    "offsetInEndSection": 1209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "This sequence mediates a specific interaction with PRC2, necessary for the LINC-PINT-dependent repression of a pro-invasion signature of genes regulated by the transcription factor EGR1.",
                    "offsetInBeginSection": 781,
                    "offsetInEndSection": 967,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "A cross-species analysis identifies a highly conserved sequence element in LINC-PINT that is essential for its function.",
                    "offsetInBeginSection": 660,
                    "offsetInEndSection": 780,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "BACKGROUND It is now obvious that the majority of cellular transcripts do not code for proteins, and a significant subset of them are long non-coding RNAs (lncRNAs).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "Many lncRNAs show aberrant expression in cancer, and some of them have been linked to cell transformation.",
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 272,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29078818",
                    "text": "However, the underlying mechanisms remain poorly understood and it is unknown how the sequences of lncRNA dictate their function.",
                    "offsetInBeginSection": 273,
                    "offsetInEndSection": 402,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a871b8d61bb38fb2400000a",
            "body": "What body process does the Dentate Gyrus Mossy Cell control?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18189312",
                "http://www.ncbi.nlm.nih.gov/pubmed/9187278",
                "http://www.ncbi.nlm.nih.gov/pubmed/17765742",
                "http://www.ncbi.nlm.nih.gov/pubmed/14999076",
                "http://www.ncbi.nlm.nih.gov/pubmed/10531454",
                "http://www.ncbi.nlm.nih.gov/pubmed/1308178",
                "http://www.ncbi.nlm.nih.gov/pubmed/18077687",
                "http://www.ncbi.nlm.nih.gov/pubmed/24811867",
                "http://www.ncbi.nlm.nih.gov/pubmed/7721998",
                "http://www.ncbi.nlm.nih.gov/pubmed/11043552"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18189312",
                    "text": "In the examined four monkey species, mossy cells were found to be calretinin-positive at the uncal pole and at variable length within the main body of the dentate gyrus but not in the tail part.",
                    "offsetInBeginSection": 580,
                    "offsetInEndSection": 774,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9187278",
                    "text": "Mossy cells in the hilus of the rat dentate gyrus are the main cells of origin of the dentate commissural and associational projections.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17765742",
                    "text": "The influence on granule cells is indirect, through hilar mossy cells and GABAergic neurons of the dentate gyrus, and appears to include direct projections in the case of CA3c pyramidal cells of ventral hippocampus.",
                    "offsetInBeginSection": 1638,
                    "offsetInEndSection": 1853,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14999076",
                    "text": "However, whether it is the disappearance of hilar mossy cells from the dentate gyrus circuitry after various insults or the subsequent synaptic-cellular alterations (e.g., reactive axonal sprouting) that lead to dentate hyperexcitability has not been rigorously tested, because of the lack of available techniques to rapidly remove specific classes of nonprincipal cells from neuronal networks.",
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 766,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531454",
                    "text": "These findings support hypotheses of temporal lobe epileptogenesis that involve mossy cell and somatostatinergic neuron loss and suggest that lateral inhibition in the dentate gyrus does not require mossy cells but, instead, may be generated directly by GABAergic interneurons.",
                    "offsetInBeginSection": 1462,
                    "offsetInEndSection": 1739,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531454",
                    "text": "Kainate-treated rats lose an average of 52% of their GAD-negative hilar neurons (putative mossy cells) and 13% of their GAD-positive cells (GABAergic interneurons) in the dentate gyrus.",
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 508,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1308178",
                    "text": "The present results indicate that connections between granule cells and hilar mossy cells of the human dentate gyrus develop through an extended postnatal period of time that may last until the fifth year.",
                    "offsetInBeginSection": 1584,
                    "offsetInEndSection": 1789,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18077687",
                    "text": "Semilunar granule cells appear to represent a distinct excitatory neuron population in the dentate gyrus that may be an important target for mossy fiber sprouting in patients and rodent models of temporal lobe epilepsy.",
                    "offsetInBeginSection": 1050,
                    "offsetInEndSection": 1269,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24811867",
                    "text": "This complex arrangement of cells and processes allowed us to study the combined effect of mossy fiber sprouting, altered apical dendritic tree and dendritic spine loss in newborn granule cells on the excitability of the dentate gyrus model.",
                    "offsetInBeginSection": 1305,
                    "offsetInEndSection": 1546,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7721998",
                    "text": "These results establish the validity of Timm staining as a marker for mossy fiber sprouting and support the view that status epilepticus provokes the formation of a novel recurrent excitatory circuit in the dentate gyrus.",
                    "offsetInBeginSection": 1829,
                    "offsetInEndSection": 2050,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f922fb750ff4455000059",
            "body": "Can canagliflozin cause euglycemic diabetic ketoacidosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27375734",
                "http://www.ncbi.nlm.nih.gov/pubmed/28090050",
                "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
                "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
                "http://www.ncbi.nlm.nih.gov/pubmed/27088018"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734",
                    "text": "We are reporting a timely case of atypical euglycemic diabetic ketoacidosis in a type 1 diabetic patient treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor canagliflozin.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734",
                    "text": "Euglycemic ketoacidosis did not recur in our patient after discontinuing canagliflozin.",
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 595,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050",
                    "text": "We herein report the case of a 27-year-old Asian woman with type 2 diabetes who was treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin) who developed euglycemic diabetic ketoacidosis and persistent diuresis in the absence of hyperglycemia.",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 442,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050",
                    "text": "Diabetic ketoacidosis is characterized by hyperglycemia, anion-gap acidosis, and increased plasma ketones.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
                    "text": "We present a case of euglycemic diabetic ketoacidosis secondary to canagliflozin in a type 2 diabetic patient.",
                    "offsetInBeginSection": 558,
                    "offsetInEndSection": 668,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
                    "text": "Ketoacidosis is a significant and often a life-threatening complication of diabetes mellitus seen mostly in type 1 diabetes mellitus as well as occasionally in type 2 diabetes mellitus.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
                    "text": "Diabetic ketoacidosis usually manifests with high blood glucose more than 250\u2009mg/dL, but euglycemic diabetic ketoacidosis is defined as ketoacidosis associated with blood glucose level less than 250\u2009mg/dL.",
                    "offsetInBeginSection": 186,
                    "offsetInEndSection": 395,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
                    "text": "SGLT2 inhibitors such as canagliflozin may predispose patients not only to diabetic ketoacidosis but also to prolonged glucosuria.",
                    "offsetInBeginSection": 1103,
                    "offsetInEndSection": 1233,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27088018",
                    "text": "However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported.",
                    "offsetInBeginSection": 333,
                    "offsetInEndSection": 478,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27088018",
                    "text": "Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e4136b750ff4455000045",
            "body": "Describe the Match BAM to VCF (MBV) method.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28186259"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28186259",
                    "text": "Results We described here MBV (Match BAM to VCF); a method to quickly solve sample mislabeling and detect cross-sample contamination and PCR amplification bias.",
                    "offsetInBeginSection": 189,
                    "offsetInEndSection": 349,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28186259",
                    "text": "Availability and Implementation MBV is implemented in C\u2009++\u2009as an independent component of the QTLtools software package, the binary and source codes are freely available at https://qtltools.github.io/qtltools/ .",
                    "offsetInBeginSection": 352,
                    "offsetInEndSection": 567,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28186259",
                    "text": "Motivation Large genomic datasets combining genotype and sequence data, such as for expression quantitative trait loci (eQTL) detection, require perfect matching between both data types.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28186259",
                    "text": "Supplementary information Supplementary data are available at Bioinformatics online.",
                    "offsetInBeginSection": 641,
                    "offsetInEndSection": 725,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28186259",
                    "text": "Contact olivier.delaneau@unige.ch or emmanouil.dermitzakis@unige.ch.",
                    "offsetInBeginSection": 570,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a897601fcd1d6a10c000008",
            "body": "A SLEDAI score is associated with Systemic Lupus Erythematosus. What is a SLEDAI score?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10685800",
                "http://www.ncbi.nlm.nih.gov/pubmed/19762400",
                "http://www.ncbi.nlm.nih.gov/pubmed/22516994",
                "http://www.ncbi.nlm.nih.gov/pubmed/27365721",
                "http://www.ncbi.nlm.nih.gov/pubmed/23172751",
                "http://www.ncbi.nlm.nih.gov/pubmed/17477466",
                "http://www.ncbi.nlm.nih.gov/pubmed/16354890",
                "http://www.ncbi.nlm.nih.gov/pubmed/23647447",
                "http://www.ncbi.nlm.nih.gov/pubmed/8235662",
                "http://www.ncbi.nlm.nih.gov/pubmed/11480850"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10685800",
                    "text": "OBJECTIVE To determine whether Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores correlate with the clinician's impression of level of disease activity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19762400",
                    "text": "The objective of this study is to determine if digital vasculitis (DV), a clinical manifestation with a high systemic lupus erythematosus disease activity index (SLEDAI) score, is associated with lupus severity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516994",
                    "text": "The antepartum SLEDAI score was 6.2\u00b11.6, the postpartum SLEDAI score  was 6.4\u00b12.9.",
                    "offsetInBeginSection": 673,
                    "offsetInEndSection": 757,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516994",
                    "text": "The impact of the disease duration, the use of cyclophosphamide, the highest systematic lupus erythematosus disease activity index  (SLEDAI) score during the disease and the antepartum SLEDAI score to the outcome of delivery were analyzed.",
                    "offsetInBeginSection": 313,
                    "offsetInEndSection": 552,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27365721",
                    "text": "Systemic lupus erythematosus disease activity index (SLEDAI), C3, C4 and anti-double stranded DNA levels were estimated and repeated monthly till remission.",
                    "offsetInBeginSection": 297,
                    "offsetInEndSection": 453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23172751",
                    "text": "METHODS Patients who met \u22654 of the American College of Rheumatology criteria, had a score of \u22656 on the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and did not have an A score on the British Isles Lupus Assessment Group (BILAG)-2004 scale were eligible.",
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 458,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17477466",
                    "text": "OBJECTIVE To determine the flare rate and the change in Safety of Estrogens in Lupus Erythematosus: National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) score with disease flare in pediatric systemic lupus erythematosus (pSLE).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 262,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16354890",
                    "text": "Secondary outcomes included the maximum SLEDAI score, change in SLEDAI score, incidence of lupus flares, median time to first flare, systemic lupus erythematosus treatment, and adverse events.",
                    "offsetInBeginSection": 637,
                    "offsetInEndSection": 829,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16354890",
                    "text": "Disease activity was assessed at 0, 1, 2, 3, 6, 9, and 12 months according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).",
                    "offsetInBeginSection": 379,
                    "offsetInEndSection": 522,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11480850",
                    "text": "Sociodemographic, disease activity using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), therapy and laboratory variables were evaluated.",
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 539,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f941eb750ff445500005b",
            "body": "What is the association between kidney donation risk of gestational complications?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27591246",
                "http://www.ncbi.nlm.nih.gov/pubmed/26090646",
                "http://www.ncbi.nlm.nih.gov/pubmed/18798006",
                "http://www.ncbi.nlm.nih.gov/pubmed/22252087",
                "http://www.ncbi.nlm.nih.gov/pubmed/26558022",
                "http://www.ncbi.nlm.nih.gov/pubmed/12351541",
                "http://www.ncbi.nlm.nih.gov/pubmed/26895841",
                "http://www.ncbi.nlm.nih.gov/pubmed/19353771",
                "http://www.ncbi.nlm.nih.gov/pubmed/27271097",
                "http://www.ncbi.nlm.nih.gov/pubmed/15240849"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27591246",
                    "text": "A modest rise in uric acid levels beginning early after donation, and a small (1.4%) increase in the 8-year incidence of gout, have also been reported in comparisons to healthy nondonors.",
                    "offsetInBeginSection": 965,
                    "offsetInEndSection": 1152,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26090646",
                    "text": "Kidney donation seems to elevate the risks of gestational hypertension and pre-eclampsia.",
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 551,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26090646",
                    "text": "Living kidney donation is associated with an increased risk of end-stage renal disease, although this outcome is uncommon (<0\u00b75% increase in incidence at 15 years).",
                    "offsetInBeginSection": 296,
                    "offsetInEndSection": 461,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22252087",
                    "text": "BACKGROUND Although older maternal age is a risk factor for pregnancy complications, an increasing number of women delay conception until the age of 40, and some must resort to IVF with oocyte donation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12351541",
                    "text": "LBW deliveries were significantly associated with PIH, STB, nulliparity and maternal smoking.",
                    "offsetInBeginSection": 950,
                    "offsetInEndSection": 1043,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12351541",
                    "text": "CONCLUSIONS There is a high risk of obstetric complications in singleton oocyte donation pregnancies, but the perinatal outcomes are favourable.",
                    "offsetInBeginSection": 1189,
                    "offsetInEndSection": 1333,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26895841",
                    "text": "We conclude that medical complications experienced by either the donor or recipient is a risk factor for deterioration in donors' mental health after living kidney donation.",
                    "offsetInBeginSection": 1165,
                    "offsetInEndSection": 1338,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26895841",
                    "text": "A minority of living kidney donors (between 5-25%) have poor psychological outcomes after donation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 99,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27271097",
                    "text": "WIDER IMPLICATIONS Oocyte donation pregnancies are associated with a higher rate of placental disorders of pregnancy, such as gestational hypertension and pre-eclampsia.",
                    "offsetInBeginSection": 1320,
                    "offsetInEndSection": 1489,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15240849",
                    "text": "Major complications after kidney donation are rare.",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e4592b750ff4455000047",
            "body": "What is the 959 Nematode Genomes initiative?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24058822",
                "http://www.ncbi.nlm.nih.gov/pubmed/22044053"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822",
                    "text": "To inspire, promote and coordinate genomic sequencing across the diversity of the phylum, we have launched a community wiki and the 959 Nematode Genomes initiative (www.nematodegenomes.org/).",
                    "offsetInBeginSection": 1003,
                    "offsetInEndSection": 1194,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822",
                    "text": "Just as the deciphering of the developmental lineage of the 959 cells of the adult hermaphrodite C. elegans was the gateway to broad advances in biomedical science, we hope that a nematode phylogeny with (at least) 959 sequenced species will underpin further advances in understanding the origins of parasitism, the dynamics of genomic change and the adaptations that have made Nematoda one of the most successful animal phyla.",
                    "offsetInBeginSection": 1195,
                    "offsetInEndSection": 1622,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822",
                    "text": "The sequencing of the complete genome of the nematode Caenorhabditis elegans was a landmark achievement and ushered in a new era of whole-organism, systems analyses of the biology of this powerful model organism.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 212,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822",
                    "text": "The advent of second-generation sequencing technologies, improvements in computing algorithms and infrastructure and growth in bioinformatics and genomics literacy is making the addition of genome sequencing to the research goals of any nematode research program a less daunting prospect.",
                    "offsetInBeginSection": 714,
                    "offsetInEndSection": 1002,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058822",
                    "text": "The success of the C. elegans genome sequencing project also inspired communities working on other organisms to approach genome sequencing of their species.",
                    "offsetInBeginSection": 213,
                    "offsetInEndSection": 369,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053",
                    "text": "These efforts are being coordinated through the 959 Nematode Genomes initiative.",
                    "offsetInBeginSection": 1379,
                    "offsetInEndSection": 1459,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053",
                    "text": "Many nematode species have been investigated through the use of the expressed sequence tag approach, which samples from the transcribed genome.",
                    "offsetInBeginSection": 710,
                    "offsetInEndSection": 853,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053",
                    "text": "The development of new high-throughput DNA-sequencing technologies has facilitated transcriptomic and genomic approaches to parasite biology.",
                    "offsetInBeginSection": 1116,
                    "offsetInEndSection": 1257,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053",
                    "text": "The diversity of biology in nematodes is reflected in the diversity of their genomes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044053",
                    "text": "Wide sampling across nematode diversity allows phylogenetically informed formulation of research hypotheses, identification of core features shared by all species or important evolutionary novelties present in isolated clades.",
                    "offsetInBeginSection": 483,
                    "offsetInEndSection": 709,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a897927fcd1d6a10c00000a",
            "body": "What does A1C measure?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20923490",
                "http://www.ncbi.nlm.nih.gov/pubmed/18030866",
                "http://www.ncbi.nlm.nih.gov/pubmed/16336550",
                "http://www.ncbi.nlm.nih.gov/pubmed/23990520",
                "http://www.ncbi.nlm.nih.gov/pubmed/18509211",
                "http://www.ncbi.nlm.nih.gov/pubmed/28843470",
                "http://www.ncbi.nlm.nih.gov/pubmed/22301123",
                "http://www.ncbi.nlm.nih.gov/pubmed/24511995",
                "http://www.ncbi.nlm.nih.gov/pubmed/20861123",
                "http://www.ncbi.nlm.nih.gov/pubmed/28964455"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18030866",
                    "text": "A CONCEPTUAL MODEL FOR ASSESSING THE QUALITY OF GLYCEMIC CONTROL A continuous measure of A1C, as the cornerstone in quality assessment for diabetes, can incorporate each of the Institute of Medicine's (IOM)'s quality domains: effectiveness and equity, patient safety, patient-centered care, timeliness, and efficiency.",
                    "offsetInBeginSection": 933,
                    "offsetInEndSection": 1251,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18030866",
                    "text": "CONCLUSIONS A continuous measure of A1C can better capture than a dichotomous measure the complexity of glycemic control at a population level.",
                    "offsetInBeginSection": 1254,
                    "offsetInEndSection": 1397,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16336550",
                    "text": "OBJECTIVE To study within-patient longitudinal changes in A1c levels at Veterans Health Administration (VHA) facilities as an alternative to cross-sectional measures of quality of diabetes care.",
                    "offsetInBeginSection": 181,
                    "offsetInEndSection": 375,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16336550",
                    "text": "PATIENTS Diabetic veteran users with A1c measurement performed using National Glycosylated Hemoglobin Standardization Project certified A1c lab assay methods.",
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 813,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18509211",
                    "text": "We assessed differences in A1C performance measure threshold attainment by case mix factors for A1C >9% and examined how lowering the threshold to A1C >8% or >7% changed these differences.",
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 437,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28843470",
                    "text": "RESULTS Among 253 dyads, the frequencies of patients compared to caregivers who could accurately describe what the A1C level assesses, identify the ideal A1C target, and identify the ideal BG range were 20 vs. 66, 31 vs. 56, and 72 vs. 76%, respectively.",
                    "offsetInBeginSection": 733,
                    "offsetInEndSection": 987,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28843470",
                    "text": "METHODS Patients (8 to 18 years) with T1D and caregivers completed questionnaires that queried their perceptions of (1) what the A1C level assesses, (2) the ideal A1C target, and (3) the ideal BG range.",
                    "offsetInBeginSection": 358,
                    "offsetInEndSection": 560,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28843470",
                    "text": "OBJECTIVES (1) to describe pediatric patients with T1D and their caregivers' perceptions of measures of glycemic control (hemoglobin [A1C] and blood glucose [BG] levels) and (2) to determine the relationship between patients' and caregivers' perceptions of measures of glycemic control with actual A1C levels and adherence to diabetes self-care behaviors.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 355,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28964455",
                    "text": "OBJECTIVES To estimate the impact of increased glycated hemoglobin (A1C) monitoring and treatment intensification for patients with type 2 diabetes (T2D) on quality measures and reimbursement within the Medicare Advantage Star (MA Star) program.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28964455",
                    "text": "Using the estimated changes in measured A1C levels, we calculated corresponding changes in the plan-level A1C quality measure, overall star rating, and reimbursement.",
                    "offsetInBeginSection": 554,
                    "offsetInEndSection": 720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f98e6b750ff445500005d",
            "body": "Which ligament is most commonly injured in dashboard injury?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3425783",
                "http://www.ncbi.nlm.nih.gov/pubmed/7377448",
                "http://www.ncbi.nlm.nih.gov/pubmed/22890899",
                "http://www.ncbi.nlm.nih.gov/pubmed/27623865",
                "http://www.ncbi.nlm.nih.gov/pubmed/15062581",
                "http://www.ncbi.nlm.nih.gov/pubmed/15474227",
                "http://www.ncbi.nlm.nih.gov/pubmed/20110155",
                "http://www.ncbi.nlm.nih.gov/pubmed/18980604",
                "http://www.ncbi.nlm.nih.gov/pubmed/21257845",
                "http://www.ncbi.nlm.nih.gov/pubmed/19468882"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425783",
                    "text": "Hyperflexion was the most common mechanism of injury, followed by pretibial trauma in the hyperflexed knee or in the \"dashboard\" injury.",
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 574,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7377448",
                    "text": "The anterior cruciate ligament (50%) is most often injured followed by the medial collateral ligament (31%), lateral collateral ligament (13%), and posterior cruciate ligament (6%).",
                    "offsetInBeginSection": 765,
                    "offsetInEndSection": 946,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890899",
                    "text": "The medial collateral ligament (MCL) is the most commonly injured ligament of the knee.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27623865",
                    "text": "CONCLUSIONS The anterior inferior tibiofibular ligament is the most commonly injured ligament in the syndesmosis in sports injury and results in subtle variations in the syndesmotic anatomy, which plain radiographs cannot assess.",
                    "offsetInBeginSection": 1181,
                    "offsetInEndSection": 1410,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15474227",
                    "text": "The ulnar collateral ligament (UCL) is more commonly injured than previously suggested.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15474227",
                    "text": "Injury to this ligament can result in secondary symptoms and problems in other parts of the elbow, including the ulnar nerve, the flexor-pronator musculotendinous unit, the radiocapitellar joint, and the posterior compartment of the elbow, in addition to being a cause of loose bodies within the elbow.",
                    "offsetInBeginSection": 88,
                    "offsetInEndSection": 390,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18980604",
                    "text": "The thigh, especially the hamstrings, was the overall most commonly injured region in both sexes, while the hip/groin was more commonly injured in male players and the knee in female players.",
                    "offsetInBeginSection": 568,
                    "offsetInEndSection": 759,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21257845",
                    "text": "BACKGROUND Humeral avulsion of the inferior glenohumeral ligament is a rare injury resulting from hyperabduction and external rotation, and it is most commonly seen with sports-related injuries, including those from volleyball.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21257845",
                    "text": "The anterior band of the inferior glenohumeral ligament is most commonly injured (93%), whereas the posterior band is infrequently injured.",
                    "offsetInBeginSection": 228,
                    "offsetInEndSection": 367,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19468882",
                    "text": "The medial collateral ligament is one of the most commonly injured ligaments of the knee.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e49a4b750ff445500004b",
            "body": "Is LDB1-mediated enhancer looping dependent on cohesin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28520978"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "text": "Moreover, ENCODE data and our chromatin immunoprecipitation results indicate that cohesin is almost completely absent from validated and predicted LDB1-regulated erythroid enhancer-gene pairs.",
                    "offsetInBeginSection": 1172,
                    "offsetInEndSection": 1364,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "text": "Thus, lineage specific factors largely mediate enhancer-promoter looping in erythroid cells independent of mediator and cohesin.",
                    "offsetInBeginSection": 1365,
                    "offsetInEndSection": 1493,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "text": "Further, Cas9-directed tethering of mutant LDB1 to the \u03b2-globin promoter forced LCR loop formation in the absence of mediator or cohesin occupancy.",
                    "offsetInBeginSection": 1023,
                    "offsetInEndSection": 1171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "text": "Mechanistic studies in erythroid cells indicate that LDB1, as part of a GATA1/TAL1/LMO2 complex, brings erythroid-expressed genes into proximity with enhancers for transcription activation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "text": "To separate the roles of LDB1 and mediator in LCR looping, we expressed a looping-competent but transcription-activation deficient form of LDB1 in LDB1 knock down cells: LCR/\u03b2-globin proximity was restored without mediator core occupancy.",
                    "offsetInBeginSection": 783,
                    "offsetInEndSection": 1022,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "text": "Additional deletion of the promoter GATA1 site eliminated LDB1 complex and mediator occupancy and resulted in loss of LCR/\u03b2-globin proximity.",
                    "offsetInBeginSection": 640,
                    "offsetInEndSection": 782,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "text": "CRISPR/Cas9 editing of the \u03b2-globin promoter to eliminate the RNA Pol II PIC by deleting the TATA-box resulted in loss of transcription, but enhancer-promoter interaction was unaffected.",
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 639,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "text": "Here we tested the contributions of the RNA Pol II pre-initiation complex (PIC), mediator and cohesin to establishment of locus control region (LCR)/\u03b2-globin proximity.",
                    "offsetInBeginSection": 282,
                    "offsetInEndSection": 451,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28520978",
                    "text": "The role of co-activators in establishing this long-range interaction is poorly understood.",
                    "offsetInBeginSection": 190,
                    "offsetInEndSection": 281,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a897a06fcd1d6a10c00000b",
            "body": "What is the normal body temperature in dogs?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/495147",
                "http://www.ncbi.nlm.nih.gov/pubmed/25854787",
                "http://www.ncbi.nlm.nih.gov/pubmed/2759725",
                "http://www.ncbi.nlm.nih.gov/pubmed/28216687",
                "http://www.ncbi.nlm.nih.gov/pubmed/21102554",
                "http://www.ncbi.nlm.nih.gov/pubmed/22058348",
                "http://www.ncbi.nlm.nih.gov/pubmed/9656028",
                "http://www.ncbi.nlm.nih.gov/pubmed/11913416",
                "http://www.ncbi.nlm.nih.gov/pubmed/19575699",
                "http://www.ncbi.nlm.nih.gov/pubmed/6617751"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147",
                    "text": "The effect of intraventricular injection of thyroxine 1 microgram/animal on body temperature was studied in dogs under resting conditions: at normal ambient temperature, at high ambient temperature (35 degrees C) and during administration of pyrogen.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147",
                    "text": "Thyroxine exerted its central action on body temperature only in dogs performing physical exercise.",
                    "offsetInBeginSection": 387,
                    "offsetInEndSection": 486,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/495147",
                    "text": "Besides, changes in body temperature were elucidated in dogs performing physical exercise following I.V.",
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 355,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21102554",
                    "text": "CONCLUSION These findings document an association between obesity and reduced body temperature in dogs and support the hypothesis that obesity in this and other species of homeotherms may result from an increase in metabolic efficiency achieved by a regulated lowering of body temperature.",
                    "offsetInBeginSection": 1097,
                    "offsetInEndSection": 1386,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21102554",
                    "text": "METHODS We compared the rectal temperature of lean dogs and obese dogs by (a) conducting cross-sectional measurements in 287 dogs of many breeds varying greatly in body size, (b) conducting longitudinal measurements in individual dogs over 7-10 years and (c) tracking rectal temperature of lean and obese dogs at 3-h intervals for 48 consecutive hours in the laboratory.",
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 817,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22058348",
                    "text": "All dogs with TB had a normal body temperature, and three had systemic disease and one had clinical signs limited to testicular disease.",
                    "offsetInBeginSection": 629,
                    "offsetInEndSection": 765,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11913416",
                    "text": "Compared with normal gravity controls, exposed dogs showed a slower growth rate and a reduced amount of body fat.",
                    "offsetInBeginSection": 557,
                    "offsetInEndSection": 670,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11913416",
                    "text": "Initially, centrifuged dogs showed transient decreases in heart rate and body temperature along with changes in their diurnal rhythm patterns.",
                    "offsetInBeginSection": 414,
                    "offsetInEndSection": 556,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11913416",
                    "text": "In spite of the various changes noted, results from this and other studies affirm the view that dogs can tolerate and adapt to sustained loads as high as 2.5 g without serious impairment of their body structure and function.",
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1262,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6617751",
                    "text": "The effects of morphine and pentobarbital on body temperature and heart rate were studied in a line of pointer dogs characterized as genetically nervous.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70d12899e2c3af26000001",
            "body": "List symptoms of Heerfordt syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17637529",
                "http://www.ncbi.nlm.nih.gov/pubmed/20184241",
                "http://www.ncbi.nlm.nih.gov/pubmed/18454397",
                "http://www.ncbi.nlm.nih.gov/pubmed/22565854",
                "http://www.ncbi.nlm.nih.gov/pubmed/25087562",
                "http://www.ncbi.nlm.nih.gov/pubmed/26885424",
                "http://www.ncbi.nlm.nih.gov/pubmed/25685372",
                "http://www.ncbi.nlm.nih.gov/pubmed/2307892",
                "http://www.ncbi.nlm.nih.gov/pubmed/21706840",
                "http://www.ncbi.nlm.nih.gov/pubmed/27549672"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17637529",
                    "text": "This case demonstrates the importance of being aware of the leading clinical signs and symptoms in case of Heerfordt syndrome.",
                    "offsetInBeginSection": 774,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241",
                    "text": "Various clinical symptoms indicated Heerfordt syndrome.",
                    "offsetInBeginSection": 638,
                    "offsetInEndSection": 693,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184241",
                    "text": "We found no cases of familial sarcoidosis with Heerfordt syndrome in the literature.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397",
                    "text": "Chest computed tomography and transbronchial lymph node biopsy set the diagnosis of sarcoidosis.",
                    "offsetInBeginSection": 668,
                    "offsetInEndSection": 764,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397",
                    "text": "BACKGROUND Heerfordt syndrome is rare and is characterized by fever, uveitis, parotid gland enlargement, and facial nerve palsy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18454397",
                    "text": "We hereby present a case of Heerfordt syndrome with unilateral facial nerve palsy as a presentation of sarcoidosis.",
                    "offsetInBeginSection": 129,
                    "offsetInEndSection": 244,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22565854",
                    "text": "Angiography revealed a dense pattern of hyperfluorescent lesions and these observations resulted in the diagnosis of Heerfordt syndrome.",
                    "offsetInBeginSection": 401,
                    "offsetInEndSection": 537,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25087562",
                    "text": "Other examinations revealed bilateral hilar lymphadenopathy, high serum titer of angiotensin coenzyme, and no response in a tuberculin-tested, non-caseating epithelioid granuloma from lip biopsy, leading to the diagnosis of complete Heerfordt syndrome.",
                    "offsetInBeginSection": 479,
                    "offsetInEndSection": 731,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685372",
                    "text": "Heerfordt's syndrome as a cause of facial palsy is very rare.",
                    "offsetInBeginSection": 124,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2307892",
                    "text": "Heerfordt syndrome is an unusual manifestation of systemic sarcoidosis and is characterized by parotitis, uveitis, and facial nerve paralysis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e4b72b750ff445500004c",
            "body": "Is there any link between ERCC1-XPF and cohesin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                "http://www.ncbi.nlm.nih.gov/pubmed/14512883",
                "http://www.ncbi.nlm.nih.gov/pubmed/20518486",
                "http://www.ncbi.nlm.nih.gov/pubmed/24158589",
                "http://www.ncbi.nlm.nih.gov/pubmed/14706347",
                "http://www.ncbi.nlm.nih.gov/pubmed/10882712",
                "http://www.ncbi.nlm.nih.gov/pubmed/12509251",
                "http://www.ncbi.nlm.nih.gov/pubmed/11160918",
                "http://www.ncbi.nlm.nih.gov/pubmed/12202770",
                "http://www.ncbi.nlm.nih.gov/pubmed/15199134"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "text": "We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders.",
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 1051,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "text": "Using an in vivo biotinylation tagging approach in mice, we show that the nucleotide excision repair (NER) structure-specific endonuclease ERCC1-XPF complex interacts with the insulator binding protein CTCF, the cohesin subunits SMC1A and SMC3 and with MBD2; the factors co-localize with ATRX at the promoters and control regions (ICRs) of imprinted genes during postnatal hepatic development.",
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 521,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368372",
                    "text": "Loss of Ercc1 or exposure to MMC triggers the localization of CTCF to heterochromatin, the dissociation of the CTCF-cohesin complex and ATRX from promoters and ICRs, altered histone marks and\u00a0the aberrant developmental expression of imprinted genes without altering DNA methylation.",
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20518486",
                    "text": "This binding between FANCG and the ERCC1-XPF endonuclease, combined with our previous studies which show that FANCG is involved in the incision step mediated by ERCC1-XPF, establishes a link between an FA protein and the critical unhooking step of the ICL repair process.",
                    "offsetInBeginSection": 1428,
                    "offsetInEndSection": 1699,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24158589",
                    "text": "Occurrence of theses variations adversely affected the regular interaction between ERCC1 and XPF protein.",
                    "offsetInBeginSection": 875,
                    "offsetInEndSection": 980,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14706347",
                    "text": "Bulky DNA lesions are mainly repaired by nucleotide excision repair (NER), in which the interaction of ERCC1 with XPA protein recruits the ERCC1-XPF complex, which acts as a structure-specific endonuclease in the repair process.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10882712",
                    "text": "However, in mammalian cells there is evidence that the ERCC1-XPF nuclease has a specialized additional function during interstrand DNA cross-link repair, beyond its role in nucleotide excision repair.",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 392,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12509251",
                    "text": "ERCC1-XPF is also involved in recombinational repair processes distinct from NER.",
                    "offsetInBeginSection": 127,
                    "offsetInEndSection": 208,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11160918",
                    "text": "ERCC1-XPF is a structure-specific nuclease with two subunits, ERCC1 and XPF.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12202770",
                    "text": "In contrast to cells bearing mutations in other components of the nucleotide excision repair apparatus (XPB, XPD, XPG and CSB), cells defective for the ERCC1-XPF structure-specific nuclease are highly sensitive to cisplatin.",
                    "offsetInBeginSection": 155,
                    "offsetInEndSection": 379,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8afbf2fcd1d6a10c00001c",
            "body": "In quadruped mammals, what bones make up the stifle?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17266668",
                "http://www.ncbi.nlm.nih.gov/pubmed/19378290",
                "http://www.ncbi.nlm.nih.gov/pubmed/21113010",
                "http://www.ncbi.nlm.nih.gov/pubmed/19378269",
                "http://www.ncbi.nlm.nih.gov/pubmed/24323904",
                "http://www.ncbi.nlm.nih.gov/pubmed/25709597",
                "http://www.ncbi.nlm.nih.gov/pubmed/23554931",
                "http://www.ncbi.nlm.nih.gov/pubmed/16226434",
                "http://www.ncbi.nlm.nih.gov/pubmed/23977887",
                "http://www.ncbi.nlm.nih.gov/pubmed/3218668"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17266668",
                    "text": "In the stifle joints of quadrupeds, the MFL is a substantial structure and appears to be related to the caudal tibial slope.",
                    "offsetInBeginSection": 1234,
                    "offsetInEndSection": 1358,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378290",
                    "text": "Based on this survey, I suggest that olecranon orientation can be used for inferring the elbow joint angles of quadruped mammals with prominent olecranons, regardless of taxon, body size, and locomotor guild.",
                    "offsetInBeginSection": 919,
                    "offsetInEndSection": 1127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113010",
                    "text": "Monophasic lateral bending and long-axis rotation, biphasic sagittal bending and maximal amplitude of sagittal bending at the lumbo-sacral joint were also found in other quadruped mammals and may represent general aspects of mammalian symmetric gaits.",
                    "offsetInBeginSection": 1270,
                    "offsetInEndSection": 1521,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21113010",
                    "text": "Given the importance of thoraco-lumbar spine movements in the locomotion of mammals, it is surprising that in vivo three-dimensional (3-D) data on the intervertebral movement of the mammalian thoraco-lumbar vertebral column during symmetrical gaits is limited to horses and dogs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378269",
                    "text": "Determining scapular position is a major issue in reconstructing the skeletal systems of extinct quadruped archosaurs and mammals, because the proximal portion of the scapulae has no direct skeletal joint with the vertebrae or ribs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 232,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19378269",
                    "text": "This implies that the location of robust ribs is associated with the arrangement of the serratus muscle, and provides a probable candidate for determination of the scapular position for extinct quadruped archosaurs and mammals.",
                    "offsetInBeginSection": 1209,
                    "offsetInEndSection": 1436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24323904",
                    "text": "High-resolution microtomographic scans were collected of the lunate, scaphoid, and capitate in 41 individuals and eight genera (Homo, Gorilla, Pan, Papio, Pongo, Symphalangus, Hylobates, and Ateles).",
                    "offsetInBeginSection": 632,
                    "offsetInEndSection": 831,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23977887",
                    "text": "CONCLUSIONS AND CLINICAL RELEVANCE Compared with results for quadruped dogs, the vertebral column, carpus, and ipsilateral hip and stifle joints had significant biomechanical changes after amputation of a thoracic limb.",
                    "offsetInBeginSection": 1323,
                    "offsetInEndSection": 1542,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3218668",
                    "text": "MACN-SC 101 may represent the incipient divergence of a generalized platyrrhine arboreal quadruped toward a more suspensory form.",
                    "offsetInBeginSection": 951,
                    "offsetInEndSection": 1080,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3218668",
                    "text": "Primate scapula and ulna fragments of uncertain taxonomic affinity (MACN-SC 101) have been recovered from the Pinturas deposits at Arroyo Feo, Santa Cruz, Argentina in association with Santacrucian (Early Miocene) land mammals.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70d42899e2c3af26000002",
            "body": "Mutation of which gene causes arterial tortuosity syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18818946",
                "http://www.ncbi.nlm.nih.gov/pubmed/18774132",
                "http://www.ncbi.nlm.nih.gov/pubmed/16550171",
                "http://www.ncbi.nlm.nih.gov/pubmed/19622975",
                "http://www.ncbi.nlm.nih.gov/pubmed/22488877",
                "http://www.ncbi.nlm.nih.gov/pubmed/22734312",
                "http://www.ncbi.nlm.nih.gov/pubmed/19028722",
                "http://www.ncbi.nlm.nih.gov/pubmed/19781076",
                "http://www.ncbi.nlm.nih.gov/pubmed/17935213",
                "http://www.ncbi.nlm.nih.gov/pubmed/20735855"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946",
                    "text": "This syndrome is caused by mutations in the SLC2A10 gene.",
                    "offsetInBeginSection": 212,
                    "offsetInEndSection": 269,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818946",
                    "text": "This mutation in the SLC2A10 gene replaces a cysteine encoding codon with a stop signal.",
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 743,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132",
                    "text": "This syndrome is caused by mutation in SLC2A10 gene which encodes for the facilitative glucose transporter, GLUT10.",
                    "offsetInBeginSection": 310,
                    "offsetInEndSection": 425,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18774132",
                    "text": "In the single patient of Family 1, sequencing of the candidate gene, SLC2A10, identified a novel missense c.313C>T mutation encoding a p.Arg105Cys substitution in the second extracellular domain of GLUT10.",
                    "offsetInBeginSection": 718,
                    "offsetInEndSection": 923,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16550171",
                    "text": "GLUT10 deficiency is associated with upregulation of the TGFbeta pathway in the arterial wall, a finding also observed in Loeys-Dietz syndrome, in which aortic aneurysms associate with arterial tortuosity.",
                    "offsetInBeginSection": 568,
                    "offsetInEndSection": 773,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19622975",
                    "text": "BACKGROUND Arterial tortuosity syndrome is a rare, autosomal recessive, severe, connective tissue disorder caused by a mutation in the SLC2A10 gene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19028722",
                    "text": "Mutations in the SLC2A10 gene cause arterial tortuosity syndrome (ATS) in humans.",
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19781076",
                    "text": "ATS is caused by mutations in SLC2A10 gene, encoding for the facilitative glucose transporter 10 (GLUT10).",
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 396,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20735855",
                    "text": "BACKGROUND Recent data indicate that loss-of-function mutation in the gene encoding the facilitative glucose transporter GLUT10 (SLC2A10) causes arterial tortuosity syndrome via upregulation of the TGF-\u03b2 pathway in the arterial wall, a mechanism possibly causing vascular changes in diabetes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 293,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20735855",
                    "text": "CONCLUSION Our data demonstrate that genetic polymorphism of the SLC2A10 gene is an independent risk factor for PAD in type 2 diabetes.",
                    "offsetInBeginSection": 1186,
                    "offsetInEndSection": 1321,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f940bb750ff445500005a",
            "body": "What is the aim of the 4D nucleome project?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28905911",
                "http://www.ncbi.nlm.nih.gov/pubmed/29168505"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911",
                    "text": "The 4D Nucleome Network aims to develop and apply approaches to map the structure and dynamics of the human and mouse genomes in space and time with the goal of gaining deeper mechanistic insights into how the nucleus is organized and functions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911",
                    "text": "The project will develop and benchmark experimental and computational approaches for measuring genome conformation and nuclear organization, and investigate how these contribute to gene regulation and other genome functions.",
                    "offsetInBeginSection": 246,
                    "offsetInEndSection": 470,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911",
                    "text": "Validated experimental technologies will be combined with biophysical approaches to generate quantitative models of spatial genome organization in different biological states, both in cell populations and in single cells.",
                    "offsetInBeginSection": 471,
                    "offsetInEndSection": 692,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29168505",
                    "text": "This corrects the article DOI: 10.1038/nature23884.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 51,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8b1264fcd1d6a10c00001d",
            "body": "Fusarium oxysporum f. sp lycopersici. is a plant pathogen in plants producing what common food?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10517025",
                "http://www.ncbi.nlm.nih.gov/pubmed/24561899",
                "http://www.ncbi.nlm.nih.gov/pubmed/18945093",
                "http://www.ncbi.nlm.nih.gov/pubmed/18944618",
                "http://www.ncbi.nlm.nih.gov/pubmed/18624637",
                "http://www.ncbi.nlm.nih.gov/pubmed/24909710",
                "http://www.ncbi.nlm.nih.gov/pubmed/18943589",
                "http://www.ncbi.nlm.nih.gov/pubmed/24024636",
                "http://www.ncbi.nlm.nih.gov/pubmed/9237400",
                "http://www.ncbi.nlm.nih.gov/pubmed/28956188"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 530,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 530,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10517025",
                    "text": "Fusarium oxysporum f. sp.",
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 223,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561899",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 456,
                    "offsetInEndSection": 468,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561899",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 456,
                    "offsetInEndSection": 468,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18945093",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 706,
                    "offsetInEndSection": 718,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18945093",
                    "text": "lycopersici.",
                    "offsetInBeginSection": 706,
                    "offsetInEndSection": 718,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24909710",
                    "text": "lycopersici (FOL).",
                    "offsetInBeginSection": 387,
                    "offsetInEndSection": 405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18943589",
                    "text": "F. oxysporum f. sp.",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 655,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9237400",
                    "text": "Fusarium oxysporum f. sp.",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 179,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70d43b99e2c3af26000003",
            "body": "Does prolactinoma increase osteoporosis risk?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11293923",
                "http://www.ncbi.nlm.nih.gov/pubmed/20205855",
                "http://www.ncbi.nlm.nih.gov/pubmed/22553947",
                "http://www.ncbi.nlm.nih.gov/pubmed/17578827",
                "http://www.ncbi.nlm.nih.gov/pubmed/26319389"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11293923",
                    "text": "The relative risk for developing osteoporosis in women with prolactinoma was found to be 4.5, indicating that hyperprolactinemia in women is a major risk factor for osteoporosis.",
                    "offsetInBeginSection": 1145,
                    "offsetInEndSection": 1323,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205855",
                    "text": "Prolactinoma in old people may present insidiously with chronic anaemia and osteoporosis with or without sexual dysfunction.",
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553947",
                    "text": "CONCLUSION In the premenopausal women, patients with prolactinoma or craniopharyngioma are often accompanied with osteopenia or osteoporosis, and disease duration and hypogonadism are the risk factors of bone loss in prolactinoma.",
                    "offsetInBeginSection": 1085,
                    "offsetInEndSection": 1315,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553947",
                    "text": "OBJECTIVE Patients with prolactinoma seem to be at high risk for osteopenia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17578827",
                    "text": "INTRODUCTION Osteopenia and osteoporosis because of hyperprolactinaemia caused by prolactinoma may be followed by an increased risk of fracture.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17578827",
                    "text": "CONCLUSIONS Hyperprolactinaemia caused by prolactinoma in women influences bone metabolism unfavourably, more by the impact on the activity of bone turnover markers than on BMD.",
                    "offsetInBeginSection": 1274,
                    "offsetInEndSection": 1451,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26319389",
                    "text": "Hyperprolactinaemia related to prolactinoma significantly (more than functional hyperprolactiaemia) increases the risk of osteopenia, osteoporosis and bone fractures.",
                    "offsetInBeginSection": 1014,
                    "offsetInEndSection": 1180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26319389",
                    "text": "High serum prolactin levels lead to increase of the risk of osteopenia or/and osteoporosis.",
                    "offsetInBeginSection": 782,
                    "offsetInEndSection": 873,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26319389",
                    "text": "Important group of patients threatened by osteoporosis and bone fracture is constituted by women which use antipsychotic drugs (which induce hyperprolactinaemia).",
                    "offsetInBeginSection": 1181,
                    "offsetInEndSection": 1343,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26319389",
                    "text": "Hyperprolactinaemic patients should be diagnosed in the direction of osteopenia and osteoporosis.",
                    "offsetInBeginSection": 1425,
                    "offsetInEndSection": 1522,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6fa31ab750ff445500005e",
            "body": "Which method has been developed for assignment of enhancers to target genes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29070071"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071",
                    "text": "We devised a machine learning approach, McEnhancer, which links target genes to putative enhancers via a semi-supervised learning algorithm that predicts gene expression patterns based on enriched sequence features.",
                    "offsetInBeginSection": 178,
                    "offsetInEndSection": 393,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071",
                    "text": "Transcriptional enhancers regulate spatio-temporal gene expression.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 67,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071",
                    "text": "While genomic assays can identify putative enhancers en masse, assigning target genes is a complex challenge.",
                    "offsetInBeginSection": 68,
                    "offsetInEndSection": 177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071",
                    "text": "Our model provides a general framework to link globally identified enhancers to targets and contributes to deciphering the regulatory genome.",
                    "offsetInBeginSection": 611,
                    "offsetInEndSection": 752,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29070071",
                    "text": "Predicted expression patterns were 73-98% accurate, predicted assignments showed strong Hi-C interaction enrichment, enhancer-associated histone modifications were evident, and known functional motifs were recovered.",
                    "offsetInBeginSection": 394,
                    "offsetInEndSection": 610,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8dc6b4fcd1d6a10c000026",
            "body": "List 2 approved drug treatments for Inflammatory Bowel Disease (IBD).",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27753694",
                "http://www.ncbi.nlm.nih.gov/pubmed/23051720",
                "http://www.ncbi.nlm.nih.gov/pubmed/21936033",
                "http://www.ncbi.nlm.nih.gov/pubmed/27570643",
                "http://www.ncbi.nlm.nih.gov/pubmed/21484967",
                "http://www.ncbi.nlm.nih.gov/pubmed/17129810",
                "http://www.ncbi.nlm.nih.gov/pubmed/25685145",
                "http://www.ncbi.nlm.nih.gov/pubmed/17461487",
                "http://www.ncbi.nlm.nih.gov/pubmed/28868386",
                "http://www.ncbi.nlm.nih.gov/pubmed/26631943"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694",
                    "text": "BACKGROUND Currently, 200 genetic risk loci have been identified for inflammatory bowel disease (IBD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753694",
                    "text": "CONCLUSIONS We confirm that proteins encoded by IBD candidate genes are targeted by approved IBD therapies.",
                    "offsetInBeginSection": 1283,
                    "offsetInEndSection": 1390,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23051720",
                    "text": "First-line treatments were defined as the following drug categories: 5-aminosalicylates, budesonide, systemic steroids, azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab and certolizumab pegol.",
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 664,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23051720",
                    "text": "The following drug categories were not included: cyclosporine and tacrolimus (not yet approved by Swissmedic for IBD treatment).",
                    "offsetInBeginSection": 665,
                    "offsetInEndSection": 793,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21936033",
                    "text": "Infliximab, adalimumab, and certolizumab are monoclonal antibodies against tumor necrosis factor-\u03b1 (TNF\u03b1), a proinflammatory cytokine with an increased expression in the inflamed tissues of inflammatory bowel disease (IBD) patients.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21936033",
                    "text": "Currently, infliximab is the only anti-TNF drug that has been approved for use in refractory pediatric Crohn's disease (CD).",
                    "offsetInBeginSection": 235,
                    "offsetInEndSection": 359,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27570643",
                    "text": "Inflammatory Bowel Disease (IBD) is a chronic and relapsing disorder, which affects millions people worldwide.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685145",
                    "text": "Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD.",
                    "offsetInBeginSection": 307,
                    "offsetInEndSection": 425,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17461487",
                    "text": "Mainstays of drug treatments for IBD include aminosalicylates, corticosteroids and immunosuppressants such as azathioprine, methotrexate and cyclosporin.",
                    "offsetInBeginSection": 190,
                    "offsetInEndSection": 343,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26631943",
                    "text": "More recently, vedolizumab, an anti-\u03b14\u03b27 integrin monoclonal antibody, has been approved for the treatment of Crohn's disease and ulcerative colitis.",
                    "offsetInBeginSection": 893,
                    "offsetInEndSection": 1044,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70e4b399e2c3af26000008",
            "body": "Glecaprevir and Pibrentasvir are used for tratment of which disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28688001",
                "http://www.ncbi.nlm.nih.gov/pubmed/28800195",
                "http://www.ncbi.nlm.nih.gov/pubmed/28807904",
                "http://www.ncbi.nlm.nih.gov/pubmed/28412293",
                "http://www.ncbi.nlm.nih.gov/pubmed/29020583",
                "http://www.ncbi.nlm.nih.gov/pubmed/28818546"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195",
                    "text": "Glecaprevir and pibrentasvir are direct-acting antiviral agents being developed as combination therapy for the treatment of chronic hepatitis C virus infection.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800195",
                    "text": "The results of these studies demonstrate that race/ethnicity has no clinically meaningful impact on direct-acting antiviral agent exposures, safety, or tolerability of the glecaprevir and pibrentasvir combination.",
                    "offsetInBeginSection": 1388,
                    "offsetInEndSection": 1601,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28807904",
                    "text": "The combination of glecaprevir (formerly ABT-493), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and pibrentasvir (formerly ABT-530), an NS5A protein inhibitor, is being developed as treatment for HCV genotype 1 to 6 infection.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28807904",
                    "text": "The pharmacokinetics, pharmacodynamics, safety, and tolerability of methadone or buprenorphine-naloxone when coadministered with the glecaprevir-pibrentasvir combination in HCV-negative subjects on stable opioid maintenance therapy were investigated in a phase 1, single-center, two-arm, multiple-dose, open-label sequential study.",
                    "offsetInBeginSection": 240,
                    "offsetInEndSection": 571,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28412293",
                    "text": "LAY SUMMARY The combination of direct-acting antivirals glecaprevir and pibrentasvir comprise a once-daily, all-oral, pangenotypic treatment for HCV genotype 1-6 infection.",
                    "offsetInBeginSection": 1749,
                    "offsetInEndSection": 1921,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28412293",
                    "text": "The efficacy and safety of 8- and 12-week treatments with glecaprevir (ABT-493; NS3/4A protease inhibitor) and pibrentasvir (ABT-530; NS5A inhibitor) were evaluated in non-cirrhotic patients with chronic HCV genotype 1-6 infection.",
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 400,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28412293",
                    "text": "BACKGROUND & AIMS Hepatitis C virus (HCV) therapy that is highly efficacious, pangenotypic, with a high barrier to resistance and short treatment duration is desirable.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29020583",
                    "text": "METHODS We conducted a multicenter, open-label, phase 3 trial to evaluate the efficacy and safety of treatment with the combination of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults who had HCV genotype 1, 2, 3, 4, 5, or 6 infection and also had compensated liver disease (with or without cirrhosis) with severe renal impairment, dependence on dialysis, or both.",
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 876,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29020583",
                    "text": "Patients had stage 4 or 5 chronic kidney disease and either had received no previous treatment for HCV infection or had received previous treatment with interferon or pegylated interferon, ribavirin, sofosbuvir, or a combination of these medications.",
                    "offsetInBeginSection": 877,
                    "offsetInEndSection": 1127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28818546",
                    "text": "BACKGROUND The once-daily, ribavirin-free, pangenotypic, direct-acting antiviral regimen, glecaprevir coformulated with pibrentasvir, has shown high rates of sustained virological response in phase 2 and 3 studies.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 214,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6fa417b750ff445500005f",
            "body": "Describe the RNA Centric Annotation System (RCAS)",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28334930"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                    "text": "Here, we present the RNA Centric Annotation System (RCAS), an R package, which is designed to ease the process of creating gene-centric annotations and analysis for the genomic regions of interest obtained from various RNA-based omics technologies.",
                    "offsetInBeginSection": 288,
                    "offsetInEndSection": 536,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                    "text": "The meta-gene profiles, gene-centric annotation, motif analysis and gene-set analysis provided by RCAS provide contextual knowledge which is necessary for understanding the functional aspects of different biological events that involve RNAs.",
                    "offsetInBeginSection": 966,
                    "offsetInEndSection": 1207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                    "text": "The design of RCAS is modular, which enables flexible usage and convenient integration with other bioinformatics workflows.",
                    "offsetInBeginSection": 537,
                    "offsetInEndSection": 660,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                    "text": "In the field of RNA, the technologies for studying the transcriptome have created a tremendous potential for deciphering the puzzles of the RNA biology.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                    "text": "RCAS is an R/Bioconductor package but we also created graphical user interfaces including a Galaxy wrapper and a stand-alone web service.",
                    "offsetInBeginSection": 661,
                    "offsetInEndSection": 798,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                    "text": "The application of RCAS on published datasets shows that RCAS is not only able to reproduce published findings but also helps generate novel knowledge and hypotheses.",
                    "offsetInBeginSection": 799,
                    "offsetInEndSection": 965,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                    "text": "RCAS is available at http://bioconductor.org/packages/release/bioc/html/RCAS.html and http://rcas.mdc-berlin.de.",
                    "offsetInBeginSection": 1337,
                    "offsetInEndSection": 1449,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                    "text": "Along with the excitement, the unprecedented volume of RNA related omics data is creating great challenges in bioinformatics analyses.",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 287,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334930",
                    "text": "In addition, the array of different interfaces and deployment options adds the convenience of use for different levels of users.",
                    "offsetInBeginSection": 1208,
                    "offsetInEndSection": 1336,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76018c83b0d9ea6600000e",
            "body": "List the ten types of conjoined twins.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/1412053",
                "http://www.ncbi.nlm.nih.gov/pubmed/24193193",
                "http://www.ncbi.nlm.nih.gov/pubmed/8787375",
                "http://www.ncbi.nlm.nih.gov/pubmed/12483645",
                "http://www.ncbi.nlm.nih.gov/pubmed/29064095",
                "http://www.ncbi.nlm.nih.gov/pubmed/19060714",
                "http://www.ncbi.nlm.nih.gov/pubmed/16122113",
                "http://www.ncbi.nlm.nih.gov/pubmed/19361646",
                "http://www.ncbi.nlm.nih.gov/pubmed/16677900",
                "http://www.ncbi.nlm.nih.gov/pubmed/27369817"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193",
                    "text": "OBJECTIVES Conjoined twins are rare.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 36,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193",
                    "text": "In evaluating conjoined twins, 2-dimensional ultrasound is the criterion standard.",
                    "offsetInBeginSection": 796,
                    "offsetInEndSection": 878,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193193",
                    "text": "DESIGN A PubMed literature search was performed using the terms ultrasound, Doppler, MRI, and CT combined with first-trimester and conjoined twins.",
                    "offsetInBeginSection": 407,
                    "offsetInEndSection": 554,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8787375",
                    "text": "A case study describes the perioperative management of conjoined twins at Texas Children's Hospital's, Houston.",
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 420,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12483645",
                    "text": "RESULTS Three sets of female conjoined twins underwent successful separation 2 pygopagus, one ischiopagus tripus) with 5 surviving infants.",
                    "offsetInBeginSection": 577,
                    "offsetInEndSection": 716,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12483645",
                    "text": "This study reviews the authors' experience with the perineal reconstruction of these types of conjoined twins.",
                    "offsetInBeginSection": 209,
                    "offsetInEndSection": 319,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29064095",
                    "text": "Eight different types of conjoined twins have been described in the literature.",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 233,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19060714",
                    "text": "Conjoined twins are a rare complication of monochorionic twinning.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16677900",
                    "text": "RESULTS Ten sets of complete conjoined twins and two sets of parasitic conjoined twins were successfully separated.",
                    "offsetInBeginSection": 392,
                    "offsetInEndSection": 507,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27369817",
                    "text": "We describe the urologic presentation, evaluation, and treatment of thoracoomphalopagus conjoined twins.",
                    "offsetInBeginSection": 485,
                    "offsetInEndSection": 589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70e6e899e2c3af26000009",
            "body": "What is the mechanism of action of Fremanezumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                "http://www.ncbi.nlm.nih.gov/pubmed/28642283"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "To investigate the basis for this selective inhibitory effect, and further explore the mechanism of action of CGRP-mAbs, we tested the effect of fremanezumab on the cortical spreading depression-evoked activation of mechanosensitive primary afferent meningeal nociceptors that innervate the cranial dura, using single-unit recording in the trigeminal ganglion of anesthetized male rats.",
                    "offsetInBeginSection": 742,
                    "offsetInEndSection": 1128,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "The selectivity in its peripheral inhibitory action may partly account for fremanezumab's selective inhibition of high-threshold, as a result of a predominant A-\u03b4 input to high-threshold neurons, but not wide dynamic-range dorsal horn neurons, and why it may not be effective in all migraine patients.SIGNIFICANCE STATEMENT Recently, we reported that humanized CGRP monoclonal antibodies (CGRP-mAbs) prevent activation and sensitization of high-threshold (HT) but not wide-dynamic range trigeminovascular neurons by cortical spreading depression (CSD).",
                    "offsetInBeginSection": 1474,
                    "offsetInEndSection": 2027,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "We recently tested the effect of fremanezumab (TEV-48125), a CGRP-mAb, on the activity of second-order trigeminovascular dorsal horn neurons that receive peripheral input from the cranial dura, and found a selective inhibition of high-threshold but not wide-dynamic range class of neurons.",
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 741,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "As the main CGRP-mAb site of action appears to be situated outside the brain, we conclude that the initiation of the headache phase of migraine depends on activation of meningeal nociceptors, and that for selected patients, activation of the A\u03b4-HT pain pathway may be sufficient for the generation of headache perception.",
                    "offsetInBeginSection": 2295,
                    "offsetInEndSection": 2617,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "Fremanezumab pretreatment selectively inhibited the responsiveness of A\u03b4 neurons, but not C-fiber neurons, as reflected in a decrease in the percentage of neurons that showed activation by cortical spreading depression.",
                    "offsetInBeginSection": 1129,
                    "offsetInEndSection": 1349,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28972120",
                    "text": "These findings identify A\u03b4 meningeal nociceptors as a likely site of action of fremanezumab in the prevention of headache.",
                    "offsetInBeginSection": 1350,
                    "offsetInEndSection": 1473,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283",
                    "text": "However, their mechanism of action is unknown.",
                    "offsetInBeginSection": 1875,
                    "offsetInEndSection": 1921,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283",
                    "text": "To answer this question, we used single-unit recording to determine the effects of fremanezumab (30 mg/kg, IV) and its isotype control Ab on spontaneous and evoked activity in naive and cortical spreading depression (CSD)-sensitized trigeminovascular neurons in the spinal trigeminal nucleus of anesthetized male and female rats.",
                    "offsetInBeginSection": 571,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283",
                    "text": "The study demonstrates that, in both sexes, fremanezumab inhibited naive high-threshold (HT) neurons, but not wide-dynamic range trigeminovascular neurons, and that the inhibitory effects on the neurons were limited to their activation from the intracranial dura but not facial skin or cornea.",
                    "offsetInBeginSection": 901,
                    "offsetInEndSection": 1194,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642283",
                    "text": "The purpose of this study was to better understand how the CGRP-mAb fremanezumab (TEV-48125) modulates meningeal sensory pathways.",
                    "offsetInBeginSection": 440,
                    "offsetInEndSection": 570,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6fa61ab750ff4455000060",
            "body": "Which tool exists for microsatellite (SSR) loci detection and primer design?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27366148"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148",
                    "text": "FullSSR is a new bioinformatic tool for microsatellite (SSR) loci detection and primer design using genomic data from NGS assay.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 278,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148",
                    "text": "FullSSR simplifies the detection of SSRs and primer design on a big data set.",
                    "offsetInBeginSection": 850,
                    "offsetInEndSection": 927,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148",
                    "text": "FullSSR performance was compared against other similar SSR search programs.",
                    "offsetInBeginSection": 579,
                    "offsetInEndSection": 654,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148",
                    "text": "Microsatellites are genomic sequences comprised of tandem repeats of short nucleotide motifs widely used as molecular markers in population genetics.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148",
                    "text": "The command line interface of FullSSR was intended to be used as part of genomic analysis tools pipeline; however, it can be used as a stand-alone program because the results are easily interpreted for a nonexpert user.",
                    "offsetInBeginSection": 928,
                    "offsetInEndSection": 1147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148",
                    "text": "The software was tested with 2000 sequences of Oryza sativa shotgun sequencing project from the National Center of Biotechnology Information Trace Archive and with partial genome sequencing with ROCHE 454\u00ae from Caiman latirostris, Salvator merianae, Aegla platensis, and Zilchiopsis collastinensis.",
                    "offsetInBeginSection": 279,
                    "offsetInEndSection": 578,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148",
                    "text": "The results of the use of this kind of approach depend on the parameters set by the user.",
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 744,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366148",
                    "text": "In addition, results can be affected by the analyzed sequences because of differences among the genomes.",
                    "offsetInBeginSection": 745,
                    "offsetInEndSection": 849,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70e88699e2c3af2600000a",
            "body": "Describe mechanism of action of Nusinersen.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27939059",
                "http://www.ncbi.nlm.nih.gov/pubmed/28884620"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059",
                    "text": "INTERPRETATION Administration of multiple intrathecal doses of nusinersen showed acceptable safety and tolerability, pharmacology consistent with its intended mechanism of action, and encouraging clinical efficacy.",
                    "offsetInBeginSection": 2944,
                    "offsetInEndSection": 3158,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059",
                    "text": "METHODS This open-label, phase 2, escalating dose clinical study assessed the safety and tolerability, pharmacokinetics, and clinical efficacy of multiple intrathecal doses of nusinersen (6 mg and 12 mg dose equivalents) in patients with infantile-onset spinal muscular atrophy.",
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 626,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059",
                    "text": "Results informed the design of an ongoing, sham-controlled, phase 3 clinical study of nusinersen in infantile-onset spinal muscular atrophy.",
                    "offsetInBeginSection": 3159,
                    "offsetInEndSection": 3299,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059",
                    "text": "The study is registered at ClinicalTrials.gov, number NCT01839656.",
                    "offsetInBeginSection": 1731,
                    "offsetInEndSection": 1797,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059",
                    "text": "HINE-2, CHOP-INTEND, and compound motor action potential were compared between baseline and last visit using the Wilcoxon signed-rank test.",
                    "offsetInBeginSection": 1494,
                    "offsetInEndSection": 1633,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884620",
                    "text": "Clinical use of nusinersen is also reviewed.",
                    "offsetInBeginSection": 750,
                    "offsetInEndSection": 794,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884620",
                    "text": "This review article focuses on a novel antisense oligonucleotide treatment, first ever approved for SMA (nusinersen, SpinrazaTM) and describes the exciting journey from early ASO clinical trials to regulatory approval of the first ever known effective treatment for SMA.",
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884620",
                    "text": "Areas covered: This article reviews the results of the published open label nusinersen studies in infants and children, and briefly covers the preliminary findings of the recently completed but as yet unpublished nusinersen-sham controlled trials, as well as the presymptomatic nusinersen trial known as Nurture.",
                    "offsetInBeginSection": 437,
                    "offsetInEndSection": 749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884620",
                    "text": "Nusinersen should be considered as standard of care for the treatment of SMA of all types.",
                    "offsetInBeginSection": 1253,
                    "offsetInEndSection": 1343,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28884620",
                    "text": "Nusinersen was found to be safe and well tolerated across all age groups studied.",
                    "offsetInBeginSection": 1036,
                    "offsetInEndSection": 1117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6fa9f7b750ff4455000061",
            "body": "Describe Click-PEGylation",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28366801",
                "http://www.ncbi.nlm.nih.gov/pubmed/22988919",
                "http://www.ncbi.nlm.nih.gov/pubmed/18590303",
                "http://www.ncbi.nlm.nih.gov/pubmed/28205176",
                "http://www.ncbi.nlm.nih.gov/pubmed/27213717",
                "http://www.ncbi.nlm.nih.gov/pubmed/23106398",
                "http://www.ncbi.nlm.nih.gov/pubmed/22243664",
                "http://www.ncbi.nlm.nih.gov/pubmed/23613182",
                "http://www.ncbi.nlm.nih.gov/pubmed/21618993",
                "http://www.ncbi.nlm.nih.gov/pubmed/9279893"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801",
                    "text": "To establish a more robust method for redox-selective PEGylation, we have utilised a Click chemistry approach, where free thiol groups are first labelled with a reagent modified to contain an alkyne moiety, which is subsequently Click-reacted with a PEG molecule containing a complementary azide function.",
                    "offsetInBeginSection": 1551,
                    "offsetInEndSection": 1856,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28366801",
                    "text": "Here we show how the Click-PEGylation technique can be used to interrogate the redox state of proteins.",
                    "offsetInBeginSection": 2068,
                    "offsetInEndSection": 2171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22988919",
                    "text": "To this end, we describe the development of copper-catalyzed azide-alkyne cycloaddition (CuAAC, a click chemistry reaction) for site-specific PEGylation of interferon \u03b2-1b (IFNb) containing azidohomoalanine (Aha) at the N-terminus.",
                    "offsetInBeginSection": 381,
                    "offsetInEndSection": 613,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18590303",
                    "text": "In this work, we investigate the PEGylation of porous silicon wafers using click chemistry.",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28205176",
                    "text": "Here, we describe the method of PEGylation, which uses a cysteine-reactive molecule, maleimide polyethylene glycol (mPEG), to determine the cytosolic accessibility of introduced cysteine residues.",
                    "offsetInBeginSection": 188,
                    "offsetInEndSection": 384,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27213717",
                    "text": "In an effort to develop new enabling technologies to integrate bioprocessing and protein modification, we describe the use of disulfide-bridging conjugation to conduct PEGylation during protein refolding.",
                    "offsetInBeginSection": 252,
                    "offsetInEndSection": 456,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27213717",
                    "text": "Our results demonstrate that the simultaneous refolding and disulfide bridging PEGylation of proteins could be a useful strategy in the development of affordable modified protein therapeutics.",
                    "offsetInBeginSection": 1153,
                    "offsetInEndSection": 1345,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23106398",
                    "text": "Protein PEGylation (attaching PEG chains to proteins) has been widely used in pharmaceuticals and nanotechnology.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613182",
                    "text": "CONCLUSIONS We describe a novel method for effective monopegylation of apoAI in HDL particles, in which lipid binding seems to protect against pegylation of key functional residues.",
                    "offsetInBeginSection": 1520,
                    "offsetInEndSection": 1701,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21618993",
                    "text": "Here, we describe a novel method for the site-specific C-terminal PEGylation of recombinant proteins.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70ea8299e2c3af2600000b",
            "body": "Does Evolocumab improve cognitive function?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28207168",
                "http://www.ncbi.nlm.nih.gov/pubmed/28813214"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168",
                    "text": "EBBINGHAUS will evaluate whether the addition of evolocumab to statin therapy affects cognitive function over time in patients with stable cardiovascular disease.",
                    "offsetInBeginSection": 1748,
                    "offsetInEndSection": 1910,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168",
                    "text": "Patients with prior cardiovascular disease treated with maximally tolerated statin enrolled in FOURIER (the randomized, double-blind, placebo-controlled cardiovascular outcome study of the PCSK9i evolocumab) could participate in this prospective assessment of cognitive function (EBBINGHAUS).",
                    "offsetInBeginSection": 388,
                    "offsetInEndSection": 680,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168",
                    "text": "Key additional exclusion criteria for EBBINGHAUS were dementia, cognitive impairment, or other significant mental or neurological disorder.",
                    "offsetInBeginSection": 681,
                    "offsetInEndSection": 820,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28207168",
                    "text": "The primary hypothesis was that evolocumab would be noninferior to placebo in the mean change from baseline over time in SWMSI.",
                    "offsetInBeginSection": 1187,
                    "offsetInEndSection": 1314,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214",
                    "text": "Conclusions In a randomized trial involving patients who received either evolocumab or placebo in addition to statin therapy, no significant between-group difference in cognitive function was observed over a median of 19 months.",
                    "offsetInBeginSection": 2301,
                    "offsetInEndSection": 2529,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214",
                    "text": "Background Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 275,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214",
                    "text": "There were no significant between-group differences in the secondary end points of scores for working memory (change in raw score, -0.52 in the evolocumab group and -0.93 in the placebo group), episodic memory (change in raw score, -1.53 and -1.53, respectively), or psychomotor speed (change in raw score, 5.2 msec and 0.9 msec, respectively).",
                    "offsetInBeginSection": 1847,
                    "offsetInEndSection": 2191,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214",
                    "text": "The primary analysis was a noninferiority comparison of the mean change from baseline in the score on the spatial working memory strategy index of executive function between the patients who received evolocumab and those who received placebo; the noninferiority margin was set at 20% of the standard deviation of the score in the placebo group.",
                    "offsetInBeginSection": 1145,
                    "offsetInEndSection": 1489,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214",
                    "text": "Methods In a subgroup of patients from a randomized, placebo-controlled trial of evolocumab added to statin therapy, we prospectively assessed cognitive function using the Cambridge Neuropsychological Test Automated Battery.",
                    "offsetInBeginSection": 276,
                    "offsetInEndSection": 500,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28813214",
                    "text": "The primary end point was the score on the spatial working memory strategy index of executive function (scores range from 4 to 28, with lower scores indicating a more efficient use of strategy and planning).",
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 708,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75dff883b0d9ea66000003",
            "body": "Name curated data resources for ChIP-seq data",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27789702",
                "http://www.ncbi.nlm.nih.gov/pubmed/26969372",
                "http://www.ncbi.nlm.nih.gov/pubmed/22495751",
                "http://www.ncbi.nlm.nih.gov/pubmed/24253304",
                "http://www.ncbi.nlm.nih.gov/pubmed/28529706",
                "http://www.ncbi.nlm.nih.gov/pubmed/29069466",
                "http://www.ncbi.nlm.nih.gov/pubmed/19892823",
                "http://www.ncbi.nlm.nih.gov/pubmed/21097880",
                "http://www.ncbi.nlm.nih.gov/pubmed/22827163",
                "http://www.ncbi.nlm.nih.gov/pubmed/27863463"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702",
                    "text": "Although rapidly accumulating publicly available ChIP-seq, DNase-seq and ATAC-seq data are a valuable resource for the systematic investigation of gene regulation processes, a lack of standardized curation, quality control and analysis procedures have hindered extensive reuse of these data.",
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 527,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27789702",
                    "text": "To overcome this challenge, we built the Cistrome database, a collection of ChIP-seq and chromatin accessibility data (DNase-seq and ATAC-seq) published before January 1, 2016, including 13 366 human and 9953 mouse samples.",
                    "offsetInBeginSection": 528,
                    "offsetInEndSection": 751,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22495751",
                    "text": "We have created CistromeMap as a web server to provide a comprehensive knowledgebase of all of the publicly available ChIP-Seq and DNase-Seq data in mouse and human.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 283,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24253304",
                    "text": "Within this database, we collected all publicly available ChIP-Seq data on CRs in human and mouse and categorized the data into four cohorts: the reader, writer, eraser and remodeler cohorts, together with curated introductions and ChIP-Seq data analysis results.",
                    "offsetInBeginSection": 761,
                    "offsetInEndSection": 1024,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28529706",
                    "text": "Therefore, a relational database in which available ChIP-Seq datasets are curated is essential.",
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 533,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28529706",
                    "text": "Results: We present Expresso (database and webserver) as a tool for the collection and integration of available Arabidopsis ChIP-Seq peak data, which in turn can be linked to a user's gene expression data.",
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 739,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28529706",
                    "text": "Known target genes of transcription factors were identified by motif analysis of publicly available GEO ChIP-Seq data sets.",
                    "offsetInBeginSection": 740,
                    "offsetInEndSection": 863,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097880",
                    "text": "MPromDb (Mammalian Promoter Database) is a curated database that strives to annotate gene promoters identified from ChIP-seq results with the goal of providing an integrated resource for mammalian transcriptional regulation and epigenetics.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 240,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27863463",
                    "text": "CONCLUSIONS The various ChIP-Seq command line tools and web services either complement or compare favorably to related bioinformatics resources in terms of computational efficiency, ease of access to public data and interoperability with other web-based tools.",
                    "offsetInBeginSection": 888,
                    "offsetInEndSection": 1148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27863463",
                    "text": "RESULTS Here we present the ChIP-Seq command line tools and web server, implementing basic algorithms for ChIP-seq data analysis starting with a read alignment file.",
                    "offsetInBeginSection": 295,
                    "offsetInEndSection": 460,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a72284b2dc08e987e000001",
            "body": "Can radius fracture cause carpal tunnel syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29169594",
                "http://www.ncbi.nlm.nih.gov/pubmed/23026468",
                "http://www.ncbi.nlm.nih.gov/pubmed/21786553",
                "http://www.ncbi.nlm.nih.gov/pubmed/21505639",
                "http://www.ncbi.nlm.nih.gov/pubmed/26566562",
                "http://www.ncbi.nlm.nih.gov/pubmed/27454517",
                "http://www.ncbi.nlm.nih.gov/pubmed/11514776"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594",
                    "text": "Carpal tunnel syndrome (CTS) after distal radius fractures can present in 3 forms: acute, transient, and delayed.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594",
                    "text": "Prophylactic carpal tunnel release in the absence of signs and symptoms of CTS after a distal radius fracture is not indicated.",
                    "offsetInBeginSection": 314,
                    "offsetInEndSection": 441,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29169594",
                    "text": "Many patients with transient CTS after distal radius fracture do not require surgical release of the carpal tunnel once the fracture is repaired.",
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 313,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468",
                    "text": "Delayed carpal tunnel syndrome presenting after a distal radius fracture has healed is best managed in standard fashion.",
                    "offsetInBeginSection": 465,
                    "offsetInEndSection": 585,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026468",
                    "text": "Carpal tunnel syndrome is a common condition and is a well-recognized phenomenon following a distal radius fracture.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21786553",
                    "text": "CONCLUSION Simultaneous anterior transverse carpal ligament resection can effectively prevent the delayed carpal tunnel syndrome occurrence for the distal radius fracture with open reduction by palm side.",
                    "offsetInBeginSection": 1211,
                    "offsetInEndSection": 1415,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21505639",
                    "text": "We report the incidence of late onset post-operative carpal tunnel syndrome (late carpal tunnel syndrome) and late median nerve neuropathy after volar plating of distal radius fracture by conducting a retrospective study on volar plating for distal radius fracture performed during 2002 to 2006.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 295,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566562",
                    "text": "We report a case of acute rupture of the flexor pollicis longus and flexor carpi radialis tendons with acute carpal tunnel syndrome after a Gustilo-Anderson type II open distal radius fracture.",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 334,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454517",
                    "text": "Carpal tunnel syndrome is a common complication associated with distal radius fractures.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454517",
                    "text": "Being well known and accepted techniques of carpal tunnel release, we believe that the techniques described in this paper provide a viable alternative for carpal tunnel release in the setting of distal radius fracture fixation; with the added advantages of the original minimally invasive techniques.",
                    "offsetInBeginSection": 628,
                    "offsetInEndSection": 928,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75f1f383b0d9ea66000006",
            "body": "Can Logic Alignment Free (LAF) be used for bacterial genomes classification?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26664519"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                    "text": "In this paper, we present Logic Alignment Free (LAF), a method that combines alignment-free techniques and rule-based classification algorithms in order to assign biological samples to their taxa.",
                    "offsetInBeginSection": 315,
                    "offsetInEndSection": 511,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                    "text": "We apply LAF successfully to the classification of bacterial genomes to their corresponding taxonomy.",
                    "offsetInBeginSection": 690,
                    "offsetInEndSection": 791,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                    "text": "Alignment-free algorithms can be used to estimate the similarity of biological sequences and hence are often applied to the phylogenetic reconstruction of genomes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                    "text": "State of the art methods to adjust the frequency of k-mers to the character distribution of the underlying genomes have negligible impact on classification performance, suggesting that the signal of each class is strong and that LAF is effective in identifying it.",
                    "offsetInBeginSection": 971,
                    "offsetInEndSection": 1235,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                    "text": "This method searches for a minimal subset of k-mers whose relative frequencies are used to build classification models as disjunctive-normal-form logic formulas (if-then rules).",
                    "offsetInBeginSection": 512,
                    "offsetInEndSection": 689,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                    "text": "In particular, we succeed in obtaining reliable classification at different taxonomic levels by extracting a handful of rules, each one based on the frequency of just few k-mers.",
                    "offsetInBeginSection": 792,
                    "offsetInEndSection": 970,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664519",
                    "text": "Most of these algorithms rely on comparing the frequency of all the distinct substrings of fixed length (k-mers) that occur in the analyzed sequences.",
                    "offsetInBeginSection": 164,
                    "offsetInEndSection": 314,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a722a052dc08e987e000002",
            "body": "Is Marfan syndrome associated with chordal rupture?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10441700",
                "http://www.ncbi.nlm.nih.gov/pubmed/14658812",
                "http://www.ncbi.nlm.nih.gov/pubmed/7790334",
                "http://www.ncbi.nlm.nih.gov/pubmed/18172522",
                "http://www.ncbi.nlm.nih.gov/pubmed/17317544"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700",
                    "text": "The neonatal Marfan syndrome is an autosomal dominantly inherited disease with an extremely poor prognosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700",
                    "text": "This report gives a clinical and echocardiographic description of an infant with a mutation in exon 29 of the fibrillin-1 gene (FBN1), a region in which this severe form of Marfan syndrome seems to cluster.",
                    "offsetInBeginSection": 108,
                    "offsetInEndSection": 314,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812",
                    "text": "Three patients underwent mitral annuloplasty and chordal shortening.",
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 840,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812",
                    "text": "CONCLUSION This experience in mitral valve procedures indicated that the connective tissue defect might compromise the results of such surgery, but that mitral valve operations could be performed satisfactorily in young Marfan syndrome patients, despite complications of left ventricular dilatation.",
                    "offsetInBeginSection": 1109,
                    "offsetInEndSection": 1408,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812",
                    "text": "BACKGROUND AND AIM OF THE STUDY Although, in patients with Marfan syndrome, the most common cardiovascular abnormalities are aortic root dilatation and aortic valve regurgitation, mitral valve dysfunction is the most frequently accompanying cardiac lesion.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14658812",
                    "text": "Mitral regurgitation was caused by annulus dilatation in all patients, by leaflet prolapse in five patients, and by chordal rupture due to endocarditis in two.",
                    "offsetInBeginSection": 481,
                    "offsetInEndSection": 640,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7790334",
                    "text": "It is worthy to report this case because of rarities such as Marfan's syndrome accompanied by Prinzmetal's variant angina, perioperative coronary artery spasm in modified Bentall's operation, and perioperative chordal rupture of the mitral valve and progression of mitral valve regurgitation.",
                    "offsetInBeginSection": 659,
                    "offsetInEndSection": 951,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7790334",
                    "text": "In a modified Bentall's operation (button technique), perioperative severe coronary artery spasm occurred in spite of the preventive use of nitroglycerin infusion, which resulted in profound ventricular fibrillation and subsequent chordal rupture of the mitral valve with Sellers IV regurgitation.",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 427,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18172522",
                    "text": "Repair of the mitral valve in children who have Marfan syndrome is especially difficult due to the presence of generalized connective tissue disorder, which may lead to future elongation and rupture of chordae tendineae that were unaffected at the time of mitral valve repair.",
                    "offsetInBeginSection": 205,
                    "offsetInEndSection": 481,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17317544",
                    "text": "INTRODUCTION There are multiple causes of mitral regurgitation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 63,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75f2fc83b0d9ea66000007",
            "body": "What is TCGA2BED?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28049410"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "We also provide and maintain an automatically updated data repository with publicly available Copy Number Variation, DNA-methylation, DNA-seq, miRNA-seq, and RNA-seq (V1,V2) experimental data of TCGA converted into the BED format, and their associated clinical and biospecimen meta data in attribute-value text format.",
                    "offsetInBeginSection": 814,
                    "offsetInEndSection": 1132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "RESULTS We propose TCGA2BED a software tool to search and retrieve TCGA data, and convert them in the structured BED format for their seamless use and integration.",
                    "offsetInBeginSection": 417,
                    "offsetInEndSection": 580,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "Furthermore, TCGA2BED extends TCGA data with information extracted from other genomic databases (i.e., NCBI Entrez Gene, HGNC, UCSC, and miRBase).",
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 813,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "CONCLUSIONS The availability of the valuable TCGA data in BED format reduces the time spent in taking advantage of them: it is possible to efficiently and effectively deal with huge amounts of cancer genomic data integratively, and to search, retrieve and extend them with additional information.",
                    "offsetInBeginSection": 1135,
                    "offsetInEndSection": 1431,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "In this work, we focus on The Cancer Genome Atlas, a comprehensive archive of tumoral data containing the results of high-throughout experiments, mainly Next Generation Sequencing, for more than 30 cancer types.",
                    "offsetInBeginSection": 203,
                    "offsetInEndSection": 414,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "BACKGROUND Data extraction and integration methods are becoming essential to effectively access and take advantage of the huge amounts of heterogeneous genomics and clinical data increasingly available.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "The BED format facilitates the investigators allowing several knowledge discovery analyses on all tumor types in TCGA with the final aim of understanding pathological mechanisms and aiding cancer treatments.",
                    "offsetInBeginSection": 1432,
                    "offsetInEndSection": 1639,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049410",
                    "text": "Additionally, it supports the conversion in CSV, GTF, JSON, and XML standard formats.",
                    "offsetInBeginSection": 581,
                    "offsetInEndSection": 666,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a722ccd2dc08e987e000003",
            "body": "What is the mechanism of action of Tezepelumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28877011"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
                    "text": "This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled despite treatment with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids.",
                    "offsetInBeginSection": 148,
                    "offsetInEndSection": 491,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
                    "text": "RESULTS The use of tezepelumab at a dose of 70 mg every 4 weeks (low dose; 145 patients), 210 mg every 4 weeks (medium dose; 145 patients), or 280 mg every 2 weeks (high dose; 146 patients) resulted in annualized asthma exacerbation rates at week 52 of 0.26, 0.19, and 0.22, respectively, as compared with 0.67 in the placebo group (148 patients).",
                    "offsetInBeginSection": 785,
                    "offsetInEndSection": 1132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
                    "text": "METHODS In this phase 2, randomized, double-blind, placebo-controlled trial, we compared subcutaneous tezepelumab at three dose levels with placebo over a 52-week treatment period.",
                    "offsetInBeginSection": 494,
                    "offsetInEndSection": 674,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
                    "text": "CONCLUSIONS Among patients treated with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids, those who received tezepelumab had lower rates of clinically significant asthma exacerbations than those who received placebo, independent of baseline blood eosinophil counts.",
                    "offsetInBeginSection": 1825,
                    "offsetInEndSection": 2119,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
                    "text": "(Funded by MedImmune [a member of the AstraZeneca Group] and Amgen; PATHWAY ClinicalTrials.gov number, NCT02054130 .",
                    "offsetInBeginSection": 2120,
                    "offsetInEndSection": 2236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
                    "text": "The prebronchodilator forced expiratory volume in 1 second at week 52 was higher in all tezepelumab groups than in the placebo group (difference, 0.12 liters with the low dose [P=0.01], 0.11 liters with the medium dose [P=0.02], and 0.15 liters with the high dose [P=0.002]).",
                    "offsetInBeginSection": 1388,
                    "offsetInEndSection": 1663,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
                    "text": "Thus, exacerbation rates in the respective tezepelumab groups were lower by 61%, 71%, and 66% than the rate in the placebo group (P<0.001 for all comparisons).",
                    "offsetInBeginSection": 1133,
                    "offsetInEndSection": 1292,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
                    "text": "A total of 2 patients in the medium-dose group, 3 in the high-dose group, and 1 in the placebo group discontinued the trial regimen because of adverse events.",
                    "offsetInBeginSection": 1664,
                    "offsetInEndSection": 1822,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
                    "text": "BACKGROUND In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
                    "text": "The primary end point was the annualized rate of asthma exacerbations (events per patient-year) at week 52.",
                    "offsetInBeginSection": 675,
                    "offsetInEndSection": 782,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75f5aa83b0d9ea66000008",
            "body": "Describe JACUSA",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28049429"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429",
                    "text": "CONCLUSION Our software JACUSA detects single nucleotide variants by comparing data from next-generation sequencing experiments (RNA-DNA or RNA-RNA).",
                    "offsetInBeginSection": 1974,
                    "offsetInEndSection": 2123,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429",
                    "text": "RESULTS We present JACUSA, a versatile one-stop solution to detect single nucleotide variant positions from comparing RNA-DNA and/or RNA-RNA sequencing samples.",
                    "offsetInBeginSection": 870,
                    "offsetInEndSection": 1030,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429",
                    "text": "Intriguingly, JACUSA captures most A\u2192I events from RRD comparisons of RNA sequencing data derived from Drosophila and HEK-293 data sets.",
                    "offsetInBeginSection": 1833,
                    "offsetInEndSection": 1971,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429",
                    "text": "We further validated JACUSA's performance by testing its ability to detect A\u2192I events using sequencing data from a human cell culture experiment and publicly available RNA-seq data from Drosophila melanogaster heads.",
                    "offsetInBeginSection": 1351,
                    "offsetInEndSection": 1569,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429",
                    "text": "JACUSA outperforms other algorithms in terms of the F measure, which combines precision and recall, in all benchmark scenarios.",
                    "offsetInBeginSection": 1151,
                    "offsetInEndSection": 1278,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429",
                    "text": "The performance of JACUSA has been carefully evaluated and compared to other variant callers in an in silico benchmark.",
                    "offsetInBeginSection": 1031,
                    "offsetInEndSection": 1150,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429",
                    "text": "The most common RNA editing modification is the single base substitution (A\u2192I) that is catalyzed by the members of the Adenosine deaminases that act on RNA (ADAR) family.",
                    "offsetInBeginSection": 197,
                    "offsetInEndSection": 369,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429",
                    "text": "JACUSA has a higher recall and comparable precision for detecting true editing sites in RDD comparisons of HEK-293 data.",
                    "offsetInBeginSection": 1712,
                    "offsetInEndSection": 1832,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429",
                    "text": "Typically, editing sites are identified as RNA-DNA-differences (RDDs) in a comparison of genome and transcriptome data from next-generation sequencing experiments.",
                    "offsetInBeginSection": 370,
                    "offsetInEndSection": 533,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28049429",
                    "text": "However, a method for robust detection of site-specific editing events from replicate RNA-seq data has not been published so far.",
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 663,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a722d9f2dc08e987e000004",
            "body": "What is mechanism of action of Benralizumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27119985",
                "http://www.ncbi.nlm.nih.gov/pubmed/27097165",
                "http://www.ncbi.nlm.nih.gov/pubmed/25306557",
                "http://www.ncbi.nlm.nih.gov/pubmed/28109128",
                "http://www.ncbi.nlm.nih.gov/pubmed/29086236",
                "http://www.ncbi.nlm.nih.gov/pubmed/28530840",
                "http://www.ncbi.nlm.nih.gov/pubmed/28919200",
                "http://www.ncbi.nlm.nih.gov/pubmed/23866823",
                "http://www.ncbi.nlm.nih.gov/pubmed/28737051",
                "http://www.ncbi.nlm.nih.gov/pubmed/25208464"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165",
                    "text": "Benralizumab is an anti-interleukin-5 receptor \u03b1 monoclonal antibody that depletes blood and airway eosinophils.",
                    "offsetInBeginSection": 215,
                    "offsetInEndSection": 328,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27097165",
                    "text": "CONCLUSIONS Benralizumab reduced asthma exacerbation and improved lung function and asthma control in adults with uncontrolled eosinophilic asthma.",
                    "offsetInBeginSection": 1393,
                    "offsetInEndSection": 1540,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25306557",
                    "text": "In a phase 2b dose-ranging study, we aimed to assess the efficacy and safety of benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody that depletes blood and airway eosinophils, in adults with uncontrolled eosinophilic asthma.",
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 342,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109128",
                    "text": "Benralizumab is a humanized, afucosylated, anti-interleukin-5 receptor \u03b1, immunoglobulin G (IgG) 1 \u03ba monoclonal antibody.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28109128",
                    "text": "Stochastic simulations supported an every-8-week dosing schedule of benralizumab for a phase IIb study in patients with uncontrolled asthma.",
                    "offsetInBeginSection": 945,
                    "offsetInEndSection": 1085,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29086236",
                    "text": "Benralizumab is a monoclonal antibody that targets interleukin-5 receptor \u03b1 to deplete blood eosinophils and improve the clinical outcomes of allergic asthma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28919200",
                    "text": "BACKGROUND Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor \u03b1 monoclonal antibody that has been shown to significantly reduce asthma exacerbations and improve lung function for patients with severe, uncontrolled asthma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 237,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28737051",
                    "text": "Anti-IL-5-based therapies (mepolizumab and reslizumab are humanized monoclonal antibodies (hmAbs) that recognize free IL-5, benralizumab is a hmAb directed at the \u03b1 subunit of the IL-5R) target the IL-5-signaling in eosinophilic asthma.",
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 536,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28737051",
                    "text": "Other benefits of benralizumab are fast (within 24\u00a0h) depletion of peripheral blood eosinophils, potent suppressive activity of bone marrow eosinophils and eosinophil precursors, tissue eosinophil apoptosis regardless of the presence of eosinophil survival factors and even at low IL-5R densities.",
                    "offsetInBeginSection": 952,
                    "offsetInEndSection": 1250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25208464",
                    "text": "Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, depletes blood and sputum eosinophils.",
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 238,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75f6e083b0d9ea66000009",
            "body": "Which data simulator is available for CLIP-SEQ experiments?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26776207"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207",
                    "text": "To this date, however, it has not been assessed which of the available tools are most appropriate for the analysis of CLIP-Seq data.",
                    "offsetInBeginSection": 325,
                    "offsetInEndSection": 457,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207",
                    "text": "In this work, we also show how Cseq-Simulator can be used to perform a comparison of steps of typical CLIP-Seq analysis pipelines, such as the read alignment or the peak calling.",
                    "offsetInBeginSection": 846,
                    "offsetInEndSection": 1024,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207",
                    "text": "To address this lack of a gold-standard dataset, we here present Cseq-Simulator, a simulator for PAR-CLIP, HITS-CLIP and iCLIP-data.",
                    "offsetInBeginSection": 583,
                    "offsetInEndSection": 715,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207",
                    "text": "Some of these tools were specifically developed for CLIP-Seq data, whereas others were designed for the analysis of RNA-Seq data.",
                    "offsetInBeginSection": 195,
                    "offsetInEndSection": 324,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207",
                    "text": "CLIP-Seq protocols such as PAR-CLIP, HITS-CLIP or iCLIP allow a genome-wide analysis of protein-RNA interactions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207",
                    "text": "This simulator can be applied to generate realistic datasets that can serve as surrogates for experimental gold standard dataset.",
                    "offsetInBeginSection": 716,
                    "offsetInEndSection": 845,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207",
                    "text": "This is because an experimental gold standard dataset on which methods can be accessed and compared, is still not available.",
                    "offsetInBeginSection": 458,
                    "offsetInEndSection": 582,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207",
                    "text": "These comparisons show which tools are useful in different settings and also allow identifying pitfalls in the data analysis.",
                    "offsetInBeginSection": 1025,
                    "offsetInEndSection": 1150,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26776207",
                    "text": "For the processing of the resulting short read data, various tools are utilized.",
                    "offsetInBeginSection": 114,
                    "offsetInEndSection": 194,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a72302b2dc08e987e000005",
            "body": "Treatment of which disease was studied in the Gore REDUCE Clinical Study?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29090661",
                "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                "http://www.ncbi.nlm.nih.gov/pubmed/10847965",
                "http://www.ncbi.nlm.nih.gov/pubmed/27872317",
                "http://www.ncbi.nlm.nih.gov/pubmed/2940526",
                "http://www.ncbi.nlm.nih.gov/pubmed/26808286",
                "http://www.ncbi.nlm.nih.gov/pubmed/18559363",
                "http://www.ncbi.nlm.nih.gov/pubmed/17704480"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29090661",
                    "text": "Aims The Gore REDUCE Clinical Study (REDUCE) aims to establish superiority of patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in patients who have had a cryptogenic stroke.",
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 507,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29090661",
                    "text": "The trial should determine whether patent foramen ovale closure with the Gore septal occluders is safe and more effective than medical therapy alone for the prevention of recurrent clinical ischemic stroke or new silent brain infarct; the neuroimaging data will provide an opportunity to further support the proof of concept.",
                    "offsetInBeginSection": 1629,
                    "offsetInEndSection": 1954,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                    "text": "CONCLUSIONS Our multicenter experience with the GORE TIGRIS Vascular Stent demonstrates continued good results\u00a0at\u00a02\u00a0years for endovascular treatment of challenging obstructive superficial femoral artery and popliteal artery disease.",
                    "offsetInBeginSection": 1517,
                    "offsetInEndSection": 1752,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                    "text": "This study therefore investigated the performance of the GORE TIGRIS Vascular Stent at three different centers in France in patients with symptomatic peripheral artery disease.",
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 427,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                    "text": "METHODS This retrospective, single-arm, multicenter cohort study included 215 patients with peripheral artery disease (Rutherford-Becker category 2-6) who were treated with the GORE TIGRIS Vascular Stent, a dual-component stent consisting of a nitinol wire frame combined with a fluoropolymer-interconnecting structure.",
                    "offsetInBeginSection": 430,
                    "offsetInEndSection": 749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                    "text": "BACKGROUND Preliminary results in small single-center studies after stenting with the GORE TIGRIS Vascular Stent (W.\u00a0L.\u00a0Gore & Associates, Flagstaff, Ariz) show promising short-term primary patency rates, but larger, multicenter studies are needed.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28222987",
                    "text": "RESULTS The GORE TIGRIS Vascular Stent was used to successfully treat 239 lesions, of which 141 lesions were located in the superficial femoral artery and 98 in the popliteal artery.",
                    "offsetInBeginSection": 1044,
                    "offsetInEndSection": 1226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27872317",
                    "text": "METHODS A prospective, single-center pilot study recruited 30 symptomatic patients (mean age 64 years; 18 men) to evaluate the safety and early efficacy of the new Gore balloon-expandable covered endoprosthesis for the treatment of de novo or restenotic common and/or external iliac artery lesions.",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 413,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26808286",
                    "text": "BACKGROUND The aim of this study is to assess the safety and the short-term results of endovascular treatment of common iliac artery (CIA) aneurysms using the new GORE EXCLUDER iliac branch endoprosthesis (IBE) device.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17704480",
                    "text": "The Gore TAG endoprosthesis (W. L. Gore and Associates, Flagstaff, Ariz) was the first to enter clinical trials for the treatment of thoracic aortic aneurysms, confirming its safety and efficacy as well as its short-term advantages over open surgical repair.",
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 362,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a760e5583b0d9ea66000018",
            "body": "Which comparisons demonstrate the applicability of StereoGene in regulatory genomics?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29028265"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "These analyses provide examples for the broad applicability of StereoGene for regulatory genomics.",
                    "offsetInBeginSection": 1473,
                    "offsetInEndSection": 1571,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "We apply our method to numerous comparisons of ChIP-Seq datasets from the Human Epigenome Atlas and FANTOM CAGE to demonstrate its wide applicability.",
                    "offsetInBeginSection": 1062,
                    "offsetInEndSection": 1212,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "Results Here, we propose a method, StereoGene, that rapidly estimates genome-wide correlation among pairs of genomic features.",
                    "offsetInBeginSection": 374,
                    "offsetInEndSection": 500,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "We observe the changes in the correlation between epigenomic features across developmental trajectories of several tissue types consistent with known biology and find a novel spatial correlation of CAGE clusters with donor splice sites and with poly(A) sites.",
                    "offsetInBeginSection": 1213,
                    "offsetInEndSection": 1472,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "StereoGene enables correlation of continuous data directly, avoiding the data binarization and subsequent data loss.",
                    "offsetInBeginSection": 635,
                    "offsetInEndSection": 751,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "Motivation Genomics features with similar genome-wide distributions are generally hypothesized to be functionally related, for example, colocalization of histones and transcription start sites indicate chromatin regulation of transcription factor activity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "Availability and implementation The StereoGene C\u2009++\u2009source code, program documentation, Galaxy integration scripts and examples are available from the project homepage http://stereogene.bioinf.fbb.msu.ru/.",
                    "offsetInBeginSection": 1574,
                    "offsetInEndSection": 1783,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "These features may represent high-throughput data mapped to reference genome or sets of genomic annotations in that reference genome.",
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 634,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "Therefore, statistical algorithms to perform spatial, genome-wide correlation among genomic features are required.",
                    "offsetInBeginSection": 257,
                    "offsetInEndSection": 371,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028265",
                    "text": "Representing the correlation as a function of the genome position, StereoGene outputs the local correlation track as part of the analysis.",
                    "offsetInBeginSection": 840,
                    "offsetInEndSection": 978,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a72329e2dc08e987e000006",
            "body": "Falciform ligament sign is characteristic to which disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23133059",
                "http://www.ncbi.nlm.nih.gov/pubmed/16807665",
                "http://www.ncbi.nlm.nih.gov/pubmed/19716250",
                "http://www.ncbi.nlm.nih.gov/pubmed/26577973",
                "http://www.ncbi.nlm.nih.gov/pubmed/2003436",
                "http://www.ncbi.nlm.nih.gov/pubmed/17322659",
                "http://www.ncbi.nlm.nih.gov/pubmed/3881894",
                "http://www.ncbi.nlm.nih.gov/pubmed/907474",
                "http://www.ncbi.nlm.nih.gov/pubmed/2910743",
                "http://www.ncbi.nlm.nih.gov/pubmed/27938473"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133059",
                    "text": "Primary tumor of falciform ligament is exceedingly uncommon.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 60,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16807665",
                    "text": "The falciform ligament was prepared as a flap in all patients during the initial step of the operation and, after partial cystectomy and evacuation of the cystic components, the flap was inserted into the cystic cavity and fixed with sutures.",
                    "offsetInBeginSection": 817,
                    "offsetInEndSection": 1059,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19716250",
                    "text": "RESULTS All specific air distributions were more frequently present in patients with gastroduodenal perforation than lower GI tract perforation, but only the falciform ligament sign was statistically significant (p<0.05).",
                    "offsetInBeginSection": 1158,
                    "offsetInEndSection": 1379,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26577973",
                    "text": "Pathologies of the falciform ligament are extremely rare entities ranging from cyst and hematoma to abscess and gangrene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2003436",
                    "text": "One or more of these signs were present in 26 cases (59%) of pneumoperitoneum, including the right-upper-quadrant gas sign in 18 cases (41%), Rigler's sign in 14 cases (32%), and the falciform ligament and football signs in one case each (2%).",
                    "offsetInBeginSection": 697,
                    "offsetInEndSection": 940,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17322659",
                    "text": "The patient with the falciform ligament disease represents the first reported case of primary torsion and infarction of the falciform ligament, and the patient with the transverse colon epiploica represents the first reported case of vibration-induced appendix epiploica torsion and infarction.",
                    "offsetInBeginSection": 445,
                    "offsetInEndSection": 739,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3881894",
                    "text": "The demonstration of a vessel in the falciform ligament, traditionally presumed to be a reopened umbilical vein, is an important sonographic sign of portal hypertension.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2910743",
                    "text": "Cullen's sign can be seen to be secondary to the tracking of liberated pancreatic enzymes to the anterior abdominal wall from the inflamed gastrohepatic ligament and across the falciform ligament.",
                    "offsetInBeginSection": 721,
                    "offsetInEndSection": 917,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27938473",
                    "text": "Mesenchymal stem cells (MSCs) were isolated from the liver falciform ligament and abdominal subcutaneous adipose tissue in patients undergoing partial hepatectomy for liver disease.",
                    "offsetInBeginSection": 270,
                    "offsetInEndSection": 451,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27938473",
                    "text": "Falciform ligaments in the liver are surrounded by adipose tissue.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        }
    ]
}
